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DELIVERY OF SMALL MOLECULE AND RNA USING SYNTHETIC POLYMERIC
MICELLES AND MULTIFUNCTIONAL EXOSOMES FOR THE TREATMENT OF TYPE
1 DIABETES
Yang Peng, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: Ram I. Mahato, Ph.D.
Type 1 diabetes is one of the most challenging chronic autoimmune diseases. The
destruction and dysfunction of insulin-secreting β cells are the results of inflammatory
infiltration and the synergistic effect of multiple immune cells. The aim of this dissertation
is to develop novel and reliable therapeutic approaches to advance the treatment of T1D:
including chemical modification of a broad-spectrum immunosuppressant, co-application
of small molecule based immune intervention and siRNA based β cell preservative therapy,
and administration of a PI3K-δ/γ dual inhibitor to specifically target immune cells, utilizing
synthetic polymeric micelles or natural produced multi-functional exosomes derived from
human bone marrow mesenchymal stem cells (hBMSCs).
Chapter 1 is a comprehensive overview of the background, pathogenesis, current and
advanced therapeutic strategies of T1D. At the end of the chapter, questions and future
perspectives are raised, which may shed light on the future development and clinical
translation of T1D treatment.
Chapter

2

describes

the

chemical

modification

of

a

broad-spectrum

immunosuppressant mycophenolic acid by conjugating to quinic acid, which exhibits
potent anti-inflammatory effect, via amide bonds to attenuate the non-specific toxicity while
maintaining therapeutic efficacy. The resultant compound MQ4 may be a novel promising
immunosuppressant to minimize immune rejection after islet transplantation.

Chapter 3 utilized cationic copolymers to co-deliver sunitinib, a tyrosine kinase inhibitor,
and siRNA against Alox15 which is crucial for T1D pathogenesis by generating toxic and
inflammatory lipids/ROS, to reverse the new-onset of T1D in a NOD mouse model. The
encouraging results demonstrated the reliability and safety of this approach in the field of
T1D.
Chapter 4 explored the therapeutic role of a novel PI3K-δ/γ dual inhibitor IPI-145,
which specifically targeted immune cells, and the transportation potential as well as the
trophic function of hBMSC-derived exosomes, which hypothetically carrying intrinsic
immunoregulatory ability, paracrine effect, and migration tendency to inflamed pancreatic
islets, for T1D treatment.
Chapter 5 is the summary of key findings of each chapter, and the discussion of the
remaining concerns and future directions.
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CHAPTER 1. INTRODUCTION TO TYPE 1 DIABETES
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1.1. INTRODUCTION
Type 1 diabetes (T1D) is one of the most common chronic autoimmune diseases that
associates with multiple serious health complications and significantly compromises
individual’s quality of life with an increased rate of disability and death.1 According to the
National Diabetes Statistics Report released in 2017, an estimated 23.1 million people
were diagnosed with diabetes in 2015 and 7.2 million were undiagnosed, in total
accounting for 9.4% of the US population. Among these, about 5% were associated with
type 1 diabetes while there were still an estimated 40,000 new cases of T1D each year.2
In 2016, the American Diabetes Association dedicated 37% of the research funding to
support the study of T1D. Unlike the “relative insulin deficiency” of type 2 diabetes due to
insulin resistance, T1D is the result of “absolute insulin deficiency” caused by autoimmune
attack induced progressive dysfunction and destruction of insulin-secreting β cells in the
islets of Langerhans of the pancreas.3 Researchers have found that about 70% of the
pancreatic islets were completely destroyed and devoid of insulin in patients with newonset T1D, furthermore, within the remaining insulin-containing islets, 20% exhibited signs
of inflammation.4
Although the pathogenesis of T1D development has not been fully elucidated, the
immunohistochemistry analysis of the pancreas obtained from 29 patients with early-stage
T1D demonstrated massive infiltration of a variety of inflammatory cells which were
composed of CD8+ cytotoxic T cells, macrophages (CD68+), B lymphocytes (CD20+),
CD138+ plasma cells, and CD4+ T cells, suggesting a synergistic effect of immune cells
on destroying islets.5-7 More specifically, CD8+ T cells and macrophages were more
abundant and predominant in early insulitis, while most of the B lymphocytes presented in
late insulitis. Intriguingly, regulatory T cells (Tregs) and natural killer (NK) cells were rarely
recruited to the inflamed pancreas.5 The disease initiates after the genetic predisposition
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or environmental non-genetic factors such as virus or diet induced β cell damage to
release one or more β cell specific autoantigens, including insulin, glutamic acid
decarboxylase (GAD), islet-associated autoantibody 2 (IA-2), and zinc transporter 8
(ZnT8), which are the major T1D-related immune biomarkers and can exist in the body
months to years before the onset of T1D.8 Then these autoantigens are recognized and
processed by antigen-presenting cells (APCs), followed by presentation to and activation
of CD4+ helper T cells (Th cells). The activated CD4+ T cells release several cytokines,
such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ) which will further activate β cell
specific pre-cytotoxic T cells and macrophages, respectively to become cytotoxic. These
cells are responsible for the direct destruction of islet β cells, what’s more, their secretory
products which are granzyme and perforin generated by β cell specific CD8+ cytotoxic T
cells, as well as pro-inflammatory cytokines (IL-1β, TNF-α, and IFN-γ) and free radicals
produced by macrophages also play a pivotal role in the progressive death of β cells.9
In the past decades, although much effort has been devoted to seeking safe and
effective approaches to halt the progression or even revert the occurrence of T1D, so far
there is no satisfactory methodology that can completely cure this chronic autoimmune
disorder. Exogenous insulin replacement therapy is the current standard regimen with
numerous innovative design and improvement. For instance, insulin pump in combination
with real-time continuous glucose monitoring decreases the potential risks of inaccurate
dose and life-threatening hypoglycemia accompanied by traditional subcutaneous insulin
administration; long-acting insulin analogues exhibit prolonged blood glucose-lowering
effect over days or even weeks; and smart insulin delivery systems release their payloads
in response to specific stimuli to control glucose level more rational. However, one thing
that needs to be kept in mind is that insulin therapy is not a cure for T1D. Another clinically
approved approach is islet transplantation, which has the potential to release the insulin-
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dependence of T1D patients. Unfortunately, the outcomes are always challenged by the
recurrence of autoimmune attack and gradual deterioration of the islet grafts. Besides, the
insufficient donor pool and general adverse effects of the subsequent immunosuppressive
regimens also hinder the application of islet transplantation.10 To solve these problems,
researchers have made substantial progress with strategies to enhance the in vivo viability,
improve revascularization, and provide favorable immune modulation, such as genetically
engineering of islets and co-transplantation with human mesenchymal stem cells.
In addition to exogenous insulin therapy and islet transplantation, immune-based
intervention therapy and β cell regeneration/redifferentiation therapy are another two
essential categories for T1D treatment which hold great promise to success. In this
chapter, we will also discuss the current and advanced immunosuppressive small
molecular drugs working on different cell signaling pathways, and macromolecular
therapeutics such as monoclonal antibodies (mAbs), single chain variable fragments
(scFv), microRNA (miRNA), and small interfering RNA (siRNA) for mono- or combination
therapy. The goal of this chapter is to give a brief introduction and provide an insight into
promising and practical therapeutic approaches to prevent or treat T1D. At the end of this
chapter, several critical questions regarding the concerns of the current strategies and
future perspectives are brought up, which may advance the T1D research.
1.2. CURRENT THERAPEUTIC STRATEGIES TO TREAT TYPE 1 DIABETES
1.2.1. EXOGENOUS INSULIN THERAPY
Due to the massive inflammatory infiltration and dysregulated immune attack through
cross-talking of multiple mononuclear cells, the majority of pancreatic β cells gradually
lose the secretory function and are eventually destructed, leading to life-long insulindependence of T1D patients. Studies have shown that the event of β cell mass decreasing
happens even prior to the occurrence of T1D, and for individuals with long-term disease,
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around 70-100% of islet deficits are observed.11, 12 Therefore, exogenous insulin therapy
is the first and most commonly used regimen in the world. To overcome the hurdles
associated with regular insulin therapy, such as delayed action (15 – 30 min) after
subcutaneous administration due to the dissociation process of the hexamer structure,
transient efficacy (5 – 8 h), inaccurate dose, high-rate of hypoglycemia (three-fold
increase), and metabolic abnormalities,13 many practical and intellectual advances have
been made in the past decades.
1.2.1.1. Insulin pump and real-time continuous glucose monitoring
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study
Group conducted a clinical trial to compare the outcome of the change in the glycated
hemoglobin (HbA1c) levels between patients receiving intensive treatment with the insulin
pump in the presence or absence of continuous glucose monitoring system.14 The result
showed that the HbA1c levels of patients above 25 years old in the continuous-monitoring
group were changed significantly compared to self-monitoring group and the incident of
severe hypoglycemia was much rare, implying the necessity of real-time continuous
glucose monitoring for glycemic control. In another clinical trial, it has been demonstrated
that continuous glucose monitoring also promoted the treatment outcomes of adult T1D
patients who received daily multiple insulin injections.15 Utilizing the advantages of realtime continuous glucose monitoring, the insulin pump which is also known as continuous
subcutaneous insulin infusion (CSII) can be a more precious and compelling tool
compared to the conventional devices.16, 17
1.2.1.2. Innovative insulin analogues
Numerous innovative insulin analogues have been developed to improve the
management of T1D. This ideal insulin analogues with optimized glycemic control should
have a similar dynamic releasing pattern with the physiological insulin level, be long-acting
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to prolong the therapeutic efficacy, and react in a prompt, responsive, accurate and
targeted way based on the real-time fluctuation of blood glucose levels to minimize the
risk of hypoglycemia.13 The first generation insulin analogues in the market including
insulin lispro, insulin aspart and insulin glulisine, were designed as rapid-acting analogues
aimed to solve the problem of regular insulin which was the delayed action after
subcutaneous administration. Studies have demonstrated comparable efficacy and
superior safety profiles of these analogues compared to the regular basal insulin.18 After
then, the second generation long-acting insulin analogues appeared which had distinct
chemical structure and pharmacokinetic/pharmacodynamic (PK/PD) profiles with regular
insulin. For instance, insulin glargine provided a more stable insulin basal level, extended
insulin coverage (24 h), and significantly reduced incidence of hypoglycemia.19, 20
More researches are ongoing to advance the concept of innovative insulin analogues.
Shen and coworkers have designed a novel Proinsulin-transferrin (ProINS-Tf) fusion
protein which was administered as an inactive prodrug form to the animals. The
conversion to active form insulin-transferrin (INS-Tf) occurred specifically in liver cells
through transferrin (Tf) receptor mediated endocytosis/recycling pathway and decreased
blood glucose level in a relatively slow and sustained manner. As a result, the plasma halflife of this insulin analogue was improved, and the potential side effect was also
decreased.21, 22 In addition to insulin analogues, there are other distinct protein/peptide
analogues that may be equally efficacious in glucose-lowering activity. Fu’s group has
discovered a human glucagon-like peptide-1 (GLP-1)/Xenopus GLP-1 hybrid peptide
which exhibited even strengthened hypoglycemic effect and duration.23
1.2.1.3. Smart insulin delivery systems
In addition to the development of insulin analogues, smart drug delivery systems could
provide similar advantages such as enhanced insulin stability, long-term basal insulin
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coverage, precious release, overcoming the oral delivery barriers, and low toxicity. A
recent publication has demonstrated the advanced self-assembling polymer vesicles (PVs)
that possessed dual-stimuli responsiveness for the in vivo delivery of insulin. The PVs
were assembled from novel triblock copolymers composed of poly(ethylene glycol) (PEG)
which formed the hydrophilic corona, and poly(phenylboronic acid) (PPBA) as well as
poly(phenylboronic acid pinacol ester) (PPBEM) which formed the hydrophobic core. The
uncharged hydrophobic PBA block at the physiological condition changed to a charged
hydrophilic form upon exposure to high concentration of glucose (above 200 mg/dL). The
conversion could lead to rapid release of the encapsulated insulin to exert the
hypoglycemic effect. Then, the PBEM block was also sensitive to H2O2 and dissociated
under H2O2-enriched environment. Due to the excess H2O2 accumulation in the inflamed
islets,24, 25 the insulin release capability was further promoted. This glucose- and H2O2dual responsive insulin delivery platform exhibited superior glucose-lowering profile and
decreased cytotoxicity compared to traditional subcutaneous insulin injection.26 The
specific stimulus trigger release of encapsulated insulin was also achievable with other
polymeric blocks, such as a “smart insulin patch” system containing hyaluronic acid-based
vesicles which were sensitive to hypoxia,27 the insulin-loaded polyacrylic acid (PAA) and
polymethacrylic acid (PMA) hydrogels which had the potential to induce drug release upon
exposure to electrical stimuli,28 the chitosan/alginate nanoparticles conjugated with
peptide Cp1-11 which utilized the pH gradient for controlled insulin release.29
The polymeric nanoparticular approach could also be applied to improve the outcome
of oral insulin delivery by defecting multiple enzymatic/physical barriers and improving oral
insulin bioavailability, as well as to enhance patients’ convenience and compliance.30
Similarly, Yao and coworkers have designed chitosan-based nanocarriers functionalized
with the same PBA moiety for high-glucose responsiveness, and L-valine which could
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enhance the encapsulation efficiency, increase the transportation and absorption of insulin
in the small intestines. The result depicted that the stability of insulin in the presence of
digestive enzymes was remarkably enhanced with desirable releasing, uptake and
therapeutic profiles.31 Except for the chitosan-based nanocarriers, a variety of polymer or
lipid-polymer systems have been successfully designed and developed for optimized oral
insulin delivery such as dextran, alginate, polyglutamic acid, polycaprolactone (PCL), and
poly(lactic-co-glycolic acid).32-34
1.2.2. ISLET TRANSPLANTATION
1.2.2.1. Major obstacles to success islet transplantation
Islet transplantation has the potential to cure and release the insulin burden of T1D
patients, which is less invasive compared to whole pancreas transplantation. However,
the outcome is less satisfactory in the past decades with less than 10% insulinindependence after five years of the surgery.35 There are several major obstacles limited
the success rate and duration of normoglycemia of islet transplantation. 1) Primary
nonfunction, which is also known as instant blood-mediated inflammatory reaction,
induces massive islet graft loss within several hours after transplantation due to a rapid
inflammatory response.36 2) Autoimmune recurrence and immune rejection. As discussed
previously, T1D is a chronic autoimmune disease characterized by inflammatory cell
infiltration and production of proinflammatory cytokines which caused the destruction and
dysfunction of insulin secreting islet β cells.37 Without additional immune intervention,
transplanted islet grafts suffer from the same autoimmune attack as the remaining host
islets, including direct cell killing induced by Th1 CD4+ cells, β cell specific CD8+ cytotoxic
T cells and macrophages, as well as indirect toxicity from their soluble mediators such as
granzyme, perforin, cytokines (IL-1β, TNF-α, and IFN-γ) and free radicals.9, 10 What’s more,
compared to the host islets, the transplanted islet grafts are also challenged by adaptive
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immune rejections which further decrease the in vivo viability.38 3) Inadequate
revascularization. To improve the outcome and euglycemic duration after islet
transplantation, prompt and substantial revascularization is of great significance for
supplying oxygen and nutrients to support islet engraft and assure long-term survival as
well as insulin secretion.38 In these regards, approaches that augment the viability of
transplanted islet grafts, help to induce immune regulated environment and promote the
process of neovascular formation are in urgent need for islet transplantation mediated T1D
treatment.
1.2.2.2. Genetic engineering of transplanted islet grafts
Researchers have devoted much effort to improve the outcome of islet transplantation
through ex vivo transduction/transfection of genes of interest prior to in vivo application.
Based on the purpose of the targeted genes, the approaches of genetic engineering could
be categorized into modulation of cytokines and cytokine pathways, T cell co-stimulation,
anti-inflammation, anti-apoptosis, anti-oxidation, and revascularization.39 For instance, Wu
et al. transduced rat insulin secreting INS-1E cells and human islets with the gene of
human X-linked inhibitor of apoptosis (hXIAP) using adenoviral vectors (Adv) which
protected β cells from cytokine induced apoptosis and rendered extended normoglycemic
control after transplantation.40 Narang et al. constructed plasmids encoding human
vascular endothelial growth factor (hVEGF) to induce transient gene expression in human
islets, which demonstrated the capability to foster the initial revascularization and provided
a favorable growth environment for the transplanted islet grafts.41 Cheng et al. utilized
siRNA and adenoviral vectors encoding small hairpin RNA (shRNA) to silence the
expression of caspase-3 which aimed to inhibit the apoptosis of human islets. The results
showed that siRNA and Adv-shRNA induced short (less than 2 days) and relatively longer
(more than 5 days) downregulation of caspase-3, respectively. The in vivo administration
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of Adv-shRNA reverted blood glucose level of diabetic mice to normal range and
maintained for around two weeks.42 Thomas et al. transplanted syngeneic islet grafts
which transiently expressed transforming growth factor β (TGF-β), a well-studied
immunosuppressive cytokine, to hyperglycemic mice and concluded that the reduced
activation of dendritic cells contributed to the suppressed activation and infiltration of β cell
specific T cells, eventually ameliorated the extent of immune rejection.43
To further enhance the efficacy and duration of glycemic control, researchers
developed systems to simultaneously introduce two or more genes for targeting different
pathways. The combination of hepatocyte growth factor (HGF) and interleukin-1 receptor
antagonist (IL-1Ra) which promoted vascular formation/β cell proliferation and inhibited
apoptosis,44 and co-expression of VEGF and IL-1Ra,45 both proved to be effective. It is
worth mentioning that simultaneously engineering multiple genes may be more efficient;
however, it may also accompany with unexpected outcomes, such as the interference of
gene expression and increased side effects or toxicities.41 Therefore, more care and
evaluations should be performed before proceeding to animal studies.
1.2.2.3. Cell therapy: human mesenchymal stem cell co-transplantation and genetic
modification
Cell therapy, as one of the most popular emerging fields, holds great promise and
advantages over direct genetic engineering of transplanted islet grafts which always
suffers from low transduction/transfection efficiency and high safety concerns. Recently,
human bone marrow-derived mesenchymal stem cells (hBMSCs) have gained plenty of
interest that spans both basic and clinical fields owning to the unique merits, and explored
as an encouraging avenue in the areas of organ transplantation, tissue repair,
autoimmune and chronic diseases.46 1) hBMSCs possess multipotent properties, selfrenewal capability and the potential to differentiate into multiple lineages. 2) hBMSCs
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display potent modulatory competence on both innate and adaptive immune systems.
Researchers ascribed the mechanisms of the immunomodulation to cell contractdependent pathways and secretion of various soluble mediators including transforming
growth factor-β1 (TGF-β1), TNF-Stimulated Gene 6 (TSG6), prostaglandin E2 (PGE2),
HGF, indoleamine-pyrrole 2,3-dioxygenase (IDO), nitric oxide (NO) and interleukin-10 (IL10).46 As a result, hBMSCs can inhibit the proliferation of cytotoxic T cells, production of
pro-inflammatory cytokines, activation and maturation of dendritic cells as well as NK cells.
47

More importantly, hBMSCs have been demonstrated to hold distinct roles against

cytotoxic T cells and regulatory T cells (Tregs). The mesenchymal stem cells could
promote the population and function of Tregs, which in turn protected NOD mice from
developing diabetes and restored long-term immune tolerance.48 3) hBMSCs also produce
certain growth factors, cytokines and chemokines that exert paracrine/trophic effects to
support the survival, growth and function of transplanted organs.49 4) hBMSCs are known
as hypo-immunogenic cells due to the lack of surface expression of major
histocompatibility complex class II (MHC II) and most of the classical co-stimulatory
molecules, leading to fewer safety concerns in the clinical fields.50 5) hBMSCs have been
demonstrated to possess the potential to migrate to injured/inflamed sites after
intravenous injection and show strong binding affinity to islet grafts.51
Because of the immunoregulatory and supportive properties as well as the high
binding affinity, hBMSCs are widely utilized to co-transplant with human islet grafts for the
treatment of T1D.52 Researchers first transplanted hBMSCs alone to diabetic mice and
concluded that the majority of hBMSCs localized around host pancreatic islets and ductal
regions, promoted islet repair through β cell regeneration, but were not capable of transdifferentiating into β cells.53 After then, hBMSCs and human islet grafts were
simultaneously transplanted into humanized diabetic mice which prevented T cell
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infiltration and expanded the population of Tregs, accordingly, the rate and duration of
glucose reversal were significantly enhanced. The number of mice with insulinindependence in each group was increased with the ratio of transplanted hBMSC:islet.54
What’s more, the mesenchymal stem cells can be used as alternative vehicles for
genetic modification, instead of direct engineering of islets with virus-based vehicles which
are normally transient (less than two weeks) and associate with host immune attack and
safety concerns.52 Besides, islet cells as primary non-dividing cells are demonstrated to
be challenging to transduce/transfect with certain non-viral vectors.55 Thus, it is not
surprising that transduction/transfection of the hypo-immunogenic hBMSCs with genes of
interest, followed by in vivo co-transplantation with non-engineered human islet grafts
would achieve more remarkable glucose-lowering efficacy and less side effects. Plenty of
studies have been performed using this strategy, such as introducing human HGF or
VEGF and IL-1Ra genes to hBMSCs.52, 56 A recent study co-cultured human islets with
hBMSCs which transfected with plasmids simultaneously encoding shFas and anti-miR375. They observed potent downregulation of the expression of Fas and miR-375 not only
in the hBMSCs, but also in the islets, suggesting that the indirect genetic modification of
hBMSCs could also affect the gene expression of surrounding islets, which rendered
excellent in vivo viability of transplanted islet grafts and significant suppression of immune
rejection.57
1.2.3. SMALL MOLECULE DRUG BASED IMMUNE INTERVENTION
Due to the limitations of exogenous insulin therapy and islet transplantation, and the
risks of associated complications, it is more desirable to treat T1D with immune
intervention therapies through targeting the pathological autoimmunity and protecting the
remaining insulin secreting β cells from further destroying.58 In the past decades, small
molecular immunotherapeutic agents such as cyclosporin A, rapamycin and mycophenolic
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acid which are broad-spectrum immunosuppressive drugs, are widely used after organ
transplantation to suppress the immune rejection. Although effective in the beginning, the
therapeutic efficacy can not last long and are always accompanied by severe general
toxicity to other healthy organs. Besides, the non-specific deletion or suppression of
immune cells causes additional concerns.59 As a consequence, novel alternative
approaches of immune intervention for the treatment of T1D are under extensive
investigation, such as innovative inhibitors working on certain particular T1D pathways, or
therapies to induce tolerance to specific β cell autoantigens.
1.2.3.1. Tyrosine kinase inhibitor
Tyrosine kinase is a pivotal enzyme mediator that involves in multiple intracellular
signaling pathways and plays a critical role in a variety of biological processes such as
growth, differentiation, metabolism and apoptosis.60 Food and drug administration (FDA)
has approved a series of tyrosine kinase inhibitors (TKIs) for the treatment of malignant
cancers. Interestingly, scattered reports of clinical trials showed that certain TKIs induced
unexpected glycemic control for diabetic cancer patients or induced hypoglycemia for nondiabetic cancer patients,61 and allowed insulin-independence in one patient with 40-year
duration of T1D,62 which drawn researchers’ attention to study the immunosuppressive,
anti-inflammatory as well as glucose-lowering effect of TKIs for the treatment of T1D. In
the following study, imatinib (Gleevec) and sunitinib (Sutent), both belong to the family of
TKIs, were observed to prevent the occurrence and revert the recent-onset of T1D in mice,
followed by a remarkable duration of euglycemia after discontinuation of drug
administration for 10 weeks. The mechanism studies demonstrated that the inhibition of
the downstream target protein platelet-derived growth factor receptor (PDGFR) was the
key to the admirable outcome, suggesting that imatinib exerted glycemic control effect
mainly through inhibition of inflammation, and less relied on suppression of adaptive
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immunity.63 Another study described that imatinib showed the protective effect on
development of hyperglycemia with both spontaneous non-obese diabetes (NOD) mouse
model and streptozotocin (STZ)-induced diabetic mouse model.64
1.2.3.2. PI3K inhibitor
Phosphatidylinositide-3-kinase (PI3K)/Akt pathway has been widely studied for the
treatment of a variety of cancers which is crucial for cancer cell survival, proliferation and
differentiation. PI3K is commonly divides into four isoforms: while PI3Kα and PI3Kβ are
ubiquitously expressed in almost all cell types, PI3Kδ and PI3Kγ are preferentially
expressed in hematopoietic-origin leukocytes.65 Therefore, specifically targeted inhibition
of PI3Kδ and/or PI3Kγ can be utilized in the treatment of autoimmune and inflammation
related diseases to selectively inhibit the activation and proliferation of immune cells,
decrease the production of pro-inflammatory cytokines through NFκB pathway, and
eliminate the general toxicity against insulin secreting β cells which is unlike other small
molecular immunosuppressive drugs.66 Notably, the expression of Akt which is the
downstream target of PI3Kδ and PI3Kγ, is significantly less in regulatory T cells compared
to that in effector T cells, suggesting that inhibition of PI3Kδ and/or PI3Kγ has more
suppressive effect on cytotoxic T cells but not Tregs, making this approach even more
intriguing.67
Currently, PI3Kδ and PI3Kγ inhibitors are subjected to extensive research to prevent
or revert the pathological progression of T1D. AS605240 is a potent inhibitor of PI3Kγ
pathway which has been demonstrated to be highly activated in T1D. Experiments
displayed that administration of AS605240 indeed triggered the expansion of Tregs via
cAMP response element-binding signaling, while impeded the proliferation and infiltration
of autoreactive T cells through suppressing the phosphorylation of Akt. Consequently, the
result of preventing the development and reversing the onset of T1D using AS605240 was
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quite encouraging.67 To further confirm the role of PI3Kγ in T1D, NOD mice were
genetically engineered to knockdown the expression of PI3Kγ which exhibited similar
protective effect against T1D as the PI3Kγ inhibitor AS605240.68 Durand et al. utilized
IC87114, a selective inhibitor of PI3Kδ, and demonstrated the long-term protection to islet
β cells and capability to delay and reduce the loss of glucose homeostasis. However, in
addition to the anti-inflammatory and inhibitory effect to effector T cell, they proposed that
IC87114 also blocked the proliferation of B lymphocytes which potentiated the effect of
T1D prevention.69 Interestingly, an opposite effect of IC87114 was reported by another
group, claiming that although IC87114 greatly affected the production of pro-inflammatory
cytokines, it failed to prevent the initiation of T1D. Even worse, the administration of
IC87114 attenuated the anti-diabetic effect of CTLA4-Ig treatment with combination
therapy.70 The conflicting conclusions may be due to the different animal models they
selected: one was using the NOD spontaneous diabetic mouse model, and another one
selected the diabetogenic cell adoptive transfer mouse model. However, more
investigations should be made in future research.
1.2.3.3. TRAIL and TIMP-1 inducer
TNF-related apoptosis-inducing ligand (TRAIL) is a crucial modulator of the immune
system which has been proved to potently regulate the development of T1D. Systemic
administration of adenovirus encoding human TRAIL (Ad.hTRAIL) elicited remarkable
glucose-lowering and preventive effect against T1D in NOD mice, which could be
explained by the subsequent induction of tissue inhibitor of metalloproteinase-1 (TIMP-1)
and inhibition of matrix metalloproteinase (MMP), leading to the suppression of
diabetogenic T cell infiltration to the pancreas and prevention of insulin secreting β cells
from pro-inflammatory cytokine induced apoptosis.71 Furthermore, transgenic mice
overexpressing the downstream TIMP-1 also promoted β cell proliferation and protected
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mice from STZ induced hyperglycemia.72 On the other hand, blockage of TRAIL
expression exacerbated the occurrence of diabetogenic T cell adoptive transfer induced
diabetes.73 The following study showed that addition of TIMP-1 protein to rat islets or INS1 cells which were challenged by cytokine cocktails (IL-1β, TNF-α, and IFN-γ) at high
doses prevented β cells from dysfunction and death via inhibition of the NFκB pathway. 74
Given these findings, treatment with TRAIL or TIMP-1 inducer has excellent potential to
prevent the development or even revert the onset of T1D.
1.2.3.4. Modification of current small molecule drug
Chemical modification may provide a solution to the dilemma of the current small
molecular immunosuppressive drugs through conjugating to another compound to
minimize the toxicity while retaining the therapeutic effects. For instance, the widely used
mycophenolic acid (MPA) has been conjugated to a non-toxic compound quinic acid (QA)
which itself and its derivatives exert potent anti-inflammatory effect in the clinics. The
conjugation of MPA and QA through both ester and amide bonds demonstrated synergistic
anti-apoptotic effect against cytokine-induced death to islet β cells and associated with
significantly reduced cytotoxicity.75, 76
1.2.4. MACROMOLECULE DRUG BASED IMMUNE INTERVENTION
1.2.4.1. Antibody and single chain variable fragment
As we discussed in the previous section, the majority of the small molecular
immunosuppressive drugs, although often useful in short-term during administration, fail
to maintain the long-term effectiveness after discontinuity of the treatment. A variety of
antibodies have emerged in the clinics and elicit certain encouraging potentials for the
treatment of T1D. Most importantly, several antibodies are capable of inducing immune
tolerance and extending the duration of insulin-independence of T1D patients without
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additional treatment. At the same time, technologies of single chain variable fragments
(scFv) also have been developed which compose of a single heavy chain variable region
and a light chain variable region and join by a flexible linker. Compared to the intact
monoclonal antibody (mAb), scFv has comparable antigen-binding activity and less side
effects due to the lack of the non-specific Fc portion which normally contributes to the
burst release of cytokines and complement activation.77
Anti-CD3 monoclonal antibody
As one of the mAbs being tested in the clinical trials, anti-CD3 mAb was first used to
ameliorate immune rejection after organ transplantation. After then, anti-CD3 mAb was
found to be capable of reverting the onset of T1D and soon became a popular approach
in the field of T1D.78 The humanized anti-CD3 mAb hOKT3γ1(Ala-Ala) with a mutated Fc
portion has been demonstrated to preserve C-peptide response and decrease the level of
glycated hemoglobin (HbA1c) for newly diagnosed T1D patients for at least two years in
the absence of other immunosuppressive therapies.79 Valle et al. elucidated the
mechanism of anti-CD3 mAb for the remission of T1D as two phases: induction phase
during mAb administration which induced apoptosis and anergy of diabetogenic T cells,
and maintenance phase after the treatment which expanded the population of Tregs for
improved immune tolerance. They also proved the diabetes reversal effect of murine antiCD3 mAb 145-2C11 using NOD mouse model; however, this effect could be blocked by
the co-administration of rapamycin, suggesting the importance of selecting agents for
combination therapy.80 Another research, nevertheless, hold a different opinion on the role
of Tregs for the mechanism of anti-CD3 treatment. They concluded that the
immunoregulatory cytokine TGF-β was crucial for the effectiveness of anti-CD3 mAb,
while administration of anti-CD3 mAb did not increase the population of Tregs; at the same
time, depletion of Tregs did not alter the production of TGF-β.81 Furthermore, researchers
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have found that anti-CD3 mAb elicited distinct effects on different T cell subtypes, for
example, the induced transient depletion was more pronounced for CD4+ T cells than
CD8+ T cells, and anti-CD3 mAb exerted expansion but not deletion effect for Tregs. This
phenomenon could be explained by the heterogeneous levels of CD3 expression on the
cell surfaces.82
Anti-CD20 monoclonal antibody
The previous studies emphasized the critical role of T cells for the pathogenesis of
T1D in NOD mice, but not B cells, since the adoptive transfer of splenic T cells were more
efficient in inducing T1D than that of B cells.83 However, extensive evidences later also
pointed out the necessity of B cells in the development of T1D. The following studies
showed that early-stage depletion of B cells in NOD mice using anti-CD20 mAb decreased
islet inflammation and prevented diabetes in the majority of animals, at the same time,
late-stage depletion of B cells could delay, but not prevent the occurrence of the disease.84
Clinical trials of anti-CD20 mAb (Rituximab) exhibited similar effect as anti-CD3 mAb to
T1D patients, including improved C-peptide response, reduced glycated hemoglobin and
released insulin dependence, suggesting that anti-CD20 mAb is an alternative promising
therapeutic target for the treatment of T1D.85
Single chain variable fragment (scFv)
Although elicited remarkable efficacy of glycemic control in several initial clinical trials,
a common issue related to monoclonal antibodies is the safety concern. The non-specific
Fc-binding tends to induce burst production of pro-inflammatory cytokines, activation of
the complement system and elevation of anti-antibody immune responses.86, 87 As a result,
scFv is a perfect alternative of mAb because it lacks the non-specific Fc portion and is
less likely to generate severe side effects. Besides, scFv can be easily manipulated to
obtain relatively equivalent therapeutic efficacy and higher affinity compared to mAb. Aluri
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et al. has fused anti-CD20 scFv to a soluble protein polymer and demonstrated the
superior apoptotic effect of the fusion protein to B lymphoma cell lines compared to
Rituximab alone.87 Therefore, the Rituximab and anti-CD3 scFv can be investigated in the
future treatment of T1D which may lead to unexpected favorable outcomes.
1.2.4.2. Small non-coding RNA
The role of small non-coding RNAs such as miRNA, siRNA or shRNA in the initiation
and progression of a variety of diseases has been increasingly recognized and explored.
These small RNAs can reduce or inhibit the expression of target genes through binding to
and degrading the mRNAs with complementary sequences to regulate specific crucial
biological pathways.10 As a recent-emerging approach for the treatment of T1D, RNA
interference (RNAi) technology utilizing small non-coding RNAs has achieved plenty of
success. Tons of miRNAs with aberrant expression in T1D have been identified, such as
miR-24, miR-25, miR-26a, miR-27a, miR-27b, miR-29a, miR-30a-5p, miR-146, miR-148a,
miR-152, miR-181a, and miR-200a.88, 89 Several crucial small non-coding RNAs will be
discussed in this section.
miRNA-204 inhibitor (anti-miR-204)
The expression of miR-204 is relatively high in pancreatic islets, where the enrichment
of miR-204 occurs only in β cells as opposed to α cells. Besides, the environment of
diabetes/high glucose can further induce the overexpression of miR-204.90 A series of
studies have been performed to determine the underlying mechanisms and the
therapeutic potential of anti-miR-204 to treat T1D. First, miR-204 involves in the vascular
endoplasmic reticulum (ER) stress which is also known as unfolded protein response
(UPR), leading to cellular dysfunction and loss of viability in the development of diabetes.
Sirtuin1 (Sirt1) lysine deacetylase and protein kinase R-like ER kinase (PERK) are the
primary
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overexpression of Sirt1 mitigates the ER stress and reduces the production of reactive
oxygen species (ROS).91 Since β cells are more vulnerable to ROS attack and
inflammatory response due to the lack of antioxidant enzymes,92 anti-miR-204 can be a
potent tool to protect β cells from ER stress and ROS induced apoptosis in the
development of T1D. Second, miR-204 downregulates the expression of v-maf avian
musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) which is an insulin
transcription factor, and subsequently inhibits the level of insulin secretion of β cells.93
Third, miR-204 also exerts a pivotal function in the downregulation of glucagon-like
peptide 1 receptor (GLP1R) in T1D. Therefore, inhibition of miR-204 expression utilizing
anti-miR-204 can increase the production of insulin through upregulating the expression
of MAFA and GLP1R as well as promoting the generation of cAMP.94 Collectively, more
mechanistic studies are ongoing and inhibition of miR-204 can be a promising approach
for T1D treatment both alone and in combination with other therapeutics.
siRNA targeting Alox15 (siAlox15)
The gene Alox15 is responsible for the encoding of an enzyme highly expressed in
macrophages and pancreatic β cells, called 12/15-lipoxygenase, which has been proved
to play an essential role in the progression of T1D.95 The 12/15-lipoxygenase induces the
oxidation of a variety of polyunsaturated fatty acids to generate unstable intermediate
lipids with severe toxicity and pro-inflammatory activity.96 Genetic inactivation of 12/15lipoxygenase locus in NOD mice results in significantly decreased T1D initiation, reduced
islet inflammation, and improved mass and function of β cells, which are related with the
reduced number of macrophages and CD4+ effector T cells infiltrated in the islets and the
expanded population of Tregs.95 Besides, deletion of 12/15-lipoxygenase potently inhibits
the production of pro-inflammatory cytokines in macrophages at both protein and mRNA
levels; meanwhile, the splenocytes of 12/15-lipoxygenase deficient NOD mice lose the
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ability to transfer diabetes.97 Subsequent work further demonstrates that the aberrant
expression of 12/15-lipoxygenase in pancreatic islets alone is sufficient to induce
hyperglycemia. When the 12/15-lipoxygenase gene knockdown is specific to the pancreas,
the mice can also be protected from developing diabetes and show increased production
of insulin through upregulation of pancreatic anti-oxidant enzymes.98 Therefore, in vivo
delivery of siAlox15 is a potent and promising strategy for treating T1D. In one study,
siAlox15 was complexed with cationic lipids and short-course administration of the
complex upregulated T cell co-stimulation molecules such as programmed death 1 ligand
1 (PD-L1) and expanded Tregs which led to encouraging protection of NOD mice from the
occurrence of T1D.99 Furthermore, siAlox15 was also delivered utilizing cationic polymeric
micelles which demonstrated improved reversal rate of the new-onset of T1D, inhibited T
cell infiltration to the pancreas and preserved mass/function of islet β cells.37
1.3. QUESTIONS AND FUTURE PERSPECTIVES
Many of the current therapeutic approaches are, to some degree, effective to prevent
or halt the autoimmune destruction of β cells during the progression of T1D. However, the
following application in the clinics is always associated with certain disappointment and
unexpected pitfalls. The previous investigations may shed light on the future direction for
the disease treatment, and drive researchers to devote substantial effort and research
funding to discover and develop more suitable and reliable therapeutic approaches which
can truly cure T1D. Looking forward, there are several remaining issues and unanswered
questions that should be considered in the future which may expedite this process.
1.3.1. Will early intervention bring more satisfactory outcome? Which biomarker(s) should
be selected?
Investigation regarding the pathogenesis of T1D has shown that two or more β cell
specific autoantigens can be detected in children at high risk of T1D for months or years
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before the occurrence of the disease, and the progress of autoimmune mediated β cell
destruction is much advanced before the clinical diagnosis.100 At the time of the individual
being confirmed to be diabetic, over 70% of the pancreatic islets are permanently
destroyed, and the majority of the remaining islets are inflamed and compromised in
metabolic functions.4 In this context, it is not surprising that early intervention may be a
promising solution that is capable of rescuing the islets in danger, stopping critical loss of
β cells, and promoting the function of the remaining β cells.
However, for the purpose of early intervention, the concomitant urgent need is to
identify novel, precious and non-invasive biomarker(s) which can be used to closely
monitor and reflect the status of the pathogenesis of T1D. In addition to the conventional
β
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of

signaling/metabolic/apoptotic/inflammatory pathways in T1D can also be explored to exert
the function of biomarkers. For instance, studies showed that increased miR-21-5p level
was specific to β cell inflammation (insulitis),101 and upregulated expression of miR-21-5p
could be detected in the blood circulation of long-term T1D patients.102 Then, miR-375-5p
was reported as another circulating biomarker of T1D, however, which was specific to β
cell death but not inflammation.103 The results were quite encouraging since these
biomarkers could be detected several weeks before the occurrence of T1D in NOD mouse
model. More intriguingly, the authors proposed to measure the islet secreted exosomes
carrying these miRNA biomarkers which may advance this approach further, because
exosomes could protect miRNAs from serum enzymatic degradation and their content was
changed over the course of disease development, therefore, providing more accurate
information for the detection of the circulating miRNAs and the diagnosis of T1D.104
Increasing amount of innovative biomarkers are under investigation, and we can expect
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their wide application and consequent success in the early intervention of T1D in the near
future.
1.3.2. Can β cell regeneration/redifferentiation be effectively and safely induced and
applied in human?
A fascinating discovery about T1D patients with chronic duration is that a small portion
of islet β cells still remains functional even after more than 50 years of the disease
occurrence.105 Hypotheses about these remaining β cells include that these cells are less
immunogenic compared to other destroyed ones, or they are more resistant to the
autoimmune attack, or there are certain pathways existing to persistently compensate the
loss of β cells. No matter which mechanism is underlying this phenomenon, the remaining
β cells have the potential to be expanded to counteract the disease development.
Besides, although the autoimmune disorder induces massive damage to β cells in the
islets, other islet non-β cells such as α cells and γ cells are normal in both mass and
secreting function, even for patients who have been diagnosed with T1D for more than 5
years.5 The potential of β cell regeneration is low; however, researchers found that acute
nearly total-loss of β cells in a mouse model and administration of insulin induced the
reprogramming of glucagon producing α cells to regenerate insulin secreting β cells.106
Subsequent study transduced α cells with Adv encoding PDX1 and MAFA, which are both
β cell enriched transcription factors. Then α cells reprogrammed after the transduction to
produce insulin upon the stimulation of glucose, and reverted hyperglycemia after
transplantation into the mouse model which was demonstrated to be stable for several
months.107
Then, here raise other questions: Can the procedure of α cell reprogramming or β cell
regeneration be reliably induced in human without causing severe side effects? Will the
reprogramming affect the function of α cells to producing glucagon? How to control the
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amount of the conversion from α cells to β cells? These questions can only be answered
with further investigation.
1.3.3. What are the advantages of the combination therapy for the treatment of T1D?
Numerous efforts have been put to the translation of therapeutic approaches from
mouse models to clinical trials; however, monotherapies always fail in Phase III trials. After
decades of research, none of the current monotherapies can induce permanent prevention
or reversal of the disease progress and life-long insulin-independence, suggesting the
necessity of combination therapies. Ideally, immune intervention should be combined with
β cell augment therapy.4 Otherwise, immunoregulation alone cannot promote insulin
production to alleviate the hyperglycemia and halt the associated complications; on the
other hand, induction of β cell proliferation alone will continue to suffer from the
autoimmune attack. For instance, small molecular immunosuppressive drugs are
commonly applied to T1D individuals with islet transplantation to prevent autoimmune
recurrence and immune rejection, while tacrolimus, sirolimus and MPA elicit severe
negative effects on the viability and function of islets. However, these adverse effects can
be ameliorated by transducing XIAP gene to the islet grafts prior to transplantation.108 In
addition, the anti-CD3 mAb which potently regulates immune systems, and dipeptidyl
peptidase-4 (DPP-4) inhibitor which has the potential to promote the survival and function
of β cells, collectively generate stable remission of diabetes with new-onset NOD mice.109
Keep in mind that it is of critical importance to advisedly choose the combination.
Countless reports showed the negative impact of unreasonable selections, for example,
the reversal of T1D by anti-CD3 mAb can be mitigated by the co-administration of
rapamycin, cyclosporine A, anti-TGFβ, and anti-CTLA4 mAb through different
mechanisms.80, 110, 111
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1.4. CONCLUDING REMARKS
As one of the most challenging topics, type 1 diabetes is a chronic autoimmune
disease characterized by massive destruction and dysfunction of insulin secreting β cells,
which are induced by the synergistic interaction of a variety of immune cells and their
soluble mediators. Several current and advanced therapeutic approaches are discussed
in this chapter with the advantages and potential pitfalls. So far, none of these strategies
has the potential to successfully translate into the clinics, truly cure T1D with life-long
insulin-independence, and halt associated complications. Looking forward, several
innovative perspectives are brought up which may solve the problems and shed light on
the future directions.
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION OF
A NOVEL MYCOPHENOLIC

ACID - QUINIC ACID

CONJUGATE SERVED AS IMMUNOSUPPRESSANT WITH
DECREASED TOXICITY
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2.1. ABSTRACT
Mycophenolic acid (MPA) is one of the most commonly used immunosuppressive
drugs for improving the outcome of cell and organ transplantations. However, undesired
adverse effect of MPA impedes its application in the clinics for post-transplant patients.
We synthesized a novel immunosuppressant N-[2-[[(4E)-6-(1,3-dihydro-4-hydroxy-6methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-1-oxo-4-hexen-1-yl]amino]ethyl](1α,3R,4α,5R)-1,3,4,5-tetrakis(acetyloxy)cyclohexanecarboxamide (abbreviated as MQ4)
by conjugating MPA to quinic acid (QA) via amide bonds which exhibits improved stability
demonstrated by its incubation in vitro with human plasma, suggesting its better resistance
to hydrolytic degradation induced by plasma enzyme. While the immunosuppressive effect
of MQ4 on human lymphocyte proliferation was partially compromised as shown by flow
cytometry, significant decrease in cytotoxicity of MQ4 to insulin producing β cells could
compensate this drawback to some degree. There was decreased level of apoptotic
mediator caspase-3, which may contribute to the decreased toxicity of MQ4 to INS-1E
cells. MQ4 could further improve insulin stimulation index and down-regulate NFκB
expression than physical mixing of QA to MPA. Taken together, MQ4 is a promising
immunosuppressive agent for preventing and minimizing post-transplanted immune
rejection.
2.2. INTRODUCTION
Proper immunosuppressive therapy which prevents immune rejection is necessary to
improve the outcome of cell and organ transplantation. A variety of immunosuppressive
drugs such as tacrolimus, sirolimus, and cyclosporine either alone or in combination are
widely used in the clinics.112 While the combination of these immunosuppressive drugs is
effective, side effects accompanied with repeated administrations of these molecules limit
their long-term application. To find a balance point between the efficacy of
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immunosuppressive therapy to prevent acute rejection and their concomitant side effects
is the main impediment after transplantation.59
Mycophenolate mofetil (MMF, CellCept®), the pro-drug of mycophenolic acid (MPA),
has been used in the clinics to reduce post-transplant immune reaction. The mechanism
of MPA is specific, reversible inhibitor of the inosine monophosphate dehydrogenase
(IMPDH), preferably inhibiting both T and B cell proliferation by suppressing guanine
nucleotide biosynthesis.113, 114 He et al. claimed that T cell proliferation markers like TNFα and IFN-γ will be inhibited after stimulation, but not the production of IL-2 and expression
of surface antigen CD25 which served as activation markers.115 On the other hand,
Nguyen Le et al. observed that GTP and ErbB3-binding protein 1 (Ebp1) are required for
the regulation of rRNA synthesis and eventually T cell activation, therefore decreased
guanine level induced by MPA will inhibit lymphocytes proliferation as well as activation.116
Despite the potent efficacy, possibilities of inducing apoptotic mediators like caspase 3
and small mitochondria-derived activator of caspases (SMACs) through activation of
signal transducers and activators of transcription 1 (STAT1) or MAPK pathway or Fasassociated death domain (FADD)

10

restrict its wide applications. Severe adverse effects

of MPA such as alteration, discomfort, disability and even death have been reported. 117,
118

Type 1 diabetes, which remains the 7th leading cause of death and affects 9.3%
population in the United States (National Diabetes Statistics Report, 2014) was
exemplified in this study. Islet transplantation, the potential cure of type 1 diabetes is
hindered by autoimmune destruction and eventually progressive dysfunction of insulinproducing β-cells, leading to only less than 10% of normoglycemia in 5 years posttransplantation.10, 119 The toxicity of MPA on β-cells is the main drawback that limits its
application. Increase in the production of caspase-3, nitric oxide and JNK expression is
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the principal contributor to the dysfunction and apoptosis of β-cells after their exposure to
MPA.120
The non-toxic compound quinic acid (QA) and its ester derivatives exhibited
impressive anti-inflammatory effect as a nuclear factor kappa B (NFκB) inhibitor.121, 122 We
decided to synthesize stable conjugates of MPA and QA because of synergic effect of
MPA and QA in the apoptotic pathway. This is also because MPA shows poor
bioavailability if used alone due to glucuronidation mainly in the liver.123 QA also has poor
bioavailability due to its aromatization by gastrointestinal bacteria.122, 124 We previously
conjugated MPA to QA derivative, 3,4,5-tetrahydroxy-N-propylcyclohexanecarboxamide
(KZ41) via carbodiimide coupling, and demonstrated the immunosuppressive effect and
protective benefit to insulin production of the resulting compound JP-3-110.75 Since
stronger inhibition of NFκB nuclear translocation is reported to be observed by amide
substitution of QA at the position of carboxylic acid

122

as well as to further improve the

stability and decrease the toxicity, in this study we synthesized N-[2-[[(4E)-6-(1,3-dihydro4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-1-oxo-4-hexen-1-yl]
amino]ethyl]-(1α,3R,4α,5R)-1,3,4,5-tetrakis(acetyloxy)cyclohexanecarboxamide
(abbreviated as MQ4) by conjugating MPA to QA via the amide bond rather than ester
bond. We also synthesized a compound (4E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenamide (MQ5) to check whether the
modification of the end carboxylate group of MPA would alter its biological activity profile.
Here, we demonstrated the improved MQ4 stability, safety and insulin secretion to β cells,
and effectiveness to inhibit the alloreactivity of human peripheral blood mononuclear cells
(PBMCs).
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2.3. EXPERIMENTAL SECTION
2.3.1. Materials
RPMI 1640 medium, DPBS and 0.25% Trypsin were purchased from Hyclone (Logan,
UT). Fetal bovine serum (FBS) was purchased from Thermo Scientific (Waltham, MA).
Carboxyfluorescein succinimidyl ester (CFSE) cell division assay kit for human PBMC
proliferation assay was purchased from Cayman (Ann Arbor, MI). Caspase-Glo 3/7 Assay
kit was purchased from Promega (Madison, WI). Human IL-2, IL-2sRa and IFN-γ ELISA
kits, human IL-1β, human TNF-α, and rat IFN-γ for mimicking in vivo cytokine stimulation
were all purchased from R&D Systems (Minneapolis, MN). Insulin ELISA kits were
purchased from Calbiotech (Spring Valley, CA). RNeasy mini kit for RNA extraction was
purchased from Qiagen (Valencia, CA). Multiscribe reverse transcription kit was
purchased from Applied Biosystems (Foster City, CA). SYBR Green-I dye universal PCR
master mix was purchased from Roche (Indianapolis, IN). Primers were purchased from
Integrated DNA Technology (Coralville, IA). Pooled human liver microsomes were
purchased from Thermo Fisher Scientific (Grand Island, NY). Alamethicin was purchased
from Cayman (Ann Arbor, MI). Uridine 5′-diphosphoglucuronic acid trisodium salt (UDPGA)
was purchased from Sigma-Aldrich (St. Louis, MO).
2.3.2. Synthesis and characterization of MQ4 and MQ5
The synthesis of MQ4 and MQ5 followed a coupling route as outlined in Figure 2.1
Quinic acid tetraacetate 1 125 was converted to the active ester 2 in 77% yield using Nhydroxysuccinimide (HOSu) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)
in acetonitrile (CH3CN). The key intermediate amine 3 was obtained with 78% yield by
reaction of MPA with HOSu and EDCI followed by treatment with ethylenediamine.
Reaction of amine 3 and active ester 2 in CHCl3 resulted in the desired conjugate MQ4
with 35% yield. MQ5 was obtained with 65% yield by similar activation of MPA followed
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by treatment with ammonia. The structures of MQ4 and MQ5 were confirmed by 1H and
13

C NMR spectra. The control compound JP-3-110 was synthesized according to the

method reported in our previous paper.75
Synthesis of MQ4.
Step 1. To a mixture of quinic acid tetraacetate (1.44 g, 4 mmol) and HOSu (690 mg,
6 mmol) in CH3CN (20 mL) was added EDCI (1.15 g, 6 mmol). The mixture was stirred at
room temperature for 24 h before it was quenched with water (1 mL). After the mixture
was concentrated in vacuum, the residue was diluted with CH3CN (2 mL) followed by brine
(80 mL). After aging overnight, the resulting precipitate was collected by filtration and dried
to give the corresponding active ester 2 as a colorless solid (1.41 g, 77%). Melting point:
123-125 °C; 1H NMR (500 MHz, DMSO-d6) 1.96 (s, 3H), 2.03 (s, 3H), 2.06 (s, 3H), 2.16
(s, 3H), 2.22 (dd, J = 13.2, 11.2 Hz, 1H), 2.47-2.55 (m, 1H), 2.58-2.64 (m, 2H), 2.79 (s,
4H), 5.22 (dd, J = 10.1, 3.6 Hz, 1H), 5.31 (td, J = 10.7, 4.4 Hz, 1H), 5.41 (q, J = 3.4 Hz,
1H);

13

C NMR (125.7 MHz, DMSO-d6) 20.62, 20.85, 25.66, 31.06, 36.12, 66.03, 67.50,

70.69, 77.70, 166.20, 169.42, 169.64, 169.84, 169.89.
Step 2. To a mixture of MPA (1.61 g, 5 mmol) and HOSu (864 mg, 7.5 mmol) in CH3CN
(20 mL) was added EDCI (1.44 g, 7.5 mmol). The mixture was stirred at room temperature
for 24 h and was then added to a solution of ethylenediamine (6.01 g, 100 mmol) in water
(200 mL). After the mixture was stirred at room temperature for 2 h, it was adjusted to pH
= 8 with acetic acid (HOAc) (4 mL). The resulting precipitate was collected by filtration and
dried to give the corresponding amine 3 as a colorless solid (1.42 g, 78%). Melting point:
201-203 °C; 1H NMR (500 MHz, DMSO-d6) 1.72 (s, 3H), 1.98 (s, 3H), 2.15 (bs, 4H), 2.68
(bs, 2H), 3.08 (bs, 2H), 3.17 (bs, 2H), 3.62 (s, 3H), 5.04 (s, 2H), 5.11 (s, 1H), 7.70 (s, 1H).
Step 3. A suspension of the active ester 2 (457 mg, 1 mmol), amine 3 (398 mg, 1.1
mmol) and triethylamine (TEA) (202 mg, 2 mmol) in CHCl3 (20 mL) was stirred at room
temperature for 24 h. After evaporation of the solvent, the residue was treated with water
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(50 mL) and 1 M HCl (10 mL). The resulting precipitate was collected by filtration and dried
to give diamide MQ4 as a colorless solid (247 mg, 35%). Melting point: 72-74 °C; 1H NMR
(500 MHz, DMSO-d6) 1.73 (s, 3H), 1.81-1.89 (m, 1H), 1.94 (s, 3H), 1.98 (s, 3H), 2.04 (s,
3H), 2.07 (s, 3H), 2.08 (s, 3H), 2.07-2.14 (m, 4H), 2.29-2.36 (m, 1H), 2.37-2.44 (m, 1H),
2.49-2.56 (m, 1H), 2.89-3.09 (m, 4H), 3.29 (d, J = 6.8 Hz, 2H), 5.02 (dd, J = 10.3, 3.9 Hz,
1H), 5.11 (t, J = 6.6 Hz, 1H), 5.24 (s, 2H), 5.28 (td, J = 10.7, 4.4 Hz, 1H), 5.37 (q, J = 3.4
Hz, 1H), 7.69 (s, 1H), 7.92 (s, 1H), 9.31 (bs, 1H); 13C NMR (125.7 MHz, DMSO-d6) 11.21,
16.23, 20.63, 20.82, 20.91, 21.74, 22.56, 30.43, 34.40, 35.03, 37.43, 37.91, 39.01, 60.77,
66.57, 68.12, 68.80, 71.47, 80.45, 107.10, 116.14, 122.59, 122.64, 134.16, 145.94, 152.84,
162.73, 169.50, 169.70, 169.81, 169.86, 170.34, 172.14.
Synthesis of MQ5. To a mixture of MPA (644 mg, 2 mmol) and HOSu (346 mg, 3 mmol)
in CH3CN (10 mL) was added EDCI (576 mg, 3 mmol). After the mixture was stirred at
room temperature for 24 h, 28% aqueous NH4OH (1 mL, 7.1 mmol) was added. The
mixture was stirred at room temperature for 2 h, diluted with water (40 mL), and then
adjusted to pH = 8 with HOAc (1 mL). The resulting precipitate was collected by filtration
and dried to give amide MQ5 as a colorless solid (413 mg, 65%). Melting point: 178-180 °C;
1

H NMR (500 MHz, DMSO-d6) 1.73 (s, 3H), 2.08 (s, 3H), 2.03-2.16 (m, 4H), 3.29 (d, J =

6.8 Hz, 2H), 3.69 (s, 3H), 5.11 (t, J = 6.7 Hz, 1H), 5.24 (s, 2H), 6.66 (s, 1H), 7.19 (s, 1H),
9.35 (s, 1H);

13

C NMR (125.7 MHz, DMSO-d6) 11.22, 16.24, 22.58, 34.06, 34.99, 60.82,

68.78, 107.12, 116.12, 122.51, 122.65, 134.31, 145.95, 152.88, 162.75, 170.30, 173.97.
2.3.3. Solubility measurement
Excess amount (2.5 mg) of MQ4 or MQ5 was added into 1 mL PBS, followed by 24 h
shaking at room temperature. At the end of study, any undissolved particles were removed
by centrifugation for 5 min at the speed of 5000g for twice. The solubility of MQ4 and MQ5
were determined by high performance liquid chromatography (HPLC). The column we
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used was Inertsil® ODS-3 C-18, and the mobile phase was ACN: water (40: 60) at the
rate of 1 mL/min. Wavelength of MQ4 is 262 nm, of MQ5 is 255 nm. All samples were run
in triplicates.
2.3.4. In vitro plasma stability
To assess the in vitro stability profile, the stock solution of MQ4 dissolved in DMSO
was added to human plasma and vortexed for 2 min. The final concentration of DMSO,
MQ4 and human plasma were 1%, 50 g/mL and 50%, respectively.126 Samples were
incubated in a shaker at 37 °C. MQ4 was analyzed by HPLC after extraction from the
plasma as follows: At the end of incubation, 3 volume of cold ACN was added into each
sample tube to deproteinize the plasma, followed by shaking for 3 min, vortexing for 2 min,
and centrifuging at 4 ⁰C for 15 min at 5,000g.127 The supernatant was withdrawn and ran
for HPLC after filtration through 0.2 µm filter. The stability profile of the ester conjugate
JP-3-110 was obtained in the same manner and was used to compare with that of MQ4.
2.3.5. In vitro glucuronidation assay
To determine the role of glucuronidation played in MQ4 metabolism, we performed in
vitro glucuronidation study by using pooled human liver microsomes (HLMs). In a 500 µl
system, HLMs (0.5 mg/mL) and MgCl2 (5 mM) was suspended in PBS (pH 7.4). The
microsomes were activated by pore forming peptide alamethicin (50 µg/mg protein) for 15
min on ice and then pre-incubated with MQ4 (200 µM) or MPA (200 µM) for 5 min while
shaking at 37 °C. The reaction was carried out at 37 °C after addition of substrate UDPGA
(5 mM) and terminated by adding 3 volume of ACN after 0, 30 and 60 min. 123, 128, 129 The
remaining compound was extracted and analyzed by HPLC.
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2.3.6. Cell culture
Rat insulinoma INS-1E cells (a kind gift from Dr. Pierre Maechler, Geneva University)
were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS),
1% antibiotic-antimycotic, 10 mM HEPES, 1mM sodium pyruvate, 50 µM 2mercaptoethanol.130
2.3.7. Human PBMC proliferation
The inhibitory activity of MQ4 against IMPDH was elucidated by human PBMC
proliferation assay. Human PBMCs were labeled with carboxyfluorescein succinimidyl
ester (CFSE) and adjusted to 5 x 105 cells/mL in 12 well plates. After diffusion into the
cells, CFDA-SE can be cleaved to CFSE, generating fluorescence that is detectable with
flow cytometry. Every division of PBMCs will result in halving fluorescence signal of
daughter cells. Therefore, the percentages of each generation can be determined by the
intensity of CFSE signal.54 20 µM of MQ4, MPA, MQ5 and QA were added to PBMCs
followed by activation with phytohaemagglutinin (PHA) (5 µg/mL). After 6 days of
incubation, PBMC proliferation was determined by flow cytometry. The cytokine
production of IL-2, IL-2sRα and IFN-γ after 48 h incubation was examined by ELISA. All
samples were run in triplicates and the data were calculated as the mean of the three
individual experiments.
2.3.8. Caspase 3/7 activity
The activity of caspase 3/7 in INS-1E cells was determined by Caspase-Glo 3/7 Assay
kit per the manufacturer’s protocol. In 96-well plate, MPA (20 µM), MPA + QA (20 µM
each), QA (20 µM) and MQ4 (20 µM) were given to INS-1E cells for 24 and 48 h. Treated
cells in culture medium was mixed with Caspase-Glo 3/7 Reagent at the ratio of 1:1 and
incubated for 1 h at room temperature.131 Luminescence generated by caspase cleavage
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of DEVD sequence was measured by a multimode plate reader in a white-walled plate
(SpectraMax M5e, Molecular Devices, Sunnyvale, CA).
2.3.9. Cell viability
INS-1E cells were seeded in a 96 well plate at a density of 50,000 cells per well two
days before treatment. A variety of treatments were added to cells for indicated time (24,
48 and 72 h); cells without treatment and with 0.1% DMSO containing medium were
served as controls. At the end of the study, INS-1E cells were incubated with 0.5 mg/ml
3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) containing complete
medium for 3h in 37°C. The purple formazan crystals were dissolved by removing the
previous medium and adding 200 µL DMSO.40 The absorbance was measured in 560 and
630 nm using a microplate reader (BioTek, Winooski, VT).
2.3.10. Static insulin release study
INS-1E cells were treated with MPA (20 µM), MPA + QA (20 µM each), QA (20 µM)
and MQ4 (20 µM) for 72 h at 37 ⁰C. At the end of the study, INS-1E cells were preincubated in Krebs-Ringer bicarbonate HEPES buffer (KRB buffer) 54 for 30 min, and then
incubated in KRB buffer containing glucose at basal concentration (1.67 mmol/L) and
stimulated concentration (16.7 mmol/L) for 30 min. The collected supernatant was used
for insulin release analysis by ELISA. Insulin stimulation index was calculated as the ratio
of insulin release amount at stimulated glucose level to that at the basal glucose level.
2.3.11. Quantitative Real-time PCR
5 x 105 INS-1E cells were seeded in 12 well plated. A cytokine cocktail (0.5 ng/mL
human IL-1β, 1 ng/mL human TNF-α, and 1 ng/mL rat IFN-γ) which mimics in vivo
inflammatory challenge was added to each well followed by different treatment for 24 h.
The mRNA levels of IκBα in INS-1E cells were determined by RT-PCR.
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At the end of the treatment, INS-1E cells were lysed and the total RNA was extracted
using RNeasy Mini Kit. The concentration of total RNA was determined by UV
spectrophotometer at 260 nm. Multiscribe reverse transcription kit was employed to
convert 340 ng total RNA to cDNA with random hexamers in a volume of 20 µL system.
Then, in a 10 µL system, 2 µL cDNA and 8 µL SYBR Green-I dye universal PCR master
mix including primers were used as starting materials to run RT-PCR on a LightCycler 480
Instrument (Roche). The primer sequences are listed as below: rat IκBα, forward: 5'- AGT
AAC CTA CCA GGG CTA CTC -3'; reverse: 5'- ATA GCT CTC CTC ATC CTC ACT C -3';
rat GAPDH was used as the housekeeping gene, forward: 5'- GCA AGG ATA CTG AGA
GCA AGA G -3' reverse: 5'- GGA TGG AAT TGT GAG GGA GAT G -3'.
2.3.12. Statistical analysis
Results are presented as means ± SD. Unpaired t-test was used for comparison of
mean values. Asterisk * denotes statistically significant difference p < 0.05, and ** denotes
statistically significant difference p < 0.01.
2.4. RESULTS
2.4.1. Synthesis and characterization of MQ4 and MQ5
MQ4 was synthesized by first activating MPA and quinic acid tetraacetate with HOSu
and EDCI, followed by the reaction of the active ester 2 with the linker-bearing intermediate
amine 3. MQ5 was synthesized in a similar manner by adding NH4OH to the activated
MPA (Figure 2.1). The chemical structures of these two compounds were confirmed by
1

H and 13C NMR. Standard curves were generated with HPLC. The solubility of MQ4 was

calculated to be 0.53 ± 0.04 mg/mL which is very slightly soluble according to USP
solubility criteria; the solubility of MQ5 was determined to be 21.77 ± 0.34 µg/ml which is
practically insoluble (Figure 2.2A). The compound MQ5 and MPA were both dissolved in
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DMSO as a stock solution. MQ4 was also first dissolved in DMSO because of practical
handling difficulties to dissolve in water due to its stickiness. The final concentration of
DMSO was always 0.1% for all in vitro experiments to minimize its interference towards
INS-1E cells’ biological response except for human PBMC proliferation study which is
0.25%.

Figure 2.1. Synthesis scheme of MQ4 and MQ5.
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Figure 2.2. Solubility, in vitro plasma stability and glucuronidation characterization. (A)
Solubility of MQ4 and MQ5 were determined by HPLC after shaking in PBS for 24 h at room
temperature followed by centrifugation. (B) In vitro plasma stability curve of MQ4 and JP-3-110.
Stock solutions in DMSO were spiked in human plasma and incubated for indicated time. The
final concentration of DMSO, MQ4/JP-3-110 and human plasma were 1%, 50 g/mL and 50%,
respectively. Remaining of MQ4/JP-3-110 was analyzed by HPLC after extraction. (C) In vitro
glucuronidation study of MQ4 and MPA was performed in PBS containing pooled human liver
microsomes (0.5 mg/mL), activator alamethicin (50 µg/mg protein), MgCl 2 (5 mM). After
activated and pre-incubated with MQ4 or MPA (200 µM), the reaction was carried out at 37 ⁰C
after addition of substrate UDPGA (5 mM) and terminated by adding 3 volume of ACN after 0,
30 and 60 min. The remaining MQ4 and MPA was extracted and analyzed by HPLC. Results
are presented as the mean ± S.D., n = 4.
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2.4.2. Improved in vitro human plasma stability and decreased glucuronidation of MQ4
In vitro stability study of MQ4 was conducted in the early stage since compound with
less stability normally degraded fast, leading to poor in vivo bioavailability and efficacy.
Because of the plasma interspecies differences, we chose human plasma which
represented more real physiological condition. The recovery rate was 89.4 ± 2.7% after
MQ4 extraction from human plasma. Figure 2.2B showed that only slight degradation (4%)
after 4 h incubation, 19% degradation after 8 h incubation, and 38% degradation after 24
h incubation. Even after 48 h, 31% of intact MQ4 compound could be extracted from the
plasma. The stability profile of MQ4 was compared with that of the ester conjugate JP-3110 which showed over 70% of degradation within 24 h incubation. MQ4 exhibited good
stability after incubation in the human plasma, correlating potent resistance to enzymatic
degradation.
Clinically, MPA is subjected to extensive glucuronidation to form principal inactive
metabolite

mycophenolic

acid

glucuronide

(MPAG)

catalyzed

by

UDP

glucuronosyltransferase (UGT) mainly in the liver, resulting in rapid clearance and low
bioavailability.123, 128 Then we tested the glucuronidation susceptibility of MQ4 by using
human liver microsomes containing metabolic enzymes such as Cytochromes P450 and
UGT. HPLC analysis showed that the percentage of MQ4 remaining after 30- and 60-min
incubation was 1.15 and 1.8 fold compared with MPA, respectively (Figure 2.2C).
2.4.3. Immunosuppressive effect of MQ4 and MPA.
The immunosuppressive effect of MQ4 was determined by measuring CFSE intensity
of human PBMCs after PHA activation for 6 days. We observed that MPA and MQ5 held
similar inhibition on mitogen-induced proliferation of PBMCs, suggesting that amide
substitution of carboxylic acid of MPA did not affect its immunosuppressive effect. QA
treatment alone did not reduce the proliferation percent of PBMCs (Figure 2.3A). MQ4
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Figure 2.3. Immunosuppressive effect of MQ4, MQ5 and MPA on human PBMC
proliferation activated by PHA. (A) Flow cytometry results of the percentage of unproliferated
and proliferated PBMCs after activation by PHA (5 g/mL) and incubation for 6 days with MQ4
(20 M), MQ5 (20 M), MPA (20 M) and QA (20 M). CFSE was used for labeling PBMCs
and its intensity halved after each cell division. Black arrows indicate unproliferated cells. (B)
Relative PBMC proliferation index after incubation with MQ4 (10, 20, 30, 40 and 50 M), MQ5
(20 M), MPA (20 M) and QA (20 M) compared with cell activated by PHA only. MQ4
exhibited dose-dependent immunosuppressive effect. Results are presented as the mean ±
S.D., n = 3.

exhibited dose-dependent immunosuppressive effect. However, when compared with
MPA, the efficacy of MQ4 was partially compromised after conjugation to QA (Figure
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2.3B). These results can indirectly reflect the inhibitory activities of MPA, MQ5 and MQ4
against IMPDH since the restrained proliferation of immune cells due to the lack of de
novo guanine nucleotide biosynthesis was resulted from decreased IMPDH activity after
exposing to these compounds.
The cytokine production determined by ELISA revealed that after 48 h PHA stimulation,
the elevation of IFN-γ which represented lymphocyte proliferation level was reduced by
treatment of MPA and MQ4. Surprisingly, increase in the levels of IL-2 and IL-2sRα after
stimulation could also be partially reversed by exposing to both MPA and MQ4, indicating
their suppressive effect on lymphocyte activation, although the decreased level due to
MPA was greater than that of MQ4 (Figure 2.4). This could further confirm that both MQ4
and MPA can inhibit the activity of IMPDH, and sequentially lymphocyte activation as well
as proliferation.

Figure 2.4. Effect of MQ4 and MPA on IL-2, IL-2sRα and IFN-γ expression by human
PBMCs after mitogen-induced proliferation. PBMCs were activated by PHA (5 g/mL) for
48 h with MQ4 (20 M) and MPA (20 M). The levels of cytokine production (A) IL-2, (B) IL2sRα and (C) IFN-γ in the media were examined by ELISA. Results are presented as the mean
± S.D., n = 3.
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2.4.4. Decreased cytotoxicity and apoptotic effect of MQ4 to INS-1E cells
We determined whether conjugation with QA can reduce the pro-apoptotic effect of
MPA by determining the cytotoxicity of MPA, QA, MQ5 and MQ4. Figure 2.5A showed
that amide substitution of carboxylic acid of MPA cannot reduce its cytotoxicity to INS-1E
cells since MPA and MQ5 had similar levels of cell killing effect at the concentration of 20
µM (around 60% cell death at day 3 post incubation). INS-1E cells remained around 100%
viability after treated with 20 µM of QA. MQ4 did not show significant cytotoxicity up to 30
µM after 72 h incubation. Then, we performed caspase-3/7 pro-apoptotic assay. Treatment
of MPA induced higher amount of caspase -3/7 activity than that of MQ4 (7.82 fold higher
at 24 h and 9.18 fold higher at 48 h) and QA (8.88 fold higher at 24 h and 6.51 fold higher
at 48 h) (Figure 2.5B). The physical mixture of QA to MPA, however, could not decrease
the level of caspase-3/7.

Figure 2.5. Decreased cytotoxicity and caspase-3/7 activity in rat INS-1E cells were
shown by MQ4. (A) INS-1E cells were treated with MQ4 (20 M), MPA (20 M), MQ5 (20 M)
and QA (20 M) for 24, 48 and 72 h. Cell viability was determined by MTT assay (0.5 mg/mL)
at the end of study. 0.1% of DMSO was added to cells to serve as DMSO control. (B) MQ4
showed significant reduction in caspase-3/7 accumulation. INS-1E cells were received
treatment of MPA (20 µM), MPA + QA (20 µM of each), MQ4 (20 µM) and QA (20 µM).
Caspase-Glo 3/7 reagent was mixed with cultured media after 24 and 48 h incubation for 1 h
at room temperature. Levels of caspase-3/7 were assessed by measuring luminescence.
Results are presented as the mean ± S.D., n = 3.
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2.4.5. Uncompromised insulin release level with MQ4.
Static Insulin release study was assessed on INS-1E cells treated with MPA, MPA/QA,
QA and MQ4 (20 M) for 72 h. As expected, physical addition of QA to MPA could reverse
the impairment of INS-1E cells to release insulin, leading to the increase in the stimulation
index from approximate 1.8 to 3.0, similar with the index of INS-1E cells treated with QA
alone. This could prove the potential of QA to partially rescue the weakened insulin release
function of INS-1E cells which related with their compromised viability after MPA treatment.
MQ4 treatment could increase the stimulation index to 4.2, which was about 2.3 times
higher than that of MPA treatment alone (Figure 2.6A).

Figure 2.6. Effect of MQ4 on insulin release by INS-1E cells and NFκB pathway. (A) Insulin
stimulation index was employed to assess capacity of INS-1E cells to secrete insulin after
challenging with MQ4 (20 µM), MPA (20 µM), MPA + QA (20 µM of each) and QA (20 µM).
After 72 h incubation, insulin production by INS-1E cells in KRB buffer containing basal glucose
level (1.67 mM) and stimulated level (16.7 mM) was analyzed by ELISA. Insulin stimulation
index was calculated and showed in the figure. (B) Relative mRNA expression of IκBα which
inhibit NFκB translocation to nucleus was determined by RT-PCR. A cytokine cocktail (0.5
ng/mL human IL-1β, 1 ng/mL human TNF-α, and 1 ng/mL rat IFN-γ) was added to INS-1E cells
followed by treatment with MQ4 (20 µM) and MPA (20 µM) for 24 h. Results are presented as
the mean ± S.D., n = 3.
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2.4.6. Suppression of NFκB activity.
We mentioned that inhibitory protein IκBα suppresses NFκB translocation to the
nucleus in the unstimulated conditions. The mRNA expression of IκBα was determined. A
cytokines cocktail (IL-1β, TNF-α and IFN-γ) was added to INS-1E cells followed by
treatment with MPA or MQ4 (20 µM) for 24 hours. The mRNA expression of IκBα was
determined by RT-PCR. Compared with the group exposed to cytokines only, 40% of
reduction in the mRNA level of IκBα was observed when the cells were treated with MPA.
However, after treatment with MQ4, this reduction was reversed and further increased to
63% more expression (Figure 2.6B). The augment in IκBα level correlated with
suppressed NFκB activity.
2.5. DISCUSSION
Studies have shown MPA as a promising anticancer agent as well as a potent
immunosuppressant for cell and organ transplantation. The mechanism of MPA to
suppress and prevent immune rejection is by inhibiting de novo guanine nucleotide
biosynthesis and preferably decreasing T and B lymphocyte proliferation due to their
stringent requirement of purine nucleotides. Drawbacks of MPA regimen mainly include 1)
poor bioavailability because of its glucuronidation susceptibility; 2) long-term
administration induced health burden. In the case of islet transplantation for treatment of
type-1 diabetes, while suppressing immune rejection, MPA also cause severe side effects
and toxicity to islet grafts, leading to graft failure. A variety of modifications have been
made to MPA to address these issues.132, 133 However, some functionalities of MPA seem
to be crucial to maintain its potency, such as the double bond on the side-chain and the
C-7 phenolic hydroxyl group.134,

135

Minor changes can be detrimental to its

immunosuppressive effect. In this study, we first modified the carboxylate group on the
end of the side chain to amide group after activating MPA with HOSu and EDCI to obtain
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MQ5. We then determined whether this modification changes its immunosuppressive
effect or its cytotoxicity. Figure 2.3 shows that MQ5 had similar inhibitory effect against
human lymphocyte proliferation due to activation by PHA when compared with MPA at the
same concentration. MQ5 also induced comparable level of cytotoxicity to INS-1E cells as
shown in Figure 2.5A. These results demonstrated no significant change in biological
activity of MPA after this minor modification. Although MQ5, the simplest amide derivative
of MPA, is a known compound, its inhibitory activity against IMPDH has not been reported.
We choose MQ5 as a control to examine the function of the amide linker that lacks the QA
part. Our data suggest that the amide linker alone does not reduce toxicity of MPA,
supporting our view that QA is required to prevent serious side effects.
Previously, we reported the synergic effect of QA and MPA on the inhibition of NFκB
pathway. The synthesized compound JP-3-110 by conjugating MPA and KZ41 via an ester
bond, although effective in immunosuppression and some degree of protection to insulin
producing β cells, was facing issues like stability and difficulties in synthesis process.75 To
further improve the clinical outcomes, different route of conjugation was explored in this
study for better effect and high stability. Linker ethylenediamine was reacted with HOSu
and EDCI activated MPA, and then conjugated with similarly activated quinic acid
tetraacetate in the presence of triethylamine. The in vitro plasma stability study was
performed to demonstrate our hypothesis. Based on the literature research, we
determined the assay condition: 1%, 50 g/mL and 50% as the final concentration of
DMSO, MQ4 and human plasma, respectively. Over 24 h incubation, only approximately
39% of MQ4 was degraded (Figure 2.2B), suggesting its improved plasma enzymatic
stability against hydrolytic degradation when compared to conjugation via the ester bond
in which over 70% of JP-3-110 loss could be observed. Because that glucuronidation at
7-phenolic group is the principal metabolic pathway of MPA, we then investigated the
glucuronidation profile of MQ4 that we were not sure that whether glucuronidation was still
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the major clearance pathway. Although similarly there was no protective group to 7-OH in
MQ4, slightly higher percentage of MQ4 remaining was obtained after 30 and 60 min
incubation with human liver microsomes. Strategies need to be developed to further
decrease the glucuronidation reaction of conjugate in the future study. Combined together,
our hypothesis is that both the hydrolytic and metabolic stability improvement of MQ4
conjugate can simultaneously perform the function of MPA and QA: QA can synergistically
act with MPA on NFκB pathway, at the same time, it can also mask MPA toxicity to cells
and organs.
MQ4 exhibited dose-dependent, however partially compromised immunosuppressive
effect after conjugation. Besides, ELISA results suggest the impeded human lymphocyte
proliferation as well as activation by both MQ4 and MPA. There is a controversy of whether
MPA can suppress lymphocyte activation. Reduction of the human lymphocyte activation
marker IL-2 receptor (CD25) both in vitro and in vivo has been reported by several labs.113,
136

This dissimilarity may be caused by different experiment conditions such as MPA

concentration, types of stimulation, time of incubation and methods of analysis.
The cytotoxicity and insulin release profile of MQ4 to INS-1E cells were assessed.
Level of caspase-3/7 activity is a good indicator of apoptosis. Upon stimulation, both signal
transducers and activators of transcription 1 (STAT1) or MAPK pathway or Fas-associated
death domain (FADD) are known to activate effector caspase-3 induced apoptosis.10
Silencing of caspase-3 gene through siRNA has been proven to prevent both apoptosis
of INS-1E cells and human islets induced by cytokines.42 Our previously reported
conjugation JP-3-110 via an ester bond has been demonstrated its reduced caspase-3
expression was less than twice compared with MPA treatment.75 In this paper, however,
we observed significant reduction in caspase-3 level of MQ4 which is 7.82 fold at 24 h and
9.18 fold at 48 h lower than that of MPA (Figure 2.5B), suggesting much potent protective
effect of MQ4 against apoptosis. MTT assay further confirmed this effect. Upon 72 h
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incubation, treatment of MPA or MQ5 alone in the absence of inflammatory cytokine
produced more than 60% of apoptotic cell death, while at the same time conjugation of
QA to MPA capable of reversing the cytotoxicity. MQ4 not only induced less cell killing,
but also have beneficial effect on insulin release by β cell. Insulin stimulation index was
employed since it could better reflect the changes of insulin producing capacity after both
intrinsic and extrinsic stimulations by expression with the ratio of insulin release level at
the stimulated glucose level to that at the basal glucose level. Figure 2.6A shows that
MQ4 had the highest stimulation index, about 1.5 times higher than the control group and
2.3 times higher than MPA treated group by taking the advantage of the protective effect
of MQ4. Taking together, MQ4 can improve insulin release by β cells with less toxicity.
2.6. CONCLUSION
In

summary,

we

have

demonstrated

the

prolonged

stability

of

a

new

immunosuppressive compound MQ4 which synthesized by conjugating MPA to QA using
ethylenediamine

through

amide

bonds.

Although

exhibited

decreased

immunosuppressive effect, this conjugate provided less cytotoxicity and improved insulin
release profile. Further investigation is needed to test its in vivo stability and efficacy.
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3.1. ABSTRACT
Type 1 diabetes (T1D) is a chronic autoimmune disease caused by proinflammatory
T cell infiltration associated cytokine secretion and reactive oxygen species (ROS)
production. In this study, our objective was to determine whether co-delivery of sunitinib,
a member of tyrosine kinase inhibitor (TKI) family, and siRNA against Alox15 (siAlox15)
could reverse the new-onset of T1D in non-obese diabetic (NOD)/ShiLtJ female mice
which spontaneously develop diabetes. A cationic copolymer methoxy poly(ethylene
glycol)-block-poly(2-methyl-2-carboxyl-propylene

carbonate-graft-dodecanol-graft-

tetraethylenepentamine) (mPEG-b-PCC-g-DC-g-TEPA) was used to encapsulate
sunitinib with 8.32-9.39% loading efficacy and form complex with siAlox15 at the N/P ratio
of 16:1. These micellar formulations exhibited sustained release of sunitinib for around
50 % at 24 h and protected siAlox15 from serum degradation for at least 10 h. Further,
both sunitinib and siAlox15 inhibited human peripheral blood mononuclear cell (PBMC)
proliferation and activation by downregulating the phosphorylation of Akt, platelet-derived
growth factor receptor (PDGFR) at protein levels and Alox15 in mRNA levels, respectively.
Besides, siAlox15 treatment reversed the cytokine induced ROS upregulation in rat INS1E β cells. Finally, systemic administration of these micelles carrying sunitinib and
siAlox15 efficiently reversed T1D in NOD mice as indicated by decreased blood glucose
concentration to below 250 mg/dL. The mice showed fast response to high glucose which
was determined by intraperitoneal glucose tolerance test and promoted serum insulin
production. Tissue staining indicated that sunitinib and siAlox15 combination could inhibit
T cell infiltration to mouse islets, thereby promoting islet survival and function. In summary,
our results demonstrated that combination therapy of sunitinib and siAlox15 could be a
novel, reliable and safe approach for patients who were recently diagnosed with T1D.
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3.2. INTRODUCTION
Type 1 diabetes (T1D) is a chronic autoimmune disease caused by autoreactive T cell
infiltration, accompanied by proinflammatory cytokine secretion and reactive oxygen
species (ROS) production due to genetic predisposition and environmental factors.9, 58, 137
These pathological changes induce the activation of β cell specific autoantigens and
disturb the balance of effector and regulatory T cells (Tregs), eventually lead to β cell
dysfunction and apoptosis. Exogenous insulin therapy which is the current standard
regimen, however has limitations such as unprecise glucose control, risk of hypoglycemia
due to the constant blood glucose fluctuation, and most importantly, it could not cure
T1D.138 Compared to insulin therapy, regimens that target the pathologic autoimmune
system and pancreatic β cells are more promising and preferable. By impairing adaptive
and innate immune systems as well as reestablishing long-term immune tolerance,
immunotherapies could protect β cells from T cell attack and preserve their functions of
producing insulin and C-peptide which have been demonstrated in both mouse model and
phase I/II clinical trials.79, 80, 139, 140 Therefore, immunotherapies are gaining increasing
attention for preventing or reversing the new-onset of T1D.
Previously, sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI), was approved for
the treatment of renal cell carcinoma (RCC), gastrointestinal stromal tumor and metastatic
neuroendocrine tumors by inhibiting tumor angiogenesis, metastasis and progression.141143

Researchers anecdotally observed that TKIs could induce high glucose level remission

in several diabetic cancer patients or induce hypoglycemia in non-diabetic patients.61, 144
These results draw researchers’ interest to investigate the function of TKIs in the treatment
of T1D. The mechanism of sunitinib and other TKIs to decrease blood glucose level is not
clear so far, however, several groups had correlated it with sunitinib’s roles in inhibiting
the phosphorylation of multiple protein receptors like vascular endothelial growth factor
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receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) which are the key
targets of sunitinib.63, 145-147 Similar to other traditional anti-cancer drugs, monotherapy
using sunitinib showed a variety of adverse effects including hematologic toxicity, dermal
toxicity, gastrointestinal reactions, cardiac and skin disorders.141, 148
Arachidonate 12/15-lipoxygenase (Alox15) which belongs to the lipoxygenase enzyme
family was encoded by Alox15 gene and highly expressed in pancreatic β cells and
macrophages.96,

97

This enzyme plays an important role in the pathogenesis of T1D

because Alox15 oxidizes polyunsaturated fatty acids including arachidonic acid and
linoleic acid to generate toxic unstable proinflammatory lipids and will soon convert to a
more stable compound 12- hydroxyeicosatetraenoic acid (12-HETE). Studies have
demonstrated that 12-HETE induces pancreatic oxidative stress and local inflammation
by releasing reactive oxygen species (ROS) and cytokines, eventually leading to
apoptosis of β cell and decreased insulin secretion.149,

150

Researchers genetically

modified NOD mice to globally inactivate Alox15 expression (NOD-Alox15null mice) and
monitored for glucose level which showed that Alox15 deficiency resulted in significant
reduction in T1D incidence.95 Furthermore, silencing of 12-lipoxygenase gene expression
in islets also protected mice from the development of hyperglycemia after low-dose
streptozotocin or high-fat diet treatment.98 This study suggested that Alox15 knockdown
in murine islets alone was sufficient to reverse the onset of T1D. Besides, a group recently
screened two Alox15 inhibitors, ML127 and ML351.150 Both inhibitors could attenuate the
oxidative stress and preserve the viability and function of mouse and human β cells. Thus,
Alox15 might be a potent therapeutic target to inhibit the immune response and reverse
the islet damage in T1D.
To downregulate Alox15 expression, small interfering RNA (siRNA) against Alox15
(siAlox15) was used. siRNA is a double stranded RNA duplex of 21-25 base pairs which
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degrades target mRNA with complementary sequences. Due to the fast enzymatic
degradation in the serum, poor cellular uptake, and rapid renal clearance, 151 we will use
cationic

copolymer

methoxy

poly(ethylene

glycol)-block-poly(2-methyl-2-carboxyl-

propylene carbonate-graft- dodecanol-graft-tetraethylenepentamine) (mPEG-b-PCC-gDC-g-TEPA) for co-delivery of sunitinib and siAlox15 in this study. This copolymer is
composed of hydrophilic and hydrophobic sections for micelle formation and cationic lipid
chains for siRNA complexation via electrostatic interaction.152 The developed formulation
was characterized for particle size, zeta potential, sunitinib loading, siAlox15 complexation,
dissociation, stability and transfection efficiency. Then, in vitro and in vivo efficacy and
underlying mechanisms of the formulation on T1D was subsequently tested using human
PBMCs, rat insulinoma β cell line INS-1E cells and NOD mice which spontaneously
develop T1D. Our results demonstrated that combination of sunitinib and siAlox15 using
mPEG-b-PCC-g-DC-g-TEPA could efficiently inhibit the autoimmune reaction and thereby
reverse the onset of T1D.
3.3. MATERIAL AND METHODS
3.3.1. Materials
RPMI 1640 medium, Dulbecco's phosphate-buffered saline (DPBS) and 0.25%
Trypsin were purchased from Hyclone (Logan, UT). Heat inactivated fetal bovine serum
(FBS), antibiotic-antimycotic, sodium pyruvate for cell culture, RIPA buffer for cell lysis,
halt™ protease and phosphatase inhibitor cocktail (100X) and Pierce™ BCA protein assay
kit were purchased from Thermo Fisher Scientific (Waltham, MA). HEPES buffer and
Phytohemagglutinin (PHA) were purchased from Millipore Sigma (St. Louis, MO).
Carboxyfluorescein succinimidyl ester (CFSE) cell division assay kit was purchased from
Cayman (Ann Arbor, MI). Human Interleukin 2 (IL-2) and Interleukin 2 soluble receptor α
(IL-2sRα) ELISA kits were purchased from R&D Systems (Minneapolis, MN). Antibodies
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against Akt, PDGFR, phospho-PDGFR and β-actin were purchased from Santa Cruz
Biotechnology (Dallas, TX). Phospho-Akt (Ser473) antibody was purchased from Cell
signaling technology (Danvers, MA). 4 x Laemmli buffer, 10x Tris/Glycine/SDS protein
electrophoresis running buffer (pH 8.3) and 10 X TBS buffer were purchased from BioRad (Hercules, CA). Odyssey blocking buffer was purchased from LI-COR (Lincoln, NE).
ROS-ID Total ROS/Superoxide Detection Kit was purchased from Enzo Life Sciences
(Farmingdale, NY). CellTiter-Blue® Cell Viability Assay kit was purchased from Promega
Corporation (Madison, WI). Ultra Sensitive Mouse Insulin ELISA Kit was purchased from
Crystal Chem (Elk Grove Village, IL). Sunitinib (free base) was purchased from LC
Laboratories (Woburn, MA), and siRNA against Alox15 was purchased from Thermo
Fisher Scientific (Waltham, MA) (sense sequence: GCGAUUUCGAGAGGACAAATT;
antisense sequence: UUUGUCCUCUCGAAAUCGCTG).
3.3.2. Cell Culture
Freshly isolated human peripheral blood mononuclear cells (PBMCs) were received
from the Elutriation Core Facility of the University of Nebraska Medical Center (UNMC)
and were tested negative for human pathogens. PBMCs were cultured in RPMI-1640
medium supplemented with 10% FBS. INS-1E cells are rat insulinoma cells which were
kindly provided by Dr. Pierre Maechler (Geneva University). INS-1E cells were cultured in
RPMI-1640 medium supplemented with 10% FBS, 1% antibiotic-antimycotic, 10 mM
HEPES (pH 7.4), 1mM sodium pyruvate, 50 µM 2-mercaptoethanol.130 All cells were
cultured in an incubator maintained at 37⁰C and 5% CO2.
3.3.3. Preparation and Characterization of Micellar Formulations
Thin film rehydration method was used to prepare micellar formulations. For sunitinib
encapsulation, mPEG-b-PCC-g-DC-g-TEPA and sunitinib were co-dissolved at the ratio
of 10:1 in methanol/chloroform 1:1 (v:v). These organic solvents were evaporated in a
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rotary evaporator at low pressure to form thin film which was rehydrate with PBS and
vortexed for 3 min to form micelles. Any un-encapsulated free drug was removed by
centrifugation at 5,000g for 5 min. For complex formation, siAlox15 was dissolved in 0.1
M HEPES buffer (pH 6.5) and added to the polymer thin film. The mixture was vortexed
for 5 min, followed by standing at the room temperature for 30 min to allow complete
complexation. Similarly, for co-encapsulation, the film of sunitinib and cationic polymer
mixture was rehydrated with siAlox15 in 0.1 M HEPES buffer (pH 6.5), vortexed for 5 min
and left at the room temperature for 30 min.
Particle size distribution, polydispersity index (PDI) and ζ potential of a variety of
formulations including blank micelles, polymer and siRNA (N:P ratio = 16:1), polymer and
siRNA (N:P ratio = 32:1), polymer and sunitinib (10% theoretical drug loading), and the
combination of polymer, siRNA and sunitinib were measured by dynamic light scattering
(DLS) using a Malvern Zetasizer. The morphology of loaded micelles was also
characterized with transmission electron microscopy (TEM). Sunitinib loading was
quantified using high performance liquid chromatography (HPLC) equipped with Inertsil
ODS-3 C-18 column (4.6 x 250 mm). The mobile phase was consisted of the mixture of
methanol/acetonitrile/water/trifluoroacetic acid (TFA) at the ratio of 38/20/42/0.1. The
maximal absorbance wavelength is 267 nm and the flow rate was set as 1 mL/min. To
dissociate the micelles, 100 µL of sunitinib formulation was dissolved in 300 µL of
methanol followed by passing through 0.2 µm filter, and then injected into the instrument.
All samples were run in triplicate.
3.3.4. Drug Release Study
The release profile of sunitinib from polymeric micelles with or without siAlox15
complexation was characterized by dialysis using Float-A-Lyzer G2 device (Spectrum labs)
with cutoff size of 3.5 - 5 kDa. The device filled with 1 ml freshly prepared formulation was
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added into 80 ml of PBS supplemented with 1% Tween 80 as releasing medium for sink
condition while shaking at 37 °C. Time points were selected as 0, 3, 6, 12, 24, 48 and 72
hours, and at each time point, 1 mL releasing medium was withdrawn for HPLC analysis
while 1mL fresh medium was added to the container. All samples were run in triplicate.
3.3.5. Characterization of siAlox15 Complexation, Dissociation and Stability
To determine the proper N:P ratio of cationic polymer/siRNA complexation, gel
retardation assay was performed.153 A series of thin films containing different amount of
cationic polymer including 2, 4, 8, 16, 32 and 64 µg were prepared. Then, 1 µg of siRNA
in 100 µL of 0.1 M HEPES buffer (pH 6.5) was added to each vial. Followed by vortexing
and standing at the room temperature, cationic polymer/siRNA complex with N:P ratio
(w:w) of 2:1, 4:1, 8:1, 16:1, 32:1 and 64:1 were formed. After mixing with loading dye,
formulations were loaded onto 1% agarose gel with ethidium bromide to check the
complexation status under UV illumination using GelDoc Ez system (Bio-Rad, Hercules,
CA). To check the complex dissociation after encountering polyanion, cationic
polymer/siRNA complex at the ratio of 16:1 was prepared and aliquoted to incubate with
different amounts of heparin sulfate. The ratio of siRNA to heparin sulfate was selected
as 1:1, 1:2, 1:4, 1:8, 1:16 and 1:32 (w/w ratio). The complex and heparin sulfate was mixed
and incubated at 37 ⁰C for 45 min followed by agarose gel electrophoresis. Furthermore,
to examine the protective effect of complexation to siRNA against plasma degradation,
free siRNA and polymer encapsulated siRNA was incubated with 50% FBS in PBS for
indicated time periods, including 0, 1, 2, 4, 6, 8, 10, and 24 hours. The mixture was then
reacted with heparin sulfate (8 µg per 1 µg of siRNA) at 37 ⁰C for 45 min and run on
agarose gel to check the remaining of siRNA.
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3.3.6. In Vitro Proliferation of Human PBMCs
Human PBMCs are populations of human immune cells and thus were used for the
immune system related experiments. Briefly, freshly isolated human PBMCs were labelled
with carboxyfluorescein succinimidyl ester (CFSE) prior to activation by the mitogen
phytohemagglutinin (PHA) (2 or 5 µg/mL). As the result of cell division, the CFSE signal
in the nucleus was halved after each generation. The percentage of each generation could
be calculated based on the CFSE signal intensity obtained from flow cytometry.76 1) To
confirm the immunosuppressive effect of sunitinib alone, human PBMCs (1 x 106 cells/mL)
were plated in a 12-well plate and activated by PHA (5 µg/mL) for 4 days with or without
different concentration of sunitinib formulation (0.2 µM, 0.4 µM and 0.8 µM). At the end of
the study, all suspended cells were collected, centrifuged, washed with cold PBS, and
processed by flow cytometry with a 488-nm excitation laser to determine the nonproliferated (passage 1) and proliferated percentage (all passages except passage 1) of
each group. The production of pro-inflammatory cytokines including interlukin-2 (IL-2) and
interlukin-2 soluble receptor α (IL-2sRα) in the cell culture supernatant were measured
using Enzyme Linked Immunosorbent Assay (ELISA) after 2 days incubation with 2 µg/mL
of PHA. 2) Then, the function of siAlox15 to immune system was first tested using
commercial transfection reagents Lipofectamine 2000 and Xfect per manufacturers’
instructions. Similarly, flow cytometry and ELISA studies were conducted after 4 and 2
days of incubation, respectively. Furthermore, the siAlox15 was encapsulated in cationic
polymer at different N:P ratio to treat PHA activated PBMCs. The inhibition on PBMC
proliferation was visualized using microscope. 3) Finally, the comparison of sunitinib (0.8
µM) formulation, polymer/siAlox15 complex, and combination of sunitinib (0.4 µM) and
siAlox15 was made using flow cytometry.
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3.3.7. Protein Extraction and Western Blot Analysis
Quiescent human PBMCs were plated in 6-well plates at the density of 2 x 106
cells/well and activated by 5 µg/mL of the mitogen PHA. Four concentrations of sunitinib
formulation including 0.2, 0.4, 0.8 and 1.6 µM were incubated with these PBMCs, while
quiescent PBMCs and PBMCs receiving PHA only were served as negative and positive
controls. At 2 days post treatment, PBMCs were collected and washed with cold PBS,
followed by lysis using RIPA buffer supplemented with protease inhibitor and phosphatase
inhibitor cocktail on ice for 30 min. Then the clear supernatant was obtained by centrifuging
at 13,000 rpm for 20 min at 4 ⁰C and the protein of each sample was adjusted to the same
concentration after BCA assay measurement at 562 nm. 3 volumes of the supernatant
were mixed with 1 volume of 4x laemmli buffer and boiled at 95 ⁰C for 5 min. 40 µl of
resulting sample containing around 30 µg of total protein was carefully loaded onto 4-15%
SDS-PAGE gel (Bio-Rad, Hercules, CA) followed by running for 10 min under 50V and
1.5 h under 120 V to separate different proteins. The bands on the gel were transferred to
a PVDF membrane, which was blocked for 1 h using Odyssey® blocking buffer, then
incubated with primary antibodies at 4 ⁰C. The primary antibodies against β-actin (anti-βactin) (1:1000 dilution), antibodies against total Akt (anti-Akt) (1:500 dilution), antibodies
against phospho-Akt (Ser473) (anti-pho-Akt) (1:1000 dilution), antibodies against PDGFR
(anti-PDGFR) (1:500 dilution) and antibodies against phospho-PDGFR (anti-pho-PDGFR)
(1:500 dilution) were used in this study. After overnight incubation, the membrane was
washed with TBS-T buffer for 5 min and repeated for three more times, afterwards, was
incubated with secondary antibodies including donkey anti-rabbit and donkey anti-goat
antibodies (1:10000 dilution) for 1 h at room temperature. The membrane was washed for
four times again and scanned by a Bio-Rad imager.
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3.3.8. Measurement of ROS Production
INS-1E cells were seeded in 96-well plate (blank wall/clear bottom) at the density of
50,000 cells/well 48 hours prior to the treatment. Then siAlox15 (100 ng/well) which was
delivered by lipofectamine 2000 was added to the cells for 6 h, followed by 18 h cytokine
challenging (IL-1β: 50 ng/mL, TNF-α: 100 ng/mL and IFN- γ: 1000 ng/mL) in 100 µL RPMI
medium without phenol red. At the end of treatment, fresh medium with oxidative stress
detection reagent (Green dye) for hydrogen peroxide (H2O2) and hydroxyl radicals (-OH)
detection as well as superoxide detection reagent (Orange dye) for superoxide detection
was added after removing the previous medium for 1 h incubation (ROS-ID® Total
ROS/Superoxide Detection Kit, Enzo Life Sciences, Farmingdale, NY). Then the
fluorescence intensities were measured using a multimode plate reader (SpectraMax M5e,
Molecular Devices, Sunnyvale, CA) with the setting of (Ex=488 nm, Em=520 nm) and
(Ex=550 nm, Em=610 nm).
3.3.9. Cytotoxicity Assay
The potential cytotoxicity of sunitinib and siAlox15 formulation was assessed using
INS-1E cells by CellTiter-Blue® Cell Viability Assay and 3-(4,5-Dimethylthiazol-2-yl)-2,5Diphenyltetrazolium Bromide (MTT) assay. Briefly, INS-1E cells were seeded in 96-well
plate at the density of 50,000 cells per well and allowed for 48 hours to settle down. A
series of sunitinib formulation which have concentration ranging from 0.4 µM to 6.4 µM
were added to the cells and incubated for 48 or 72 hours. At the end of the study, 20 µL
of CellTiter-Blue® reagent was added to each well for 3 hours’ incubation and directly read
the fluorescence intensity with the setting of (Ex=560 nm, Em=590 nm). To test the
cytotoxicity of siAlox15 in normal condition and the protective effects of siAlox15 upon
cytokine stimulation, cells in each well was reacted with 0.5 mg/mL of MTT for 2 hours,
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and the formed violet crystal was dissolved in DMSO. Cell viability was calculated using
the absorbance under the wavelength of 560 and 630 nm.
3.3.10. In Vivo Therapeutic Study
All animal experiments were performed in accordance with the guidelines and protocol
approved by the Institutional Animal Care and Use Committee (IACUC) at the UNMC.
NOD/ShiLtJ female mice could develop autoimmune T1D starting from 12-week old and
are commonly used in the research of immunology, inflammation and autoimmunity. The
mouse blood glucose level was monitored once a week before 12-week old by tail vein
pricking and measured by Lifescan® one-touch ultra blue glucose meter. Based on the
reading of blood glucose, T1D was confirmed by the glucose level above 250 mg/dL and
the treatment was started immediately when the glucose level reached 300 mg/dL. Mice
were randomly assigned to four groups receiving different treatments: 1) saline; 2)
sunitinib loaded micelles (5 mg/kg); 3) cationic polymer/siAlox15 complex (1.5 mg/kg); 4)
micelles carrying both sunitinib (5 mg/kg) and siAlox15 (1.5 mg/kg). Seven injections were
given intravenously in two weeks, and the blood glucose level and bodyweight were
measured every alternate day until the end of the study. Four mice per group were
euthanized 48 hours after the last injection (Day 15) to collect blood and pancreas.
Intraperitoneal glucose tolerance test was performed one week after the treatment (Day
20).57 Glucose solution (2g/kg) was intraperitoneally injected into the overnight food fasted
mice, and the blood glucose level was monitored at the time points 0, 15, 30, 60, 90, 120
and 180 h. At day 21, all mice were sacrificed to collect major organs (heart, liver, kidney
and spleen) for H&E staining.
3.3.11. Serum Insulin Determination and Pathohistological Staining
The collected mouse blood was allowed to clot at room temperature for 30 – 60 min
prior to centrifugation at 2,500 rpm for 20 min. Serum was stored at -80 ⁰C until analysis.
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The serum insulin concentration was measured using ELISA kit per the manufacturer’s
instruction. The organs were fixed with 4% paraformaldehyde (PFA) and 70% ethanol,
then were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry
(IHC) staining against CD3+ T lymphocytes.
3.3.12. Statistical analysis
Results are presented as means ± SEM. Two-tailed unpaired t-test was used to
calculate the significance. * denotes statistically significant difference p < 0.05, ** denotes
statistically significant difference p < 0.01, *** denotes statistically significant difference p
< 0.001, and n.s. denotes not significant.
3.4. RESULTS
3.4.1. mPEG-b-PCC-g-DC-g-TEPA could efficiently co-encapsulate sunitinib and siAlox15
mPEG-b-PCC-g-DC-g-TEPA copolymer was synthesized by attaching dodecanol (DC)
and tetraethylenepetamine (TEPA) to methoxypoly (ethylene glycol)-block-poly(2-methyl2-carboxyl-propylene carbonate) (PEG-b-PCC), which was synthesized as we previously
reported.152 There were approximately 11 units of DC and 9 units of TEPA presenting in
final copolymer. Thus, the Mn calculated according to 1H NMR was approximately 12,000
Da. Micelles were prepared by thin film rehydration. These micelles had a diameter of
115.43 ± 0.99 nm and ζ-potential of 28.73 ± 1.01 mV as determined by dynamic light
scattering (Figure 3.1A). Complex formation with siAlox15 decreased the micelle size to
around 75 nm due to the condensation effect between the cationic TEPA and anionic
siRNA. ζ potential also decreased after complexation which was 12.70 ± 0.62 mV at the
N:P ratio of 16:1 and 19.90 ± 0.69 mV at the ratio of 32:1. This polymer could efficiently
load sunitinib its micellar core which was around 9.39% when the theoretical loading was
10%, and the size of the micelles after sunitinib encapsulation was slightly increased to
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131.57 ± 2.21 nm. Finally, the micelles that were co-encapsulated with siAlox15 and
sunitinib had both decreased size and ζ potential when compared with blank micelles, and
slight decreased in loading efficacy which were 97.63 ± 0.20 nm, 21.60 ± 1.11 mV and
8.32%, respectively. The size and morphology of these micelles was also confirmed with
transmission electron microscopy (TEM) (Figure 3.1F). The co-encapsulated micelles
formed a spherical shape with an average diameter of 110 nm. All these above micelles
had narrow particle size distribution, as indicated by the polydispersity index (PDI) of
around 0.2.

Figure 3.1. Formulation characterization. (A) Micelles were prepared using thin film
rehydration at the N:P ratio of 16:1 and 32:1 for siAlox15, and theoretical drug loading of 10%
for sunitinib. The particle size, ζ potential and PDI of each formulation were measured by
dynamic light scattering. (B) Sunitinib release profiles from the polymeric micelles with or without
siAlox15 complexation were determined by dialysis in PBS supplemented with 1% Tween-80,
followed by HPLC measurement. 1% agarose gel retardation assay was used to check (C)
cationic polymer/siAlox15 complexation at different N:P ratio; (D) heparin dissociation; (E)
plasma stability of free siAlox15 and encapsulated siAlox15; (F) The TEM image showed that
the co-encapsulated micelles formed a spherical shape. The scale bar represents 100 nm.
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Sunitinib release profiles were determined by dialysis under the sink condition over 72
h. The media concentration-time curve of sunitinib loaded micelles exhibited a burst
release which was around 45% after 12 h of dialysis, followed by a more sustained release
up to 60% in the following 60 h. Co-encapsulation with siAlox15 did not affect the release
profile of sunitinib from the micelles (Figure 3.1B).
3.4.2. mPEG-b-PCC-g-DC-g-TEPA provided protection to siAlox15 against plasma
degradation
First, the cationic polymer/siAlox15 complex was prepared at different N:P ratios
ranging from 2:1 to 64:1. Agarose gel electrophoresis showed that the band of siAlox15
started to fade from the N:P ratio of 4:1 and complete complex formation was observed at
the ratio of 16:1 (Figure 3.1C). Therefore, this ratio was selected for further experiments.
Then we determined the dissociation of siRNA from the polymer/siRNA complexes by
incubating with heparin sulfate. To protect and deliver the siRNA to the target site, the
complex should be stable at physiological concentration of plasma heparin which ranges
from 1 to 5 μg/mL.154 On the other hand, the complexation should also be reversible since
siRNA will only be pharmacologically active when they were released from the complex to
enter cytoplasm. As shown in Figure 3.1D, siRNA was dissociated from the complexes at
the siRNA/heparin ratio of 1:8 (w/w ratio) in 100 µL system after 45 min incubation,
suggesting that the minimal heparin concentration needed for our complex containing 1
µg of siRNA to dissociate was 80 µg/mL. As a result, this cationic polymer/siAlox15
complexes will be stable in the blood circulation and also reversible when it encounters
polyanion after entering the cells. Finally, cationic polymer encapsulated siAlox15 and free
siAlox15 were subjected to 50% FBS to check their plasma degradation. While free
siAlox15 was completely degraded within an hour, formulated siAlox15 remained stable
for at least 10 h (Figure 3.1E). Taken together, these agarose gel electrophoresis studies
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demonstrated that our cationic polymer could efficiently encapsulate siAlox15 at low N/P
ratio, which was dissociable to release the siRNA for pharmacological function, and the
complex could protect siAlox15 from plasma degradation.
3.4.3. Sunitinib could inhibit human PBMC activation and proliferation by downregulating
tyrosine kinase activity
Human PBMCs were used as the source of immune cells for in vitro studies. Majority
of the freshly isolated human PBMCs (99.5%) stayed in the quiescent form without
stimulation according to the signal intensity of CFSE determined by flow cytometry. In
response to the mitogen PHA (5 µg/ml), PBMCs were activated and underwent
proliferation leading to half of the CFSE intensity after each division. Incubation with PHA
for 4 days rendered 38.3% of proliferating PBMCs, which could be suppressed by sunitinib
formulation in a dose-dependent manner. Treatment with 0.8 µM sunitinib decreased the
percentage of proliferating PBMCs to 15.6, which was around 60% of inhibition compared
to PHA positive control group (Figure 3.2A). At the same time, sunitinib could potently
reduce the production of pro-inflammatory cytokines including IL-2 and IL-2sRα. IL-2 and
IL-2sRα secretion in PHA-activated PBMC supernatant was measured by ELISA, which
displayed around 85% and 95% of inhibition after 0.8 µM sunitinib treatment, respectively
(Figure 3.2B).
Previously, sunitinib was found to inhibit PDGFRβ phosphorylation in mice bearing
SF767T glioma and Akt phosphorylation in prostate cancer cells.155 Thus, we determined
the expression of these proteins in human PBMCs by Western blot. The results exhibited
that PHA treatment induced the phosphorylation of Akt and PDGFRβ to activate these
proliferating pathways. Four concentrations of sunitinib were selected to check their
inhibitory effect on these pathways (Figure 3.2C). According to the ImageJ results of the
band intensity quantification, sunitinib could decrease the ratio of pho-Akt/total Akt to
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about 45% compared to 80% of PHA group regardless of sunitinib concentration we
selected (Data not shown). Similarly, sunitinib downregulated the expression of phoPDGFR to about 55% relative to the expression of total PDGFR at the concentration of
0.4, 0.8 and 1.6 µM. These results suggested that sunitinib could inhibit AKT/PI3K and
PDGF/PDGFR pathways, however, there were no significant differences between four
concentrations which we selected. We will add a set of more dispersed concentration in
the future studies.

Figure 3.2. Inhibitory effect of sunitinib on human PBMC activation and proliferation. (A)
Human PBMCs were stained with CFSE and stimulated with 5 µg/mL PHA for 4 days, and the
proliferative percentage of each group was determined by flow cytometry. (B) Human PBMCs
were stimulated with 2 µg/mL PHA for 2 days. The levels of the pro-inflammatory cytokines IL2 and IL-2sRα in the culture medium were measured by ELISA. (C) Western blot was used to
check the protein expression of Akt, phosphorylated Akt, PDGFR and phosphorylated PDGFR.
β-Actin was used as control protein.
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3.4.4. siAlox15 exhibited immunosuppressive effects on PBMCs
Before formulating with our cationic polymer, siAlox15 was first formulated with
commercially available transfection reagents. siAlox15 formulated with Lipofectamine
2,000 or Xfect could reverse the PHA induced proliferation of PBMCs from 92.2% to 69.5%
and 63.9%, respectively (Figure 3.3A). One important point needed to mention is that the
PHA induced proliferative rate of human PBMCs were different in each experiment due to
the variations between different batches of PBMCs which were isolated from different
patients. Similarly, the production of pro-inflammatory cytokines was diminished
significantly whilst Xfect rendered more potent effect (Figure 3.3B). We also confirmed
that siAlox15 could efficiently downregulate Alox15 mRNA expression (Figure 3.3C). Next,
we investigated whether siAlox15 could inhibit ROS production upon cytokine challenging.
Briefly, INS-1E cells were treated with siAlox15 (100 ng/well) for 6 h, followed by 18 h
cytokine challenging (IL-1β: 50 ng/mL, TNF-α: 100 ng/mL and IFN- γ: 1000 ng/mL). The
results showed that siAlox15 treatment inhibited the cytokine induced superoxide
production from 171% to 133%, however, has no effect on the hydrogen peroxide (H2O2)
and hydroxyl radicals (-OH) production (Figure 3.3D).
After confirming its immunosuppressive effect, siAlox15 was complexed with mPEGb-PCC-g-DC-g-TEPA for further studies. The inhibition of human PBMC proliferation was
visualized under a microscopy. As shown in Figure 3.4A, the control PBMCs were in
quiescent state which appeared as single suspended cells, but 5 µg/mL PHA induced cell
activation and proliferation which exhibited as large clustered cells. The size of the clusters
was decreased after siAlox15 treatment depending on the N:P ratio. At the ratio of 32:1,
the PBMC cell clusters were almost disappeared (Figure 3.4A). The transfection
efficiency was then evaluated using Alexa 549 labeled siRNA by the uptake study. Figure
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3.4B was the PBMC cellular uptake of siAlox15, which showed a dose dependent
transfection efficiency with increased N/P ratio.

Figure 3.3. Immunosuppressive effect and decreased ROS production effect of siAlox15.
Immunosuppressive effects of siAlox15 delivered by commercially available carriers such as
Lipofectamine 2000 and Xfect were determined by (A) flow cytometry; and (B) ELISA. (C)
Alox15 gene expression after transfection of siAlox15 for 2 days were determined by RT-PCR.
(D) The effects of siAlox15 on the ROS production including hydrogen peroxide/hydroxyl
radicals and superoxide upon cytokine challenge of INS-1E cells.
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Figure 3.4. Microscope visualization of the immunosuppressive effect and PBMC uptake
of siAlox15. (A) Immunosuppressive effect of siAlox15 delivered by PEG-b-PCC-g-DC-gTEPA was determined using human PBMCs after PHA stimulation by visualization under a
fluorescent microscope. (B) PBMC uptake study of cationic polymer/siRNA-Alexa 549 at
different N:P ratio.
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3.4.5. Sunitinib and siAlox15 combination showed synergistic effect on inhibition of
immune cells

Figure 3.5. The combination therapy showed synergistic suppression on immune cells.
(A) Immunosuppressive effect of sunitinib and siAlox15 combination therapy was determined
by flow cytometry. Quantification of the proliferative percentage of each group was showed in
panel (B). (C) The effect of the combination therapy on regulatory T cells. Treated human
PBMCs were stained with CD4-FITC and CD25-PE, followed by fixation, permeabilization and
stained with FoxP3-APC. Flow cytometry was gating on CD4+ lymphocytes, then regulatory T
cells are CD25+FoxP3+ cells.

For the purpose of combination immunotherapy, sunitinib and siAlox15 were coencapsulated into mPEG-b-PCC-g-DC-g-TEPA polymeric micelles at the theoretical
loading of 10% and the N:P ratio of 16:1, respectively. While mitogen PHA induced 91.7%
PBMC proliferation, 0.8 µM sunitinib decreased the proliferation from 91.7 to 64.3%, and
siAlox15 could decrease to 74.2%. For combination therapy, half doses of sunitinib and
siAlox15 were incubated with PHA activated PBMCs for 4 days, leading to decreased
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proliferation to 54.4% (Figure 3.5A and 3.5B). Since the combination of sunitinib and
siAlox15 at half dose exhibited better efficacy than full dose of sunitinib or siAlox15 alone,
we could conclude that sunitinib and siAlox15 showed synergistic immunosuppressive
effect. The regulatory T lymphocyte (Treg) population was also measured by flow
cytometry. The PHA, 0.8 µM sunitinib, siAlox15, sunitinib and siAlox15 combination at half
dose were added to the PBMC cells, and resulted in 25.3%, 18.3%, 14.9% and 9.8% of
Treg populations, respectively (Figure 3.5C). The effect of these formulations on Tregs
was controversial and will be discussed in the discussion section.
3.4.6. Cytotoxicity of sunitinib and siAlox15 combination therapy to rat β cells
To evaluate the potential toxicity of the combination therapy of sunitinib and siAlox15
to insulin-secreting β cells, rat INS-1E cells were used. Sunitinib formulation showed slight
decrease in cell viability and the blank polymeric micelles did not show any cell killing
effect. At the concentration of 0.8 µM which was used as working concentration to inhibit
immune system, negligible toxicity was observed. The cell viabilities were 96 and 93%
after 48 and 72 h of incubation (Figure 3.6A and 3.6B). Even when we increased the
concentration to 6.4 µM, the cell viability remained 84 and 81%, respectively. According
to the guide of ISO 10993-5 that agents result in above 80% of cell viability are considered
as non-cytotoxicity,156 we could conclude that sunitinib loaded micelles are safe to INS-1E
cells up to 6.4 µM. Then, the cytotoxicity of the combination formulation was assessed
using MTT assay. siAlox15 formulation induced around 20% of INS-1E cell death, and the
combination of 0.8 µM sunitinib and siAlox15 caused 27% of cell death (Figure 3.6C).
These results suggest that the combination formulation caused minor toxicity to β cells at
physiological condition. However, in the condition of β cells facing challenge of
inflammatory cytokine cocktails (IL-1β: 0.5 ng/mL, TNF-α: 1 ng/mL and IFN- γ: 10 ng/mL),
INS-1E cell viability was 63% and 37% after 48 and 96 h incubation. The treatment of
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siAlox15 could provide protective effect to INS-1E cells resulting in increased cell viability
to 76% and 63%, which were about 1.2 and 1.7-fold increase of cell viability (Figure 3.6D).
Based on our previous results, siAlox15 protected INS-1E cells from cytokine induced
killing effect which may be related with its capacity to inhibit ROS production.

Figure 3.6. Both formulations showed minimal toxicity to INS-1E cells and siAlox15 alone
could protect INS-1E cells from cytokine attack. CellTiter-Blue assay was performed to
check cell viability of rat INS-1E cells treated with sunitinib formulation for 48 h (A) or 72 h (B),
and MTT assay was used for the combination therapy (C). (D) INS-1E cells was pre-incubated
with siAlox15 formulation for 2 days followed by cytokine cocktail challenge (IL-1β: 0.5 ng/mL,
TNF-α: 1 ng/mL and IFN- γ: 10 ng/mL) for 48 h or 96 h.
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3.4.7. Sunitinib and siAlox15 combination therapy could reverse the new-onset of type 1
diabetes using spontaneously T1D mouse model
NOD/ShiLtJ female mice which mimic the pathogenetic progress of T1D was utilized
to determine the in vivo efficacy of the combination therapy. Mice with blood glucose level
above 250 mg/dL were considered as diabetic mice and the treatment was started
immediately after the glucose level reaching 300 mg/dL. The new-onset diabetic mice
received 7 injections on day 1, 3, 5, 7, 9, 11, 13 and their blood glucose levels were
recorded until day 19. In Figure 3.7, each line represents one mouse’s blood glucose
fluctuation during the study period and the dash lines indicate glucose level of 250 mg/dL.
After treatment, animals with glucose level reversed to ˂250 mg/dL were considered as
normoglycemic mice. It is clear that without any treatment, blood glucose level of all control
animals (9/9) grew fast to above 600 mg/dL (detection limit) within two weeks (Figure
3.7A). For sunitinib and siAlox15 monotherapies, the rates of euglycemic mice at the end
of treatment were 40% and 11%, respectively (Figure 3.7B and 3.7C). Notably, the
combination of these two drugs significantly enhanced the therapeutic efficacy, leading to
80% (8/10) reversal to normoglycemia during the treatment period (Figure 3.7D).
The bodyweights for all treatment groups did not show significant decrease,
suggesting that our formulation had no obvious toxicity to diabetic mice at the selected
dose. In contrast, the diabetic mice without any treatment showed a tendency of
bodyweight loss but not in a significant way (Figure 3.8A). The potential side effect of our
formulations was also determined by H&E staining of major organs. No noticeable
abnormalities were observed in heart, liver, kidney and spleen (Figure 3.10). We further
performed intraperitoneal glucose tolerance test at the end of study to assess islet
metabolic function. After overnight food fasting, mice received 2 g/kg of glucose solution
and their blood glucose levels were monitored at 0, 15, 30, 60, 90, 120, 180 min. Diabetic
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control mice could not secrete sufficient insulin to control blood glucose level, which was
still above 500 mg/dL after 3 h of injection. While monotherapies of sunitinib and siAlox15
could induce moderate regulation, the combination therapy could promptly decrease the
blood glucose level to normal range (Figure 3.8B). These results demonstrated that mice
receiving the combination therapy of sunitinib and siAlox15 possessed better islet function
to secrete insulin upon glucose stimulation. This conclusion could also be confirmed by
the results of after-treatment serum insulin measurement and H&E staining. Figure 3.8C
showed that the combination therapy could significantly promote the secretion of insulin
to around 1.3 ng/mL, whilst untreated diabetic mice had an average serum insulin level of
0.27 ng/mL.

Figure 3.7. Sunitinib and siAlox15 combination therapy could reverse the onset of T1D.
NOD/ShiLtj female mice with blood glucose level above 300 mg/dL were divided into four
groups receiving treatment including (A) saline; (B) sunitinib formulation (5 mg/kg); (C) cationic
polymer/siAlox15 complex (1.5 mg/kg); (D) combination therapy (5 mg/kg of sunitinib and 1.5
mg/kg of siAlox15). The blood glucose level was monitored every alternate day. Each line
represents one mouse’s blood glucose fluctuation during the study period.

73

Figure 3.8. Mouse body weight, Intraperitoneal glucose tolerance test, and serum insulin
level after different treatment. (A) Mouse body weight. (B) Intraperitoneal glucose tolerance
test was carried out to evaluate the metabolic capability of islets. One week after the treatment,
glucose solution (2g/kg) was intraperitoneally injected to the overnight food fasted mice, and
the blood glucose level was monitored at the time points 0, 15, 30, 60, 90, 120 and 180 h. (C)
Serum insulin level was determined by ELISA.

Furthermore, the pancreas was fixed and subjected to H&E and IHC staining at the
end of the study (Figure 3.9A and 3.9B). H&E staining could provide size and morphology
information of insulin-secreting pancreatic islets, and IHC staining against CD3 aided in
confirming the number and degree of T lymphocyte infiltration. Based on the staining
results, the islets of untreated control mice had decreased size and were accompanied by
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substantial amount of CD3+ T cell infiltration throughout the islets. Compared to the control
group and monotherapy treated groups, the islets of mice receiving sunitinib and siAlox15
had well-preserved size. Although CD3+ T lymphocytes were also observed in the islets,
they appeared mainly on the surface of the islets, leaving the middle of islets (where β
cells reside) less disturbed. These results further demonstrated that by suppressing
tyrosine kinase and Alox15 activity, the combination therapy could inhibit pancreatic T cell
infiltration and protect islets from immune attack.

Figure 3.9. (A) H&E staining of mouse pancreas and (B) IHC staining against CD3 + T
lymphocytes. The white arrows indicate islets and the brown color indicates CD3 + T
lymphocytes.
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Figure 3.10. H&E staining of major organs. Major organs including heart, liver, kidney and
spleen at Day 21 post first administration of micelles carrying sunitinib (5 mg/kg) or siAlox15
(1.5 mg/kg) or the combination were collected and subjected to H&E staining to assess the
potential toxicity. No noticeable abnormalities were observed. The magnification is 20x.

3.5. DISCUSSION
Initiation and progression of type 1 diabetes depends on progressive loss of pancreatic
β cells as a result of inflammatory response and infiltration of immune cells to the islets
due to both genetic and environmental factors.9 Among a variety of T1D treatment
approaches, sunitinib is a multi-targeted TKI which has the potential to inhibit the activation,
proliferation and infiltration of immune cells.143 On the other hand, Alox15 which was highly
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expressed in β cells and macrophages catalyzes polyunsaturated fatty acids into proinflammatory lipids which is a key contributor of diabetes.96 Thus, downregulation of
Alox15 expression by siAlox15 should be capable of improving the therapeutic effect of
sunitinib in treating T1D. The objective of this study was to determine whether this TKI
and siAlox15 could be co-delivered and exerted synergistic effects.
Our results demonstrated the feasibility and efficacy of the combination of sunitinib
and siAlox15 to reverse the onset of T1D. Tyrosine kinases, including PDGFRβ and c-KIT,
play crucial role in T cell receptor (TCR) signal transduction, which controls physiologic
activation of T cells in response to antigen.63 Thus, T cell activation might be blocked by
TKIs including sunitinib. Figure 3.2 showed that sunitinib monotherapy indeed inhibit
human T cell proliferation as evidenced by decreased CFSE signal and excretion of IL-2
and IL-2sRα cytokines. There was also significant decrease in the protein level of
phospho-PDGFR and phospho-Akt. Phosphorylation of Akt is a key step in the
phosphatidylinositide-3-kinase (PI3K)/Akt pathway which is one of the most well-studies
pathways that regulates cell proliferation.66 Therefore, decreased phospho-Akt protein
level represented the inhibition on T cell proliferative pathways. Also, researches have
showed that increased VEGFR expression will lead to elevated formation of islet
vascularity and further cytotoxic T cell infiltration to the islets during the progression of
T1D.147 As a result, by inhibiting VEGFR expression, sunitinib could depress the amount
of islet T cells, restore islet function and glucose control. This hypothesis was consistent
with our H&E and IHC staining that significantly decreased T lymphocytes in the pancreas
of the mice receiving sunitinib monotherapy and combination therapy (Figure 3.9A and
3.9B).
Increased production of Alox15 was reported to accelerate endothelial cell activation
and monocyte/endothelial adhesion, which are the key early events in the vascular
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inflammation of T1D.157 Further reports showed that mice deficient in Alox15 were
resistant to development of streptozotocin-induced diabetes and inhibition of Alox15
reversed the process of T1D in NOD mice.98 Our results confirmed the in vitro
immunosuppressive effects of siAlox15 on human PBMCs (Figure 3.3 and 3.4). For in
vivo therapeutic efficacy study, we found that siAlox15 monotherapy could only reverse
11% of diabetic mice to blood glucose level below 250 mg/dL (Figure 3.7C). The
combination of sunitinib and siAlox15, however, was capable of inducing 80% of reversal
to normoglycemia during the 2-week treatment period and 1-week after treatment,
suggesting the synergistic effect of sunitinib and siAlox15. Furthermore, the intraperitoneal
glucose tolerance test results exhibited the remarkable beneficial outcome of the
combination therapy (Figure 3.8B). The lowest area under the curve (AUC) of the
combination group suggested that sunitinib and siAlox15 together could better preserve
the function of islets, improve mouse glucose tolerance and metabolism. It is noteworthy
that Louvet et al. showed better therapeutic efficacy of sunitinib monotherapy as a potent
PDGFR inhibitor which was almost 100% T1D remission in NOD mice when compared
with 40% success remission in our study (Figure 3.7B).63 It is possible due to the
differences of the regimens used between our two groups. Louvet et al. administered
sunitinib through oral gavage at the dose of 2 mg/mouse (80 mg/kg given the mouse
bodyweight is 25g) daily for 5 weeks after the onset of T1D. The benefits of micellar drug
delivery system include improved drug bioavailability, prolonged blood circulation time and
controlled drug release,158 resulting in reduced dose and side effects. Therefore, in our
group, we decreased the dose of sunitinib to 5 mg/kg based on literature which is using
10 mg/kg of sunitinib after physical encapsulation to treat advanced melanoma.159 The
formulation was administered intravenously for only 7 times in total within two weeks. We
hypothesized that similar therapeutic efficacy with lower sunitinib concentration combined
with gene therapy should be achieved by using our polymeric micelles.
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One issue was raised during the experiments which is downregulated population of
Tregs after the treatments of sunitinib monotherapy, siAlox15 monotherapy and the
combination therapy. Sunitinib has been reported to promote anticancer effect in
metastasis renal cancer patients, by decreasing the number of peripheral blood Treg
cells.160 Our data are in agree with this phenomenon (Figure 3.5C). However, the role of
Tregs in T1D is known to be immunosuppressive and important for the prevention of many
autoimmune diseases including T1D. Since there are three stages in the treatment of T1D:
first is the acute reversal of new onset, then maintenance of normoglycemia during the
treatment period, followed by long-term remission after the completion of treatment. Our
results suggested that the combination of sunitinib and siAlox15 may only be effective
during the first and second stages but will be failed to induce long-term remission of T1D
after treatment due to downregulation of Tregs. On the other hand, studies had reported
that 30-week-old NOD mice deficient in Alox15 had decreased inflammation and
substantially enhanced Treg recruitment among pancreatic islets which was in
contradiction to our result.95 Because in our group the decreased population of Tregs was
only observed in in vitro human PBMC studies after 4 d treatment, there are possibilities
of different regulatory effects of the combination of sunitinib and siAlox15 on Treg
population for in vivo studies. We also need to determine the kinetics of Treg population
change since it is possible that sunitinib and siAlox15 together will upregulate the number
and function of Tregs after temporary decrease. We will test these hypotheses in the future
studies.
3.6. CONCLUSION
In summary, we co-delivered sunitinib and siAlox15 using mPEG-b-PCC-g-DC-gTEPA copolymer and demonstrated their synergistic effect in reversing the new-onset of
T1D in a spontaneous diabetic mouse model. For in vitro studies, the combination therapy
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inhibited T cell activation and proliferation, pro-inflammatory cytokine and ROS production.
What’s more, for in vivo studies, the combination therapy preserved the mass and function
of islets, decreased CD3+ T cell infiltration and exhibited minimal toxicity. Because
sunitinib is an FDA approved tyrosine kinase inhibitor with severe side effects,
encapsulation using the biodegradable nontoxic polymeric drug delivery system may
provide a safe approach to treat T1D in the clinics. Currently there are no effective
therapeutics for T1D and our sunitinib and siAlox15 combination may be a novel and
reliable treatment for patients who were recently diagnosed as T1D. The future direction
of our research is to discover a non-invasive biomarker for early T1D diagnosis which will
further promote the success rate of our combination therapy.
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4.1. ABSTRACT
Type 1 diabetes (T1D) is a chronic autoimmune disease which is associated with
critical loss of insulin producing β cells, leading to hyperglycemia, exogenous insulindependence and a variety of severe complications. To halt the progression of T1D, a novel
PI3K-δ/γ dual inhibitor IPI-145 which specifically interferes immune cells with minimal
disturbance to islet β cells was investigated. The study showed that IPI-145 inhibited the
activation and proliferation of PBMCs, reduced the production and transcription of proinflammatory cytokines including IL-2 and IFN-γ, leading to suppressed damage of
immune cells to islet β cells and arrested cell cycle from G1 to S phase. The RT-PCR
results demonstrated that cyclin D1 and cyclin E, but not cyclin D3, were responsible for
the cell cycle arrest. IPI-145 also directly killed PBMCs without PHA activation through
inducing apoptosis/necrosis, inhibited in vivo infiltration of CD3+ T cells to the spleen, and
decreased the generation of serum IgG from B cells. We also explored the transportation
potential and trophic role of human bone marrow mesenchymal stem cell (hBMSC)
derived exosomes. hBMSC-derived exosomes promoted the survival and growth of
human islets in vitro and tended to migrate to the inflamed pancreas in vivo after both I.V.
and I.P. administration while the route of I.P. was more desirable. More investigation is
ongoing to identify the genes or proteins that are responsible for the trophic effect, and to
determine the in vivo therapeutic efficacy of IPI-145 in both free and encapsulated forms
to prevent or revert the occurrence of T1D.
4.2. INTRODUCTION
Type 1 diabetes (T1D) is a chronic autoimmune disease which is associated with
critical loss of insulin producing β cells, leading to hyperglycemia, exogenous insulindependence and a variety of severe complications.161 The number of T1D patients is
continuously increasing, by 3% each year globally, and United States is one of the
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countries that have the highest T1D occurrence including senior patients as well as a large
portion of children and teenagers.162 Extensive research has been accomplished to study
the initiation and development of T1D which revealed that the pathogenesis is related to
the complicated cross-talking of immune cells from both innate and adaptive systems and
their secretory factors.5 The aberrant production of β cell specific autoantigens, which is
triggered by genetic susceptibility and environmental risks, induces a series of
subsequence immune reactions, including recognition by antigen-presenting cells (APCs),
activation of CD4+ helper T cells (Th cells), β cell specific CD8+ cytotoxic T cells and
macrophages, as well as the generation of cytotoxic enzymes and soluble mediators.9
This process causes massive destruction of pancreatic islets and inflammation of the
remaining ones with impaired insulin secreting function.4 The complexity hinders the
translation of the current therapeutic approaches such as exogenous insulin replacement
therapy, islet transplantation, small molecule and macromolecule based immune
intervention from mouse models to the clinics. The wide-spreading solution for optimized
and effective treatment of the chronic autoimmune diabetes is to advisedly combine two
or more approaches targeting different pathways or exerting distinct functions, i.e.,
simultaneously regulating the immune system and promoting the survival/mass/function
of pancreatic islets.163
Nevertheless, the majority of the commercially available immunosuppressive drugs
have negative impacts on the pancreatic islets due to the non-specific toxicity. For
example, the mTOR inhibitor Rapamycin elicits concomitantly immunosuppressive and
anti-angiogenic effects, adversely influencing the cell outgrowth and formation of capillarylike structures of islets.164 Mycophenolic acid (MPA), an inhibitor of the inosine
monophosphate dehydrogenase (IMPDH), severely harms the morphology, viability and
insulin release of human islets and rodent β cell lines, induces apoptosis, and alters the
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expression of some key genes, including glucose transporter 2 (GLUT2), glucokinase and
the ratio of Bax/Bcl-2.76, 165 In the past decades, researchers devoted extensive effort to
identify novel targets and pathways for immunosuppression without causing severe
interference to other healthy organs or cells. Phosphatidylinositide-3-kinase (PI3K)/Akt
pathway has been demonstrated to be crucial for the survival, proliferation and metastasis
of a variety of cells through regulating multiple signaling pathways.166 PI3K can be divided
into four isoforms according to their distinct components, among which, PI3K-δ and PI3Kγ isoforms are preferentially expressed in hematopoietic-origin leukocytes and quite less
presented in other cell types, making this pathway more superior for treating autoimmune
and inflammation related diseases while less intended to cause adverse effects.66, 167 More
intriguingly, the downstream target Akt is remarkably less expressed in regulatory T cells
(Tregs) compared to effector T cells.67 Therefore, PI3K-δ and PI3K-γ inhibitors can be
utilized to specifically suppress the activation and proliferation of diabetogenic T cells, but
not Tregs, and reduce the production of pro-inflammatory cytokines. The research of PI3Kδ and PI3K-γ inhibitors in the field of T1D is substantial and still ongoing. For instance,
Abdi’s group has depicted the effect of a PI3Kγ mono-inhibitor AS605240, which not only
prevented the development of disease in prediabetic NOD mice but also reversed the
occurrence of diabetes through expanding the population of Tregs and diminishing the
autoreactive T cells.67 Besides, genetically engineered NOD mice with deficiency in PI3Kγ
expression exhibited similar protective effect against T1D.68
As a result, utilizing PI3K-δ and/or PI3K-γ inhibitors holds great promise for the
immune intervention therapy of T1D. IPI-145 is a novel PI3K-δ/γ dual inhibitor, which
blocks the PI3K/Akt pathway of leukocytes and affects the downstream genes with distinct
regulatory functions, such as apoptosis (X-linked inhibitor of apoptosis protein (XIAP) and
Bax), protein synthesis (mTORC1), and cell cycle (cyclin D1, cyclin E) (Figure 4.1).
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Therefore, IPI-145 can suppress both innate and adaptive immune systems by inhibiting
the activation, proliferation, differentiation and migration of a variety of immune cells.66, 167170

At the same time, the absence of PI3K-δ/γ expression assures the safety of insulin

secreting β cells and other normal cells. Although IPI-145 has been employed in several
human disease clinical trials such as Chronic Lymphocytic Leukemia (CLL), 171 refractory
indolent non-Hodgkin lymphoma (DYNAMO),172 and animal models such as rat collageninduced arthritis (CIA) model, ovalbumin (OVA)-induced asthma model and spontaneous
murine model of systemic lupus erythematosus,167 currently, to our knowledge, there is no
research involving the therapeutic roles of IPI-145 in T1D.

Figure 4.1. The schematic illustration of the distinct function of IPI-145 to immune cells
and β cells.
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Exosomes are naturally produced nanovesicles with the size of 30–120 nm and
secreted by almost all cell types, taking the responsibility of intracellular communication
and regulation.173 They possess similar size, structure and composition with liposomes174
and are being investigated as advanced in vivo drug delivery vehicles for proteins, RNAs
as well as small molecules.175-178 Zhang’s group demonstrated the enhanced antiinflammatory activities of the small molecular drug curcumin after encapsulation into EL4 derived exosomes compared to free curcumin for the intra-nasal delivery to treat brain
inflammatory diseases.178,

179

Compared to other drug delivery platforms, exosomes

exhibit advantages including low immunogenicity and toxicity, high cellular uptake, and
potent protection to the payloads from plasma degradation.180,

181

More importantly,

exosomes are capable of inheriting beneficial features from their cells of origin.182-184 The
cell source of exosomes we selected in this study is human bone marrow mesenchymal
stem cells (hBMSCs) which are widely applied in the basic and clinical research due to
the unique merits. For example, hBMSCs elicit potent modulatory effects on both innate
and adaptive immune systems, have the potential of expanding Tregs, own intrinsic
paracrine/trophic effects, low-immunogenicity, and migration tendency to injured/inflamed
tissues.46, 49-51 Our group has also demonstrated that the genes which are transfected to
hBMSCs can be automatically packed into the derived exosomes with high efficiency, and
subsequently transported to the nearby pancreatic islets to exert the therapeutic effect.57
In this study, we investigated the therapeutic role of the novel PI3K-δ/γ dual inhibitor
IPI-145 for the treatment of T1D. To overcome the hydrophobicity related poor oral
bioavailability and rapid clearance, the hBMSC derived exosomes were explored as the
natural carriers of IPI-145. What’s more, the trophic role of these exosomes to the
pancreatic islets was also studied.
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4.3. EXPERIMENTAL SECTION
4.3.1. Materials
Mesenchymal stem cell expansion medium was purchased from Celleng-tech
(Coralville, IA). RPMI 1640 medium, Dulbecco's phosphate-buffered saline (DPBS) and
Trypsin protease (0.25%, 1X) were purchased from Hyclone (Logan, UT). CMRL 1066
medium was purchased from Corning (Corning, NY). Heat-inactivated fetal bovine serum
(FBS), antibiotic-antimycotic solution (anti-anti) (100X), sodium pyruvate (100 mM), total
exosome isolation reagent (from cell culture media), FxCycle™ PI/RNase Staining
Solution for cell cycle analysis, and Alexa Fluor® 488 annexin V/Dead Cell Apoptosis Kit
were purchased from Thermo Scientific (Waltham, MA). HEPES buffer solution (1 M) and
Lectin from Phaseolus vulgaris (red kidney bean) (also known as PHA) were purchased
from Millipore Sigma (St. Louis, MO). CFSE Cell Division Assay Kit was purchased from
Cayman (Ann Arbor, MI). CellTiter-Glo® Luminescent Cell Viability Assay Kit was
purchased from Promega (Madison, WI). ELISA kits for detecting human Interleukin 2 (IL2) and Interferon-gamma (IFN-γ) were purchased from R&D Systems (Minneapolis, MN).
Akt antibody (sc-8312) and β-actin antibody (sc-1616) were purchased from Santa Cruz
Biotechnology (Dallas, Texas). Phospho-Akt (Ser473) antibody (4060) was purchased
from Cell signaling technology (Danvers, MA). RNeasy mini kit for total RNA extraction
was purchased from Qiagen (Valencia, CA). Multiscribe reverse transcription kit was
purchased from Applied Biosystems (Foster City, CA). SYBR Green-I dye universal PCR
master mix was purchased from Roche (Indianapolis, IN). All PCR primers were
purchased from Integrated DNA Technology and the sequences are listed in Table 4.1
(Coralville, Iowa). RIPA Lysis and Extraction Buffer, Halt™ protease and phosphatase
inhibitor cocktail (100X), and Pierce™ BCA protein assay kit for protein quantification were
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purchased from Thermo Fisher Scientific (Waltham, MA). IPI-145 was purchased from
MedChemExpress (Monmouth Junction, NJ).

Gene

IFN-γ

IL-2

Cyclin D1

Cyclin D3

Cyclin E

GAPDH

Species

Human

Human

Human

Human

Human

Human

Amplicon
length

Direction

Sequence

Forward

GCAGAGCCAAATTGTCTCCT

Reverse

ATGCTCTTCGACCTC GAAAC

Forward

CAGGATGCAACTCCTGTCTT

Reverse

TCAGTTCTGTGGCCTTCTTG

Forward

GCTGGAGCCCGTGAAAAAGAG

Reverse

GGATTGGAAATGAACTTCACA

Forward

CTGCCTCCAGGAACCACA

Reverse

GCTTGACTAGCCACCGAAAT

Forward

GGCTATGCTGGAGGAAGTAAAT

Reverse

CCAGTAACCTTGGGAATGAAGA

Forward

ACCACAGTCCATGCCATCAC

Reverse

TCCACCACCCTGTTGCTGTA

320 bp

215 bp

326 bp

146 bp

372 bp

452 bp

Table 4.1. Sequences of the primers used for RT-PCR.

4.3.2. Cell culture
Human bone marrow-derived mesenchymal stem cells (hBMSCs) were purchased
from Cellular Engineering Technologies (Coralville, IA) and cultured in mesenchymal stem
cell expansion medium supplemented with 10% FBS and 1% antibiotic-antimycotic.
Human peripheral blood mononuclear cells (PBMCs) were routinely purchased from the
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Elutriation Cell and Tissue Facility at the University of Nebraska Medical Center (UNMC)
and cultured in RPMI-1640 medium supplemented with 10% FBS. Rat insulinoma INS-1E
cells (kindly provided by Dr. Pierre Maechler, Geneva University) were cultured in RPMI1640 medium with 10% FBS, 1% antibiotic-antimycotic, 10 mM HEPES buffer, 1mM
sodium pyruvate solution, 50 µM 2-mercaptoethanol.130 Human islets were received from
integrated islet distribution program (IIDP) and cultured in CMRL 1066 medium with 10%
FBS.
4.3.3. Exosome extraction, drug encapsulation and characterization
The undifferentiated hBMSCs (Passage 2-5) were washed by PBS and cultured in
mesenchymal stem cell expansion medium without FBS for 48 hours before exosome
extraction using total exosome isolation reagent as per the manufacturer’s protocol or
modified ultracentrifugation method. Briefly, the conditioned medium was centrifuged at
2,000g for 30 min to remove cells and debris. The resultant supernatant was then filtered
through 0.22 µm membrane to further eliminate the remaining cell debris and
microvesicles. Exosomes were collected by ultracentrifugation at 150,000 g at 4 ⁰C for 2
h followed by washing with PBS and a repeat ultracentrifugation under the same condition.
The extracted exosomes were quantified by the protein concentration using BCA assay,
and stored at - 80 ⁰C for further utilization.
For drug encapsulation, exosomes were re-suspended in PBS and incubated with IPI145 on ice for 1 h while gentle shaking. The mixture was sonicated using Qsonica Q500
sonicator (with 3.2 mm Microtip probe at 20% amplitude) for 6 cycles of 8 s pulse and 4 s
pause on ice, and repeated for three times with 2 min cooling-down interval.176, 177 Unencapsulated IPI-145 was removed by centrifugation using exosome spin columns
(MW3000) (Invitrogen) for small volume or separated through Sepharose® CL-4B
columns for large volume. The drug content of IPI-145 encapsulated exosomes (exo-IPI-
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145) was determined utilizing high performance liquid chromatography (HPLC) after
protein precipitation as previously described.76 Briefly, 3 volumes of cold acetonitrile was
added to 50 µl of the formulation for exosomal protein denaturation. The mixture was then
shaken for 3 min, vortexed for 2 min, and centrifuged at 4 °C for 15 min at 5000 g. The
supernatant was collected, filtered and measured by HPLC.
The size of naïve, blank sonicated, and drug-loaded sonicated exosomes was
characterized by dynamic light scattering (DLS) using Zetasizer, and nanoparticle tracking
analysis (NTA) using Nanosight NS300.
4.3.4. Drug release study
1 mL freshly prepared formulation was loaded into a 3.5-5 kD Float-A-Lyzer G2 device
(Spectrum labs) and put into 200 mL PBS to maintain the sink condition while shaking at
37 °C.177 At each assigned time point (0, 1, 2, 4, 6 and 24 h), 50 µL of the formulation was
withdrawn from the device and proceeded to HPLC for drug content analysis. All samples
were run in triplicate.
4.3.5. Human PBMCs in vitro proliferation study
To establish the inhibitory curve of free IPI-145 on immune cells, human PBMCs were
labeled by carboxyfluorescein succinimidyl ester (CFSE) and seeded at the density of 1 x
106 cells/mL in 12-well plates. Cells were pre-incubated with free IPI-145 for 1 h followed
by addition of the mitogen phytohemagglutinin (PHA) (6 µg/mL) for cell activation and
proliferation for 5 days. The quiescent and proliferative percentages of PBMCs were
measured and calculated by flow cytometry based on the intensity of CFSE signal.76
Then, CellTiter-Glo® luminescent cell viability assay was used to further confirm and
compare the immunosuppressive effect of free IPI-145 and exo-IPI-145. Human PBMCs
were pre-treated with free IPI-145 and exo-IPI-145 containing the equivalent amount of
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IPI-145 for 1 h and activated by 6 µg/mL PHA for 4 days. The presented ATP of
metabolically active cells was quantified by the luminescence.167 The production of
inflammatory cytokines including human IL-2 and IFN-γ after 48 h treatment was
measured by ELISA. All samples were run in triplicate.
4.3.6. Cell cycles
Human PBMCs (1 x 106 cells/mL in 12-well plate) were pre-incubated with free IPI145 and exo-IPI-145 (equivalent to 250 nM IPI-145) for 1 h and further incubated for 4
days with PHA treatment (6 µg/mL). At the end of the study, cells were collected by
centrifugation and fixed with 75% cold ethanol overnight at 4 ⁰C. Then all the samples
were washed with cold PBS and stained using FxCycle™ PI/RNase Staining Solution for
30 min followed by flow cytometry analysis. The effect of IPI-145 on the cell cycle of rat β
cells was also determined with the same method to confirm its theoretically minimal
disturbance to β cells. INS-1E cells (0.5 x 106 cells /well) were treated with IPI-145 (100,
250 and 500 nM) for 3 days followed by the same staining and flow cytometry protocol. All
samples were run in triplicate.
4.3.7. MTT assay
The toxicity of IPI-145 was assessed using both rat β cells and human immune cells
to demonstrate its specific inhibition of PI3K-δ/γ isoforms. INS-1E cells were seeded in
96-well plates (50,000 cells/well) and treated with a wide concentration range of IPI-145
(0.1, 2, 10, 50, 100, 250, 500 nM, 1, 10 and 20 µM) for 48 or 72 h. MPA which is a wellknown immunosuppressive compound with severe general toxicity was used as a positive
control.
In addition to the inhibitory effect on the activation and proliferation, the direct toxicity
of IPI-145 to immune cells was also characterized by incubating PBMCs with IPI-145
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without PHA. Human PBMCs were seeded in 24-well plates at the density of 1 x 106
cells/mL and treated with free IPI-145 and exo-IPI-145 at equivalent concentrations (50,
100, 250 and 500 nM) for 4 days. At the end of the study, cell viability was measured by
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay and calculated
according to the absorbance under 560 and 630 nm. n = 6 for INS-1E cells and n = 4 for
PBMCs. Depending on the balance of immunosuppressive effect and cytotoxicity of IPI145, the concentration of 250 nM was chosen for the following experiments.
4.3.8. Cell apoptosis assay
Human PBMCs (1 x 106 cells/mL in 12-well plate) were incubated with free IPI-145
and exo-IPI-145 (equivalent to 250 nM) for 4 days without PHA activation. All cells were
collected and stained with annexin V/dead cell apoptosis kit as per the manufacturer’s
protocol. Percentages of alive, early apoptotic, late apoptotic and necrotic cells were
obtained by flow cytometry using 488 nm excitation. All samples were run in triplicate.
4.3.9. Quantitative Real-Time PCR
Human PBMCs (4 x 106 cells/well in 6-well plate) were pre-treated with free IPI-145
and exo-IPI-145 (equivalent to 250 nM) for 1 hour and activated with mitogenic PHA (6
µg/mL) for 18 hours. Then, total mRNA was extracted using RNeasy mini kit, followed by
reverse transcription to cDNA, and RT-PCR using a LightCycler 480 Instrument (Roche).
The primer sequences are available in Table 4.1. All samples were run in triplicate.
4.3.10. Western blot
Human PBMCs (10 x 106 cells/sample) were pre-treated with free IPI-145 and exo-IPI145 (equivalent to 250 nM) for 1 h and allowed to activate under 6 µg/mL mitogenic PHA
for 30 min due to the fast phosphorylation process. The cell lysis was performed on ice
using protease and phosphatase inhibitor supplemented RIPA buffer for 30 min with
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occasional vortex. The protein collection, concentration quantification, and Western blot
process were performed as previously described.37 Different dilution factors of antibodies
were used as below: the goat polyclonal antibody against β actin (1:1000 dilution), rabbit
polyclonal antibody against total Akt (1:500 dilution), rabbit monoclonal antibody against
phospho-Akt (Ser473) (1:1000 dilution), donkey anti-rabbit secondary antibody (1:10000
dilution), and donkey anti-goat secondary antibody (1:10000 dilution). The bands were
scanned using a Bio-Rad imager.
4.3.11. Human islets in vitro study
To test the potential of hBMSC-derived exosomes induced angiogenetic effect, human
islets (150 IEQs/well) were placed in a 48-well plate pre-coated with Matrigel and allowed
to culture for 7 days in the presence or absence of 100 µg/mL of hBMSC-derived
exosomes. The vascular formation was observed under the microscope. To further
determine the capability of hBMSC-derived exosomes to support islet adherence and
promote β cell outgrowth, islets were placed in a 12-well plate at the density of 150
IEQs/mL. After 5 days’ co-incubation with 100 µg/mL hBMSC-derived exosomes, the
supernatant was removed, and the adherent cells were stained with dithizone (1 mg/mL)
for 20 min. For each sample, 15 fields were randomly selected and recorded using ZEISS
microscope to count the total number of adherent dithizone positive islets. There were 3
individual samples in the control and exosome treated groups.
4.3.12. Biodistribution of hBMSC-derived exosomes
All experiments involving animals were performed in strict accordance with guidelines
and protocols approved by the Institutional Animal Care and Use Committee (IACUC) at
UNMC. 8 weeks-old NOD-scid IL2Rgammanull (NSG) mice were utilized in the
biodistribution study. Streptozotocin (STZ) was dissolved in freshly prepared 0.1 M Citrate
buffer (pH 4.5) and intraperitoneally injected to NSG mice at the dose of 70 mg/kg to
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induce diabetes which was confirmed by two consecutive blood glucose levels above 250
mg/dL. A second injection of STZ will be administered to mice not developing
hyperglycemia. The fluorescent lipophilic dye DiI-C16 labeled exosomes were obtained
through labeling of parent hBMSCs (Passage 2-5) with DiI-C16 (6 µM) supplemented
medium for 1 hour followed by washing with PBS for three times. Fluorescent exosomes
were collected from the conditioned medium after 2 d incubation and administered to
diabetic NSG mice via two routes: intraperitoneal (I.P.) or intravenous (I.V.) injection.
Major organs (brain, heart, lung, liver, kidneys, spleen and pancreas) were excised at 1
and 24 h time points and snap frozen at - 80 ⁰C till analysis. The fluorescence signals of
each organ were measured by ex vivo IVIS imaging with 570 nm excitation, 620 nm
emission, 30 s exposure time, and quantified with the software living image® version 4.5.
n = 4 for 1 h time point and n = 5 for 24 h time point.
4.3.13. In vivo immunosuppressive effect
The NSG mice with normal glycemic level were intraperitoneally administered with 5 x
106 human PBMC cells to establish the human immune system for the assessment of the
immunosuppressive effect of IPI-145. Two weeks after the PBMC infusion, IPI-145 in both
free and exosome-encapsulated forms was injected to the animals daily for 7 days at the
concentration of 5 mg/kg. At the end of the study, animals were sacrificed and the serum
as well as spleen were collected for the analysis of IgG level and CD3+ T cell infiltration.
4.3.14. Statistical analysis
Results were presented as means ± SEM, and the significance was calculated using
two-tailed unpaired t-test between two groups. The symbol “n.s.” in the figures denotes
statistically not significant, “*” denotes statistically significant difference less than 0.05, “**”
denotes statistically significant difference less than 0.01, and “***” denotes statistically
significant difference less than 0.001.
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4.4. RESULTS
4.4.1. Characterization of IPI-145 encapsulated hBMSC-derived exosomes
The naïve hBMSC-derived exosomes had the particle size around 106.7 nm which
was characterized by nanoparticle tracking analysis (NTA). However, after the process of
probe sonication for drug encapsulation, the size increased to 191.1 ± 1.4 for empty
exosomes, and 205.9 ± 7.6 for IPI-145 loaded exosomes (Figure 4.2A). The trend of
increased size was also observed with dynamic light scattering (DLS) measurement. The
IPI-145 encapsulated exosomes had the particle size of 229.9 ± 6.5 nm and empty
sonicated exosomes had a slightly smaller size of 163.1 ± 8.6 nm. The images of both
NTA and DLS characterization showed a uniform and narrow size distribution, and the
PDI was around 0.3 (Figure 4.2B). Incubation in the PBS sink condition displayed a burst
release during the first 6 hours and later a relatively sustained release which elicited 90%
release after 24 h incubation (Figure 4.2C).

Figure 4.2. Characterization of hBMSC-derived naïve, empty sonicated and IPI-145
encapsulated exosomes. (A) Size characterization. (B) NTA and DLS size of IPI-145
encapsulated exosomes. (C) Drug release of IPI-145 after encapsulation in exosomes in PBS
sink condition at 37 ºC.
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4.4.2. Immunosuppressive and anti-inflammatory effects of IPI-145 were not compromised
after encapsulated into hBMSC-derived exosomes
The mitogenic PHA induced substantial activation of PBMCs which driven 61.33 ±
5.12% PBMCs into proliferation state after 5 days’ incubation based on the result of flow
cytometry (Figure 4.3A). To investigate the suppressive effect against the immune system,
free IPI-145 with a series of concentration ranging from 2 nM to 20 µM was first prepared
to co-incubate with PBMCs, which demonstrated a dose-dependent curve on the inhibition
of T cell proliferation (Figure 4.3B). Specifically, at the concentration of 250 nM, only 20.53
± 2.28% PBMCs were resided in the proliferation phase, representing around 67%
reduction compared to the group receiving PHA alone. To further confirm the suppression
and make a parallel comparison between free IPI-145 and hBMSC-derived exosome
encapsulated IPI-145 (exo-IPI-145), CellTiter-Glo® luminescent cell viability assay was
performed to quantify the luminescent signal of the ATP presented in alive cells of each
well after different treatment (Figure 4.3C). Exo-IPI-145 showed uncompromised
inhibition on PBMC proliferation, and ever more effective at the concentration of 500 and
2000 nM (luminescence: 17790.86 ± 1368.04 vs. 24608.03 ±3363.164, p < 0.05; and
13213.49 ± 961.2458 vs. 18857.04 ±454.5421, p < 0.001). Notably, exosomes alone
elicited certain supportive role on the proliferation of PBMCs which showed around 20%
elevation compared to PHA alone group.
What’s more, the extracellular cytokine secretion in the cultured medium displayed
extensive decline after receiving treatment of 250 nM free IPI-145 or exo-IPI-145. The
ELISA results showed that the IL-2 and IFN-γ production decreased to 43% and 50% for
cells receiving free IPI-145, and 43% and 45% for cells receiving exo-IPI-145, respectively
(Figure 4.3D). These values were consistent with the results of RT-PCR, which suggested
that treatment with free IPI-145 and exo-IPI-145 could also suppress the transcription of

96

IL-2 and IFN-γ mRNA. Free IPI-145 induced around 42% and 59% inhibition on IL-2 and
IFN-γ mRNA expression, whereas, exo-IPI-145 at the same concentration induced 49%
and 76% downregulation, respectively (Figure 4.3E).

Figure 4.3. The immunosuppressive effect of IPI-145 in both free form and encapsulated
form. (A) Flow cytometry result of quiescent state, PHA induced, and free IPI-145 (250 nm)
treated human PBMCs. (B) The inhibitor curve of free IPI-145 to human PBMCs. (C) The
comparison of inhibition to PBMCs between free IPI-145 and Exo-IPI-145. (D) Cytokine
production of IL-2 and IFN-γ determined by ELISA. (E) The IL-2 and IFN-γ mRNA expression
determined by RT-PCR.
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4.4.3. Both free IPI-145 and exo-IPI-145 could block the cell cycle transition of human
PBMCs from G1 to S phase which was closely regulated by Cyclin D1 and Cyclin E, but
not Cyclin D3
Literature has demonstrated that PBMC activation induced production of IL-2
promoted the cell cycle transition from G1 to Synthesis Phase (S phase). 185 As a result,
the cell cycle analysis proved that the percentage of cells in S phase increased from 6%
to 17% after co-culturing with PHA (6 µg/ml) for 4 days (Figure 4.4A), corresponding to
the elevated population of proliferating cells with the flow cytometry analysis. Treatment
with free IPI-145 and exo-IPI-145 (250 nM) decreased the cell percentage in S phase to
7% by arresting more cells in the G1 phase. Comparing with 70% cells in G1 phase with
PHA activation alone, treatment with IPI-145 in both free form and encapsulated form
arrested about 83% cells in G1 phase (Figure 4.4A). Cyclin D in middle G1 phase and
Cyclin E in late G1 phase are the key regulators driven the progression of G1 to S
phase,185 therefore, Cyclin D1, Cyclin D3 and Cyclin E mRNA expression were
subsequently measured by RT-PCR. There was no significant change in the level of Cyclin
D3 for all groups; however, the PHA induced upregulation of Cyclin D1 mRNA was
diminished from 175% to 56% for free IPI-145 treatment and 42% for exo-IPI-145
treatment (Figure 4.4C). At the same time, the expression of Cyclin E mRNA showed the
same trend which decreased from 531% to 323% and 284% for free IPI-145 and exo-IPI145 treatment, respectively. 0.1% DMSO (working concentration of free IPI-145) and
exosomes alone did not significantly alter the cell cycle of human PBMCs (Data not shown).
In order to confirm the minimal disturbance of IPI-145 to β cells in the absence of PI3Kδ/γ isoforms, the cell cycle of rat insulin-secreting INS-1E cells was also checked which
was not affected by exposing to IPI-145 at the concentration of 100, 250 nor 500 nM after
3 days’ incubation (Figure 4.4B).
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Figure 4.4. IPI-145 arrested the progression of cell cycle from G1 to S phase and caused
direct cell-killing effect to PBMCs. (A) PHA induced PBMCs to enter into the cell cycle, and
IPI-145 at both free form and encapsulated form arrested the progression from G1 to S phase.
(B) The cell cycle of INS-1E cells did not interfere by IPI-145. (C) RT-PCR result showed that
cyclin D1 and cyclin E regulated PBMC G1 cycle, but not cyclin D3. (D) IPI-145 did not show
obvious toxicity to INS-1E cells, while MPA caused severe toxicity. (E) IPI-145 at both forms
demonstrated direct toxicity to PBMCs without PHA activation.

4.4.4. IPI-145 exhibited cytotoxicity to immune cells by inducing apoptosis and necrosis
It is critical to assure that normal cells, especially insulin-secreting β cells, will not be
destroyed by IPI-145 administration prior to demonstrate the IPI-145 induced toxicity and
inhibition to immune cells. Unlike the positive control group receiving MPA, a broadspectrum immunosuppressive agent commonly used after organ transplantation, which
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showed a significant reduction in cell viability, IPI-145 up to 20 µM (80-fold of IPI-145
working concentration) showed no obvious cytotoxicity to INS-1E cells (Figure 4.4D).
Then in addition to the previously demonstrated inhibitory effect to PHA induced activation
and proliferation of human immune cells, IPI-145 also depicted direct cell-killing effect
towards immune cells by incubating IPI-145 with quiescent human PBMCs without PHA
activation. The cell viability decreased with the augment of IPI-145 concentration, where
59% cell death generated by free IPI-145 at the concentration of 250 nM, and 70% after
encapsulated into exosomes (Figure 4.4E).
The mechanism of decreased cell viability was investigated by flow cytometry analysis
with dual staining of annexin V which had high affinity to apoptotic marker phosphatidyl
serine (PS), and propidium iodide (PI) which stained necrotic cells with incomplete
membrane integrity. For the non-treated group, the population of live cells, necrotic cells,
and apoptotic cells (including early and late apoptotic cells) were 84.4%, 0.4% and 15.3%,
respectively. For group receiving 250 nM free IPI-145, the population were 60.5%, 0.9%
and 38.6%, at the same time, exo-IPI-145 induced 59.4%, 1.8% and 38.8% for each
portion (Figure 4.5A and 4.5B). Compared to the non-treated group, IPI-145 in free form
and encapsulated form rendered 23.9% and 25.0% reduction in live cells. However, the
population of live cells for INS-1E cells was not changed after IPI-145 treatment which
was around 95%, and the number of apoptotic and necrotic cells were also similar with
the control group (Figure 4.5C).
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Figure 4.5. Apoptosis and necrosis analysis of IPI-145 which was determined by flow
cytometry. (A) Flow cytometry of IPI-145 induced apoptosis and necrosis of PBMCs. (B)
Quantification of the population of apoptotic and necrotic PBMCs. (C) Flow cytometry and
quantification of apoptosis/necrosis of IPI-145 to INS-1E cells.

4.4.5. IPI-145 downregulated the expression of phospho-Akt (Ser473) protein in human
PBMCs but not in INS-1E cells
Figure 4.6A showed that the PHA induced upregulation of phospho-Akt (Ser473) was
almost completely blocked by free IPI-145 and exo-IPI-145 while the total Akt levels were
remained constant in each group. However, the treatment with IPI-145 in both forms did
not alter the expression of phospho-Akt (Ser473) and total Akt in INS-1E cells after 24 h
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incubation, further suggesting the specific targeting of IPI-145 to immune cells (Figure
4.6B).

Figure 4.6. Western blot analysis of IPI-145 induced downregulation of p-Akt (Ser473). (A)
Human PBMCs (10 x 106 cells/sample) were pre-treated with free IPI-145 and exo-IPI-145
(equivalent to 250 nM) for 1 h and allowed to activate under 6 μg/mL mitogenic PHA for 30 min.
The cells were lyzed and the supernatant was incubated with multiple antibodies. The bands
were scanned using a Bio-Rad imager. (B) Rat INS-1E cells were treated with 250 nM free IPI145 and exo-IPI-145 for 24 h and subjected to the same procedures as human PBMCs.

4.4.6. hBMSC-derived exosomes improved human islets in vitro growth
In addition to the role of encapsulating therapeutic payload in the current work,
hBMSC-derived exosomes were hypothesized to possess certain advantages inherited
from hBMSCs, including growth supportive function to targeted islet cells. The in vitro
growth of human islets (150 IEQs) in the presence or absence of hBMSC-derived
exosomes were explored in both Matrigel-coated and regular plates. In Matrigel-coated
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wells, hBMSC-derived exosomes exerted trophic function to support islets to form
capillary-like structure after 7 days’ in vitro culture (Figure 4.7A). In wells without Matrigel,
exosomes promoted islet settlement and cell outgrowth formation after 5 days’ incubation
(Figure 4.7B). To preciously quantify the number of islets with cell outgrowth, dithizone
was utilized to stain islets and photographs were taken on 15 randomly selected fields for
each sample. There were 2.3-fold of adherent dithizone-positive islets in exosomes
treated group over the control group (Figure 4.7C).

Figure 4.7. The in vitro trophic effect and in vivo biodistribution of hBMSC-derived
exosomes. (A) hBMSC-derived exosomes promoted human islets to form vascular-like
structure. (B) hBMSC-derived exosomes promoted human islets to settle on the bottom and
form cell outgrowth. (C) Quantification of adherent dithizone positive islets. (D) Biodistribution
of DiI-C16 labeled exosomes after 1 or 24 hours of I.V. and I.P. injection. (E) The ex vivo imaging
of major organs after 24 hours of exosome injection.
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4.4.7. hBMSC-derived exosomes had the tendency to accumulate to the pancreas of
diabetic NSG mice
STZ-induced diabetic NSG mice were subjected to fluorescent exosomes which were
derived from DiI-C16 labeled hBMSCs to determine the biodistribution profiles of exosomes
under different administration routes. The fluorescence intensity of major organs after 1
or 24 hours was measured by IVIS ex vivo imaging (Figure 4.7D). The result showed that
comparable signals between I.P. and I.V. injection were observed in brain, heart, lung,
kidneys and spleen. Liver was the dominant organ of exosome accumulation, whereas
heart and spleen exhibited the least fluorescent signal. hBMSC-derived exosomes elicited
tendency to migrate to pancreas, however, the number of accumulated exosomes in
pancreas via I.P. injection was about two fold compared to I.V. injection (17 % to 8 % at 1
h time point, and 19 % to 9 % at 24 h time point), suggesting that superior protective and
supportive effect of exosomes to pancreatic islets may be achievable through I.P.
administration. Figure 4.7E was the ex vivo image of the fluorescent signal in each major
organ after 24 hours.
4.4.8. IPI-145 suppressed serum IgG level and CD3+ T cell infiltration in vivo
Human immune system was established in NSG mice after two weeks of I.P.
administration of human PBMCs, followed by 7 consecutive injection of different treatment.
At the end of the study, the serum IgG levels which represented the function of B cells
were decreased to 75% and 69% with the treatment of free IPI-145 and Exo-IPI-145 at
the concentration of 5 mg/kg (Figure 4.8A). In addition, IPI-145 also suppressed the
infiltration of effector T cells to the spleen which was reduced to 79 % and 66 %,
respectively which was determined by IHC staining (Figure 4.8B and 4.8C).

104

Figure 4.8. IPI-145 inhibited the infiltration of CD3+ T cells to the spleen and the
production of serum IgG by B cells. (A) Relative serum IgG level. (B) Quantification of
infiltrated CD3+ T cells in spleen. (C) The infiltration of CD3+ T cells in spleen with IHC staining.

4.5. DISCUSSION
As one of the most challenging fields in the world, chronic autoimmune type 1 diabetes
is devoid of true cure which could permanently halt or revert the disease progression and
render long-time insulin-independence for the patients. Numerous attempts to clinical
translation of the current monotherapies have been demonstrated disappointing. The lack
of effective and justified combination therapy as well as safe delivery vehicles hinder the
treatment of T1D. Therefore, in the study, the therapeutic efficacy of a novel PI3K-δ/γ dual
inhibitor and the trophic/delivery role of hBMSC-derived exosomes were investigated to
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improve the outcome of T1D therapy and may provide some new insight to the future
combination strategies.
The PI3K/Akt pathway has been studied for a variety of malignant cancer researches,
however, this pathway is also equally crucial for autoimmune and inflammation related
diseases.66 The PI3K/Akt pathway regulate cell activation, proliferation, survival and
metabolism, and in B cells and T cells, the Bruton agammaglobulinaemia tyrosine kinase
(BTK) and IL-2-inducible T-cell kinase (ITK) are pivotal mediators of PI3K signaling.186
Owning to the unique expression of PI3K-δ/γ isoforms specifically in the leukocytes, the
inhibitor IPI-145 could potently inhibit the activation and proliferation of human PBMCs at
nanomolar ranges (Figure 4.3A and 4.3B). IPI-145 also elicited suppression on the
extracellular secretion and transcription of pro-inflammatory cytokines such as IL-2 and
IFN-γ (Figure 4.3D and 4.3E). Previous investigation indicated that IL-2 and IFN-γ played
extremely important roles during the pathogenesis of autoimmune T1D. It has been
demonstrated that the recognition and presentation of the β cell specific autoantigens by
APCs to CD4+ Th cells broke the balance of effector T cells to regulatory T cells and
stimulated CD4+ Th cells to generate IL-2 and IFN-γ, which were responsible for the
activation of β cell specific CD8+ cytotoxic T cells and macrophages, respectively.9 The
activated cytotoxic CD8+ T cells and macrophages exerted direct cell-killing effect to β
cells and secreted toxic soluble mediators to further destroy β cells. As a result, reduction
in IL-2 and IFN-γ production of PBMCs which was induced by IPI-145 suggested less
damage to pancreatic islets.
Furthermore, literature has shown that the PHA induced transcriptional activation of
IL-2 caused quiescent T cells to enter into cell cycle and advanced the cell cycle transition
from G1 phase to S phase for proliferation.187 Figure 4.4A showed that both free IPI-145
and Exo-IPI-145 impeded the G1 to S phase transition of PBMCs which was
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corresponding to their capability to downregulate IL-2 mRNA transcription. Besides, the
mRNA expression of distinct G1 cyclins including cyclin D1, cyclin D3 and Cyclin E which
regulated the progression of G1 to S phase transition,187 were measured by RT-PCR. The
results depicted that PHA induced the upregulation of cyclin D1 and cyclin E, and IPI-145
remarkably reduced the expression of these two genes, suggesting that IPI-145 arrested
PBMC proliferation and cell cycle through regulating the transcription of cyclin D1 and
cyclin E, but not cyclin D3 (Figure 4.4C). At the same time, IPI-145 did not disturb the cell
cycle of rat β cells (Figure 4.4B).
In addition to the inhibition on the PHA induced activation and proliferation of immune
cells, IPI-145 possessed direct cytotoxicity to quiescent PBMCs without exposure to PHA,
whilst it did not cause obvious toxicity to rat β cells (Figure 4.4D and 4.4E). The
mechanism studies showed that PBMC specific cell-killing was related with increase cell
apoptosis and necrosis (Figure 4.5). Taking together, the administration of IPI-145 at 5
mg/kg prohibited the infiltration of diabetogenic T cells to the spleen, and reduced the IgG
production of B cells, suggesting the potent suppression on human immune system
(Figure 4.8). Therefore, IPI-145 as the PI3K-δ/γ dual inhibitor has the potential to be a
superior therapeutic approach for the treatment of T1D in combination with other
pancreatic islet augment therapies without causing severe adverse effect. Notably, it
should be cautious at the selection of the other PI3K-δ and/or PI3K-γ inhibitors. For
example, IC87114, a selective inhibitor of PI3K-δ, has been demonstrated with both
positive and negative effects against the progression of T1D by two groups. One group
reported that IC87114 provided long-term protection to pancreatic β cells and revert the
occurrent of T1D,69 however, another group hold opposite opinion claiming that IC87114
not only failed to prevent T1D, but also attenuated the glucose-lowering effect of CTLA4Ig treatment.70
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The other important aspect of this study is to investigate the delivery potential and
supportive role of hBMSC-derived exosomes to injured/inflamed pancreatic islets. The
drug encapsulation method we selected was probe sonication, nevertheless, this method
caused particle size augment which was characterized by both DLS and NTA (Figure 4.2).
Literature showed that particles with size greater than 100 nm tended to be recognized
and uptake by reticuloendothelial system (RES).188 However, due to low immunogenicity
of hBMSCs and the derived exosomes, the influence of the increased size of sonicated
exosomes on the in vivo delivery of IPI-145 is unknown so far. Besides, more drug
encapsulation methods will be explored in the future studies and the one with minimal size
increase will be selected for more researches. Intriguingly, although PBMCs treated with
hBMSC-derived exosomes alone elicited approximately 20% more cell proliferation, IPI145 encapsulated exosomes had slightly higher suppression on the PBMC proliferation,
more cell-killing effect, and increased necrotic cell population. This could be explained by
the superior uptake of hBMSC-derived exosomes by PBMCs. The trophic effect of
hBMSC-derived exosomes was also demonstrated by the enhanced formation of
vascular-like structure of human islets on Matrigel-coated wells, as well as improved islet
settlement and cell outgrowth on non-Matrigel coated wells (Figure 4.7A-C). Extensive
researches depicted that hBMSCs possessed angiogenesis potential through secreting
soluble factors or differentiating into endothelial-like cells,189, 190 besides, hBMSCs have
been widely used to promote the outcome of islet transplantation, aiming to provide
immune modulation and enhance the angiogenesis of islet xenografts.191 As a result, we
could claim that the hBMSC-derived exosomes inherited the trophic effect of the parental
cells to support the growth of human islets. The mediated factors will be investigated in
the future studies. We will also perform in vivo therapeutic studies using IPI-145
encapsulated exosomes to prevent and revert the onset of diabetes in NOD mice.
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4.6. CONCLUSION
To summarize, the novel PI3K-δ/γ dual inhibitor IPI-145 specifically targeted immune
cells by inhibiting the activation and proliferation of PBMCs, reduced the production and
transcription of pro-inflammatory cytokines including IL-2 and IFN-γ, leading to
suppressed damage of immune cells to islet β cells and arrested cell cycle from G1 to S
phase. The G1 phase regulator cyclin D1 and cyclin E, but not cyclin D3 were responsible
for this cell cycle arrest. What’s more, IPI-145 elicited direct cell-killing effect to PBMCs
through inducing apoptosis and necrosis. Encapsulation of IPI-145 into hBMSC-derived
exosomes did not compromise these effects. In addition, hBMSC-derived exosomes
promoted the survival and growth of human islets in vitro and tended to migrate to the
inflamed pancreas in vivo after both I.V. and I.P. administration while the route of I.P. was
more desirable. At the same time, more investigation is ongoing to identify the genes or
proteins responsible for the trophic effect and determine the in vivo therapeutic efficacy of
IPI-145 encapsulated exosomes to prevent or revert the onset of T1D.
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS
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5.1. SUMMARY
Type 1 diabetes is one of the most challenging chronic autoimmune diseases, which
is associated with critical loss of insulin producing β cells, leading to hyperglycemia,
exogenous insulin-dependence and a variety of severe complications.161 Clinical analysis
of the pancreatic islet samples depicts that the initiation and progression of T1D are closely
related with the massive infiltration and cross-talking of a variety of inflammatory cells,
including CD8+ cytotoxic T cells, macrophages (CD68+), B lymphocytes (CD20+), CD138+
plasma cells, and CD4+ T cells, leading to the destruction and dysfunction of islet β cells.5
The disappointing translation of the current monotherapies to the clinics drives the
enthusiasm of research personnel to develop effective and safe therapeutic approaches.
In this thesis, several novel strategies have been investigated for the treatment of T1D.
First, MPA is a commonly used broad-spectrum immunosuppressive agent after organ
transplantation; however, the application of MPA is hindered by the general non-selective
toxicity. To overcome this issue and make it more suitable to use after islet transplantation,
a novel immunosuppressant MQ4 was synthesized by conjugating MPA to quinic acid
(QA), which exhibits potent anti-inflammatory effect, via amide bonds to eliminate the
broad toxicity of MPA and induce the synergistic suppressive effect on the human immune
system. MQ4 exhibited improved metabolic stability and resistance to hydrolytic
degradation compared to the control conjugate utilizing ester bonds. Although the
inhibitory effect on human lymphocyte proliferation was partially compromised, MQ4
showed significantly reduced toxicity to β cells which may be explained by the decreased
level of apoptotic mediator caspase-3. MQ4 also enhanced insulin production and
downregulated NFκB expression of β cells which was a well-known inflammation pathway,
suggesting that MQ4 may be a promising immunosuppressive agent for preventing and
minimizing islet post-transplanted immune rejection.
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Secondly, a combination therapy utilizing a small molecular immunosuppressive drug
and siRNA for the treatment of T1D was studied. Sunitinib is a tyrosine kinase inhibitor
and exhibited potent inhibition on immune cells and glucose-lowering effect which may be
related to the function of downregulating the phosphorylation of multiple key protein
receptors like VEGFR and PDGFR. Alox15 plays a crucial role in the pathogenesis of T1D
which oxidizing polyunsaturated fatty acids to generate toxic lipids and release celldamaging ROS and cytokines. Therefore, in this study, sunitinib and siRNA against Alox15
(siAlox15) were co-delivered utilizing a cationic copolymer mPEG-b-PCC-g-DC-g-TEPA
to reverse the new-onset of T1D in a spontaneous diabetic NOD mouse model. The
encapsulation efficiency was about 90% and the complex formed starting at the N/P ratio
of 16:1, while the formulation exhibited sustained release of IPI-145 and remarkable
protection to siAlox15 against serum degradation. Combination of sunitinib and siAlox15
elicited synergistic immunosuppressive effect to inhibit PBMC activation and proliferation
by downregulating the phosphorylation of Akt and PDGFR at protein levels as well as the
expression of Alox15 at mRNA levels. The in vivo therapeutic effect of the combination
approach in NOD mice was encouraging which exhibited 80% reversal rate of the newonset of T1D, and enhanced the metabolic and secretory function of islet β cells,
suggesting that the novel combination of sunitinib and siAlox15 delivered by our cationic
polymeric micelles can be a reliable and safe approach in the field of T1D.
Lastly, the utilization of the PI3K pathway in the autoimmune T1D and the
transportation potential and trophic role of hBMSC-derived exosomes were explored
which may benefit the future therapeutic approaches in T1D. The PI3K pathway is
relatively unique because that PI3K-δ and PI3K-γ are specifically expressed in
hematopoietic-origin leukocytes, but not β cells. Unlike other immunosuppressants, PI3Kδ/γ inhibitors are not supposed to interfere with the viability and function of β cells and
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other normal cells. Besides, compared to current drug delivery platforms, hBMSC-derived
exosomes are hypothesized to possess immune modulatory function, paracrine/trophic
effect, and intrinsic tendency to migrate to injured/inflamed islets. In this study, the novel
PI3K-δ/γ dual inhibitor IPI-145 potently inhibited the activation and proliferation of PBMCs
through downregulation of the phosphorylation of Akt, reduced the cytokine IL-2 and IFNγ at both protein level and mRNA level, resulted in less β cell destruction and halted cell
cycle transition from G1 to S phase, which was regulated by cyclin D1 and cyclin E. IPI145 demonstrated both cytostatic and cytotoxic effects to PBMCs, induced more
apoptotic/necrotic cell population, and inhibited CD3+ T cell infiltration and B cell
production of IgG. Furthermore, hBMSC-derived exosomes demonstrated the potential to
deliver IPI-145 both in vitro and in vivo. More importantly, hBMSC-derived exosomes
promoted the settlement and formation of vascular-like structure or cell outgrowth of
human islets in vitro and tended to migrate to the inflamed pancreas in vivo, suggesting
the superiority of this type of naturally produced vehicles over other synthetic platforms.
5.2. FUTURE DIRECTIONS
The research work presented in this thesis demonstrated several novel and relatively
effective therapeutic approaches which may shed light on the future clinical translation for
the treatment of T1D. However, the work is not complete and need further advancement
and improvement. For example, the first project in chapter 2 showed the chemical
manipulation of a toxic immunosuppressive compound to become less harmful while
maintaining the original effect. This approach may, to some degree, benefit its application
in islet transplantation; meanwhile, the possible unsatisfactory efficacy of this
monotherapy in the future application depicted the necessity of adding other therapeutic
strategies for the combination therapy. The second project in chapter 3 was utilizing the
combination of a small molecule based immune intervention therapy and siRNA based β
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cell preservative therapy to revert the new-onset of T1D, and demonstrated encouraging
outcomes. Nevertheless, we need to prolong the duration of glucose monitoring to confirm
the long-term efficacy of this combination therapy since we still have doubt about the
regulatory T cells: whether the reduction is transient or permanent? If it is permanent, will
there be other compensate mechanisms to induce long-term T1D remission without
regulatory T cell induced immune tolerance? How about the in vivo biodistribution of
sunitinib and siAlox15 delivered by the cationic polymer? For the third project in chapter
4, although we proved the therapeutic efficacy and safety of IPI-145 and showed the
transportation potential and trophic role of hBMSC-derived exosomes, the underlying
mechanism of the supportive effect to human islets is unclear. Besides, the possible in
vivo angiogenetic effect and therapeutic application to prevent or revert the occurrence of
T1D are in high demand. Moreover, it is very likely that the combination of the immune
intervention of IPI-145 and the β cell supportive effect of hBMSC-derived exosomes is not
sufficient to induce satisfactory therapeutic outcome. The superior approach is to
genetically modify hBMSCs with certain potent miRNA/shRNA, generate exosomes
carrying these small non-coding RNAs, followed by the encapsulation of IPI-145. As a
result, the combination of immune intervention, small non-coding RNA and hBMSCderived exosomes which possess intrinsic immune modulation property, trophic effect and
migration tendency to pancreas will be a highly innovative and effective approach for the
treatment of T1D.
Generally speaking, there are several remaining issues and future perspectives that
should be considered in this complicated field as we mentioned in chapter 1: Will early
intervention bring more satisfactory outcome? Which biomarker(s) should be selected?
Can β cell regeneration/redifferentiation be effectively and safely induced and applied in
human? What are the advantages of the combination therapy for the treatment of T1D?
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Only after these questions have been answered, we will gain deeper acknowledge and
more insight to advance the understanding of T1D, and improve current therapeutic
approaches to seize a true cure for T1D.

115

References

1. Melendez-Ramirez, L.Y.; Richards, R.J.; Cefalu, W.T. Complications of type 1 diabetes.
Endocrinol. Metab. Clin. North Am. 2010, 39, 625-640.

2. Centers for Disease Control and Prevention National Diabetes Statistics Report, 2017.
2017,

3. van Belle, T.L.; Coppieters, K.T.; von Herrath, M.G. Type 1 diabetes: etiology,
immunology, and therapeutic strategies. Physiol. Rev. 2011, 91, 79-118.

4. Atkinson, M.A.; Eisenbarth, G.S.; Michels, A.W. Type 1 diabetes. Lancet 2014, 383, 6982.

5. Willcox, A.; Richardson, S.J.; Bone, A.J.; Foulis, A.K.; Morgan, N.G. Analysis of islet
inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155, 173-181.

6. In't Veld, P. Insulitis in human type 1 diabetes: The quest for an elusive lesion. Islets
2011, 3, 131-138.

7. Lehuen, A.; Diana, J.; Zaccone, P.; Cooke, A. Immune cell crosstalk in type 1 diabetes.
Nat. Rev. Immunol. 2010, 10, 501-513.

8. Ziegler, A.G. and Nepom, G.T. Prediction and pathogenesis in type 1 diabetes.
Immunity 2010, 32, 468-478.

9. Yoon, J.W. and Jun, H.S. Autoimmune destruction of pancreatic beta cells. Am. J. Ther.
2005, 12, 580-591.

116

10. Li, F. and Mahato, R.I. RNA interference for improving the outcome of islet
transplantation. Adv. Drug Deliv. Rev. 2011, 63, 47-68.

11. Matveyenko, A.V. and Butler, P.C. Relationship between beta-cell mass and diabetes
onset. Diabetes Obes. Metab. 2008, 10 Suppl 4, 23-31.

12. Chen, C.; Cohrs, C.M.; Stertmann, J.; Bozsak, R.; Speier, S. Human beta cell mass
and function in diabetes: Recent advances in knowledge and technologies to understand
disease pathogenesis. Mol. Metab. 2017, 6, 943-957.

13. Mathieu, C.; Gillard, P.; Benhalima, K. Insulin analogues in type 1 diabetes mellitus:
getting better all the time. Nat. Rev. Endocrinol. 2017, 13, 385-399.

14. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group;
Tamborlane, W.V.; Beck, R.W.; Bode, B.W.; Buckingham, B.; Chase, H.P.; Clemons, R.;
Fiallo-Scharer, R.; Fox, L.A.; Gilliam, L.K.; Hirsch, I.B.; Huang, E.S.; Kollman, C.; Kowalski,
A.J.; Laffel, L.; Lawrence, J.M.; Lee, J.; Mauras, N.; O'Grady, M.; Ruedy, K.J.; Tansey, M.;
Tsalikian, E.; Weinzimer, S.; Wilson, D.M.; Wolpert, H.; Wysocki, T.; Xing, D. Continuous
glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 2008, 359,
1464-1476.

15. Beck, R.W.; Riddlesworth, T.; Ruedy, K.; Ahmann, A.; Bergenstal, R.; Haller, S.;
Kollman, C.; Kruger, D.; McGill, J.B.; Polonsky, W.; Toschi, E.; Wolpert, H.; Price, D.;
DIAMOND Study Group Effect of Continuous Glucose Monitoring on Glycemic Control in
Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical
Trial. JAMA 2017, 317, 371-378.

117

16. McAdams, B.H. and Rizvi, A.A. An Overview of Insulin Pumps and Glucose Sensors
for the Generalist. J. Clin. Med. 2016, 5, 10.3390/jcm5010005.

17. Heinemann, L.; Fleming, G.A.; Petrie, J.R.; Holl, R.W.; Bergenstal, R.M.; Peters, A.L.
Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse
event reporting, and research needs: a joint statement of the European Association for the
Study of Diabetes and the American Diabetes Association Diabetes Technology Working
Group. Diabetes Care 2015, 38, 716-722.

18. Home, P.D. The pharmacokinetics and pharmacodynamics of rapid-acting insulin
analogues and their clinical consequences. Diabetes Obes. Metab. 2012, 14, 780-788.

19. Porcellati, F.; Bolli, G.B.; Fanelli, C.G. Pharmacokinetics and pharmacodynamics of
basal insulins. Diabetes Technol. Ther. 2011, 13 Suppl 1, S15-24.

20. Ratner, R.E.; Hirsch, I.B.; Neifing, J.L.; Garg, S.K.; Mecca, T.E.; Wilson, C.A. Less
hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S.
Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000, 23, 639-643.

21. Wang, Y.; Chen, Y.S.; Zaro, J.L.; Shen, W.C. Receptor-mediated activation of a
proinsulin-transferrin fusion protein in hepatoma cells. J. Control. Release 2011, 155, 386392.

22. Wang, Y.; Shao, J.; Zaro, J.L.; Shen, W.C. Proinsulin-transferrin fusion protein as a
novel long-acting insulin analog for the inhibition of hepatic glucose production. Diabetes
2014, 63, 1779-1788.

118

23. Han, J.; Wang, Y.; Meng, Q.; Li, G.; Huang, F.; Wu, S.; Fei, Y.; Zhou, F.; Fu, J. Design,
synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1
derivatives as long-acting hypoglycemic agents. Eur. J. Med. Chem. 2017, 132, 81-89.

24. Sakai, K.; Matsumoto, K.; Nishikawa, T.; Suefuji, M.; Nakamaru, K.; Hirashima, Y.;
Kawashima, J.; Shirotani, T.; Ichinose, K.; Brownlee, M.; Araki, E. Mitochondrial reactive
oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem. Biophys. Res.
Commun. 2003, 300, 216-222.

25. Lightfoot, Y.L.; Chen, J.; Mathews, C.E. Oxidative stress and beta cell dysfunction.
Methods Mol. Biol. 2012, 900, 347-362.

26. Tong, Z.; Zhou, J.; Zhong, J.; Tang, Q.; Lei, Z.; Luo, H.; Ma, P.; Liu, X. Glucose- and
H2O2-Responsive Polymeric Vesicles Integrated with Microneedle Patches for GlucoseSensitive Transcutaneous Delivery of Insulin in Diabetic Rats. ACS Appl. Mater. Interfaces
2018, 10, 20014-20024.

27. Yu, J.; Zhang, Y.; Ye, Y.; DiSanto, R.; Sun, W.; Ranson, D.; Ligler, F.S.; Buse, J.B.;
Gu, Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast
glucose-responsive insulin delivery. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 8260-8265.

28. Mallawarachchi, S.; Mahadevan, A.; Gejji, V.; Fernando, S. Mechanics of controlled
release of insulin entrapped in polyacrylic acid gels via variable electrical stimuli. Drug
Deliv. Transl. Res. 2019, 9, 783-794.

29. Chen, X.; Ren, Y.; Feng, Y.; Xu, X.; Tan, H.; Li, J. Cp1-11 peptide/insulin complex
loaded pH-responsive nanoparticles with enhanced oral bioactivity. Int. J. Pharm. 2019,
562, 23-30.

119

30. Sharma, G.; Sharma, A.R.; Nam, J.S.; Doss, G.P.; Lee, S.S.; Chakraborty, C.
Nanoparticle based insulin delivery system: the next generation efficient therapy for Type
1 diabetes. J. Nanobiotechnology 2015, 13, 74-015-0136-y.

31. Li, L.; Jiang, G.; Yu, W.; Liu, D.; Chen, H.; Liu, Y.; Tong, Z.; Kong, X.; Yao, J.
Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers
for oral delivery of insulin. Mater. Sci. Eng. C. Mater. Biol. Appl. 2017, 70, 278-286.

32. Fonte, P.; Araujo, F.; Silva, C.; Pereira, C.; Reis, S.; Santos, H.A.; Sarmento, B.
Polymer-based nanoparticles for oral insulin delivery: Revisited approaches. Biotechnol.
Adv. 2015, 33, 1342-1354.

33. Urimi, D.; Agrawal, A.K.; Kushwah, V.; Jain, S. Polyglutamic Acid Functionalization of
Chitosan Nanoparticles Enhances the Therapeutic Efficacy of Insulin Following Oral
Administration. AAPS PharmSciTech 2019, 20, 131-019-1330-2.

34. Cui, F.D.; Tao, A.J.; Cun, D.M.; Zhang, L.Q.; Shi, K. Preparation of insulin loaded
PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 2007, 96, 421-427.

35. Ryan, E.A.; Paty, B.W.; Senior, P.A.; Bigam, D.; Alfadhli, E.; Kneteman, N.M.; Lakey,
J.R.; Shapiro, A.M. Five-year follow-up after clinical islet transplantation. Diabetes 2005,
54, 2060-2069.

36. van der Windt, D.J.; Bottino, R.; Casu, A.; Campanile, N.; Cooper, D.K. Rapid loss of
intraportally transplanted islets: an overview of pathophysiology and preventive strategies.
Xenotransplantation 2007, 14, 288-297.

120

37. Peng, Y.; Wen, D.; Lin, F.; Mahato, R.I. Co-delivery of siAlox15 and sunitinib for
reversing the new-onset of type 1 diabetes in non-obese diabetic mice. J. Control. Release
2018, 292, 1-12.

38. Narang, A.S. and Mahato, R.I. Biological and biomaterial approaches for improved
islet transplantation. Pharmacol. Rev. 2006, 58, 194-243.

39. Chou, F.C.; Huang, S.H.; Sytwu, H.K. Genetically engineered islets and alternative
sources of insulin-producing cells for treating autoimmune diabetes: quo vadis? Int. J.
Endocrinol. 2012, 2012, 296485.

40. Wu, H.; Panakanti, R.; Li, F.; Mahato, R.I. XIAP gene expression protects beta-cells
and human islets from apoptotic cell death. Mol. Pharm. 2010, 7, 1655-1666.

41. Narang, A.S.; Cheng, K.; Henry, J.; Zhang, C.; Sabek, O.; Fraga, D.; Kotb, M.; Gaber,
A.O.; Mahato, R.I. Vascular endothelial growth factor gene delivery for revascularization
in transplanted human islets. Pharm. Res. 2004, 21, 15-25.

42. Cheng, G.; Zhu, L.; Mahato, R.I. Caspase-3 gene silencing for inhibiting apoptosis in
insulinoma cells and human islets. Mol. Pharm. 2008, 5, 1093-1102.

43. Thomas, D.C.; Wong, F.S.; Zaccone, P.; Green, E.A.; Wallberg, M. Protection of islet
grafts through transforming growth factor-beta-induced tolerogenic dendritic cells.
Diabetes 2013, 62, 3132-3142.

44. Panakanti, R. and Mahato, R.I. Bipartite adenoviral vector encoding hHGF and hIL1Ra for improved human islet transplantation. Pharm. Res. 2009, 26, 587-596.

121

45. Jia, X.; Cheng, K.; Mahato, R.I. Coexpression of vascular endothelial growth factor
and interleukin-1 receptor antagonist for improved human islet survival and function. Mol.
Pharm. 2007, 4, 199-207.

46. Wang, M.; Yuan, Q.; Xie, L. Mesenchymal Stem Cell-Based Immunomodulation:
Properties and Clinical Application. Stem Cells Int. 2018, 2018, 3057624.

47. Gao, F.; Chiu, S.M.; Motan, D.A.; Zhang, Z.; Chen, L.; Ji, H.L.; Tse, H.F.; Fu, Q.L.;
Lian, Q. Mesenchymal stem cells and immunomodulation: current status and future
prospects. Cell. Death Dis. 2016, 7, e2062.

48. Madec, A.M.; Mallone, R.; Afonso, G.; Abou Mrad, E.; Mesnier, A.; Eljaafari, A.;
Thivolet, C. Mesenchymal stem cells protect NOD mice from diabetes by inducing
regulatory T cells. Diabetologia 2009, 52, 1391-1399.

49. Hofer, H.R. and Tuan, R.S. Secreted trophic factors of mesenchymal stem cells
support neurovascular and musculoskeletal therapies. Stem Cell. Res. Ther. 2016, 7, 131016-0394-0.

50. Abdi, R.; Fiorina, P.; Adra, C.N.; Atkinson, M.; Sayegh, M.H. Immunomodulation by
mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes
2008, 57, 1759-1767.

51. Sordi, V.; Malosio, M.L.; Marchesi, F.; Mercalli, A.; Melzi, R.; Giordano, T.; Belmonte,
N.; Ferrari, G.; Leone, B.E.; Bertuzzi, F.; Zerbini, G.; Allavena, P.; Bonifacio, E.; Piemonti,
L. Bone marrow mesenchymal stem cells express a restricted set of functionally active
chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106,
419-427.

122

52. Wu, H.; Lu, W.; Mahato, R.I. Mesenchymal stem cells as a gene delivery vehicle for
successful islet transplantation. Pharm. Res. 2011, 28, 2098-2109.

53. Gao, X.; Song, L.; Shen, K.; Wang, H.; Niu, W.; Qin, X. Transplantation of bone marrow
derived cells promotes pancreatic islet repair in diabetic mice. Biochem. Biophys. Res.
Commun. 2008, 371, 132-137.

54. Wu, H.; Wen, D.; Mahato, R.I. Third-party mesenchymal stem cells improved human
islet transplantation in a humanized diabetic mouse model. Mol. Ther. 2013, 21, 17781786.

55. Gresch, O.; Engel, F.B.; Nesic, D.; Tran, T.T.; England, H.M.; Hickman, E.S.; Korner,
I.; Gan, L.; Chen, S.; Castro-Obregon, S.; Hammermann, R.; Wolf, J.; Muller-Hartmann,
H.; Nix, M.; Siebenkotten, G.; Kraus, G.; Lun, K. New non-viral method for gene transfer
into primary cells. Methods 2004, 33, 151-163.

56. Mundra, V.; Wu, H.; Mahato, R.I. Genetically modified human bone marrow derived
mesenchymal stem cells for improving the outcome of human islet transplantation. PLoS
One 2013, 8, e77591.

57. Wen, D.; Peng, Y.; Liu, D.; Weizmann, Y.; Mahato, R.I. Mesenchymal stem cell and
derived exosome as small RNA carrier and Immunomodulator to improve islet
transplantation. J. Control. Release 2016, 238, 166-175.

58. Luo, X.; Herold, K.C.; Miller, S.D. Immunotherapy of type 1 diabetes: where are we
and where should we be going? Immunity 2010, 32, 488-499.

59. Moini, M.; Schilsky, M.L.; Tichy, E.M. Review on immunosuppression in liver
transplantation. World J. Hepatol. 2015, 7, 1355-1368.

123

60. Paul, M.K. and Mukhopadhyay, A.K. Tyrosine kinase - Role and significance in Cancer.
Int. J. Med. Sci. 2004, 1, 101-115.

61. Agostino, N.M.; Chinchilli, V.M.; Lynch, C.J.; Koszyk-Szewczyk, A.; Gingrich, R.; Sivik,
J.; Drabick, J.J. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and
imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical
practice. J. Oncol. Pharm. Pract. 2011, 17, 197-202.

62. Huda, M.S.; Amiel, S.A.; Ross, P.; Aylwin, S.J. Tyrosine kinase inhibitor sunitinib
allows insulin independence in long-standing type 1 diabetes. Diabetes Care 2014, 37,
e87-8.

63. Louvet, C.; Szot, G.L.; Lang, J.; Lee, M.R.; Martinier, N.; Bollag, G.; Zhu, S.; Weiss,
A.; Bluestone, J.A. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic
mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 18895-18900.

64. Hagerkvist, R.; Sandler, S.; Mokhtari, D.; Welsh, N. Amelioration of diabetes by
imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic
preconditioning. FASEB J. 2007, 21, 618-628.

65. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase
pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627-644.

66. Stark, A.K.; Sriskantharajah, S.; Hessel, E.M.; Okkenhaug, K. PI3K inhibitors in
inflammation, autoimmunity and cancer. Curr. Opin. Pharmacol. 2015, 23, 82-91.

67. Azzi, J.; Moore, R.F.; Elyaman, W.; Mounayar, M.; El Haddad, N.; Yang, S.; Jurewicz,
M.; Takakura, A.; Petrelli, A.; Fiorina, P.; Ruckle, T.; Abdi, R. The novel therapeutic effect

124

of phosphoinositide 3-kinase-gamma inhibitor AS605240 in autoimmune diabetes.
Diabetes 2012, 61, 1509-1518.

68. Azzi, J.; Thueson, L.; Moore, R.; Abdoli, R.; Reijonen, H.; Abdi, R. PI3Kgamma
Deficient NOD-Mice Are Protected from Diabetes by Restoring the Balance of Regulatory
to Effector-T-Cells. PLoS One 2017, 12, e0169695.

69. Durand, C.A.; Richer, M.J.; Brenker, K.; Graves, M.; Shanina, I.; Choi, K.; Horwitz,
M.S.; Puri, K.D.; Gold, M.R. Selective pharmacological inhibition of phosphoinositide 3kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic
(NOD) mice. Autoimmunity 2013, 46, 62-73.

70. Barbera Betancourt, A.; Emery, J.L.; Recino, A.; Wong, F.S.; Cooke, A.; Okkenhaug,
K.; Wallberg, M. Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell
Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine
Production. PLoS One 2016, 11, e0146516.

71. Kang, S.; Park, E.J.; Joe, Y.; Seo, E.; Park, M.K.; Seo, S.Y.; Chung, H.Y.; Yoo, Y.H.;
Kim, D.K.; Lee, H.J. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL)
elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1
diabetes in nonobese diabetic mice. Endocrinology 2010, 151, 5638-5646.

72. Jiang, H.; Zhu, H.; Chen, X.; Peng, Y.; Wang, J.; Liu, F.; Shi, S.; Fu, B.; Lu, Y.; Hong,
Q.; Feng, Z.; Hou, K.; Sun, X.; Cai, G.; Zhang, X.; Xie, Y. TIMP-1 transgenic mice recover
from diabetes induced by multiple low-dose streptozotocin. Diabetes 2007, 56, 49-56.

73. Mi, Q.S.; Ly, D.; Lamhamedi-Cherradi, S.E.; Salojin, K.V.; Zhou, L.; Grattan, M.;
Meagher, C.; Zucker, P.; Chen, Y.H.; Nagle, J.; Taub, D.; Delovitch, T.L. Blockade of tumor

125

necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD
mice. Diabetes 2003, 52, 1967-1975.

74. Han, X.; Sun, Y.; Scott, S.; Bleich, D. Tissue inhibitor of metalloproteinase-1 prevents
cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells.
Diabetes 2001, 50, 1047-1055.

75. Wu, H.; Pagadala, J.; Yates, C.R.; Miller, D.; Mahato, R.I. Synthesis and
characterization of an anti-apoptotic immunosuppressive compound for improving the
outcome of islet transplantation. Bioconjug. Chem. 2013, 24, 2036-2044.

76. Peng, Y.; Dong, Y.; Mahato, R.I. Synthesis and Characterization of a Novel
Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with
Decreased Toxicity. Mol. Pharm. 2015, 12, 4445-4453.

77. Ahmad, Z.A.; Yeap, S.K.; Ali, A.M.; Ho, W.Y.; Alitheen, N.B.; Hamid, M. scFv antibody:
principles and clinical application. Clin. Dev. Immunol. 2012, 2012, 980250.

78. Kuhn, C. and Weiner, H.L. Therapeutic anti-CD3 monoclonal antibodies: from bench
to bedside. Immunotherapy 2016, 8, 889-906.

79. Herold, K.C.; Gitelman, S.E.; Masharani, U.; Hagopian, W.; Bisikirska, B.; Donaldson,
D.; Rother, K.; Diamond, B.; Harlan, D.M.; Bluestone, J.A. A single course of anti-CD3
monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide
responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Diabetes 2005, 54, 1763-1769.

126

80. Valle, A.; Jofra, T.; Stabilini, A.; Atkinson, M.; Roncarolo, M.G.; Battaglia, M.
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes
2009, 58, 875-881.

81. Chen, G.; Han, G.; Wang, J.; Wang, R.; Xu, R.; Shen, B.; Qian, J.; Li, Y. Essential
roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic
mice independent of Foxp3+CD4+ regulatory T cells. J. Leukoc. Biol. 2008, 83, 280-287.

82. Valle, A.; Barbagiovanni, G.; Jofra, T.; Stabilini, A.; Perol, L.; Baeyens, A.; Anand, S.;
Cagnard, N.; Gagliani, N.; Piaggio, E.; Battaglia, M. Heterogeneous CD3 expression levels
in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation.
J. Immunol. 2015, 194, 2117-2127.

83. Miller, B.J.; Appel, M.C.; O'Neil, J.J.; Wicker, L.S. Both the Lyt-2+ and L3T4+ T cell
subsets are required for the transfer of diabetes in nonobese diabetic mice. J. Immunol.
1988, 140, 52-58.

84. Xiu, Y.; Wong, C.P.; Bouaziz, J.D.; Hamaguchi, Y.; Wang, Y.; Pop, S.M.; Tisch, R.M.;
Tedder, T.F. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in
nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector
functions. J. Immunol. 2008, 180, 2863-2875.

85. Pescovitz, M.D.; Greenbaum, C.J.; Krause-Steinrauf, H.; Becker, D.J.; Gitelman, S.E.;
Goland, R.; Gottlieb, P.A.; Marks, J.B.; McGee, P.F.; Moran, A.M.; Raskin, P.; Rodriguez,
H.; Schatz, D.A.; Wherrett, D.; Wilson, D.M.; Lachin, J.M.; Skyler, J.S.; Type 1 Diabetes
TrialNet Anti-CD20 Study Group Rituximab, B-lymphocyte depletion, and preservation of
beta-cell function. N. Engl. J. Med. 2009, 361, 2143-2152.

127

86. Carpenter, P.A.; Pavlovic, S.; Tso, J.Y.; Press, O.W.; Gooley, T.; Yu, X.Z.; Anasetti,
C. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated
human T cells. J. Immunol. 2000, 165, 6205-6213.

87. Aluri, S.R.; Shi, P.; Gustafson, J.A.; Wang, W.; Lin, Y.A.; Cui, H.; Liu, S.; Conti, P.S.;
Li, Z.; Hu, P.; Epstein, A.L.; MacKay, J.A. A hybrid protein-polymer nanoworm potentiates
apoptosis better than a monoclonal antibody. ACS Nano 2014, 8, 2064-2076.

88. Zhang, Y.; Feng, Z.P.; Naselli, G.; Bell, F.; Wettenhall, J.; Auyeung, P.; Ellis, J.A.;
Ponsonby, A.L.; Speed, T.P.; Chong, M.M.; Harrison, L.C. MicroRNAs in CD4(+) T cell
subsets are markers of disease risk and T cell dysfunction in individuals at risk for type 1
diabetes. J. Autoimmun. 2016, 68, 52-61.

89. Lu, L.F.; Boldin, M.P.; Chaudhry, A.; Lin, L.L.; Taganov, K.D.; Hanada, T.; Yoshimura,
A.; Baltimore, D.; Rudensky, A.Y. Function of miR-146a in controlling Treg cell-mediated
regulation of Th1 responses. Cell 2010, 142, 914-929.

90. Xu, G.; Chen, J.; Jing, G.; Grayson, T.B.; Shalev, A. miR-204 Targets PERK and
Regulates UPR Signaling and beta-Cell Apoptosis. Mol. Endocrinol. 2016, 30, 917-924.

91. Kassan, M.; Vikram, A.; Li, Q.; Kim, Y.R.; Kumar, S.; Gabani, M.; Liu, J.; Jacobs, J.S.;
Irani, K. MicroRNA-204 promotes vascular endoplasmic reticulum stress and endothelial
dysfunction by targeting Sirtuin1. Sci. Rep. 2017, 7, 9308-017-06721-y.

92. Lenzen, S.; Drinkgern, J.; Tiedge, M. Low antioxidant enzyme gene expression in
pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 1996,
20, 463-466.

128

93. Xu, G.; Chen, J.; Jing, G.; Shalev, A. Thioredoxin-interacting protein regulates insulin
transcription through microRNA-204. Nat. Med. 2013, 19, 1141-1146.

94. Jo, S.; Chen, J.; Xu, G.; Grayson, T.B.; Thielen, L.A.; Shalev, A. miR-204 Controls
Glucagon-Like Peptide 1 Receptor Expression and Agonist Function. Diabetes 2018, 67,
256-264.

95. McDuffie, M.; Maybee, N.A.; Keller, S.R.; Stevens, B.K.; Garmey, J.C.; Morris, M.A.;
Kropf, E.; Rival, C.; Ma, K.; Carter, J.D.; Tersey, S.A.; Nunemaker, C.S.; Nadler, J.L.
Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase
are protected from autoimmune diabetes. Diabetes 2008, 57, 199-208.

96. Weisberg, S.P. and Leibel, R.L. An apparent role for Alox15 in the pathogenesis of
diabetes in the NOD mouse: parsing the supporting genetic data. Diabetes 2008, 57, 1-2.

97. Green-Mitchell, S.M.; Tersey, S.A.; Cole, B.K.; Ma, K.; Kuhn, N.S.; Cunningham, T.D.;
Maybee, N.A.; Chakrabarti, S.K.; McDuffie, M.; Taylor-Fishwick, D.A.; Mirmira, R.G.;
Nadler, J.L.; Morris, M.A. Deletion of 12/15-lipoxygenase alters macrophage and islet
function in NOD-Alox15(null) mice, leading to protection against type 1 diabetes
development. PLoS One 2013, 8, e56763.

98. Tersey, S.A.; Maier, B.; Nishiki, Y.; Maganti, A.V.; Nadler, J.L.; Mirmira, R.G. 12Lipoxygenase Promotes Obesity-Induced Oxidative Stress in Pancreatic Islets. Mol. Cell.
Biol. 2014, 34, 3735-3745.

99. Leconet, W.; Petit, P.; Peraldi-Roux, S.; Bresson, D. Nonviral delivery of small
interfering RNA into pancreas-associated immune cells prevents autoimmune diabetes.
Mol. Ther. 2012, 20, 2315-2325.

129

100. Sherr, J.; Sosenko, J.; Skyler, J.S.; Herold, K.C. Prevention of type 1 diabetes: the
time has come. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4, 334-343.

101. Sims, E.K.; Lakhter, A.J.; Anderson-Baucum, E.; Kono, T.; Tong, X.; Evans-Molina,
C. MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells.
Diabetologia 2017, 60, 1057-1065.

102. Seyhan, A.A.; Nunez Lopez, Y.O.; Xie, H.; Yi, F.; Mathews, C.; Pasarica, M.; Pratley,
R.E. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a
pilot cross-sectional study. Sci. Rep. 2016, 6, 31479.

103. Erener, S.; Mojibian, M.; Fox, J.K.; Denroche, H.C.; Kieffer, T.J. Circulating miR-375
as a biomarker of beta-cell death and diabetes in mice. Endocrinology 2013, 154, 603608.

104. Lakhter, A.J.; Pratt, R.E.; Moore, R.E.; Doucette, K.K.; Maier, B.F.; DiMeglio, L.A.;
Sims, E.K. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to
inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia 2018,
61, 1124-1134.

105. Keenan, H.A.; Sun, J.K.; Levine, J.; Doria, A.; Aiello, L.P.; Eisenbarth, G.; BonnerWeir, S.; King, G.L. Residual insulin production and pancreatic ss-cell turnover after 50
years of diabetes: Joslin Medalist Study. Diabetes 2010, 59, 2846-2853.

106. Thorel, F.; Nepote, V.; Avril, I.; Kohno, K.; Desgraz, R.; Chera, S.; Herrera, P.L.
Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss.
Nature 2010, 464, 1149-1154.

130

107. Furuyama, K.; Chera, S.; van Gurp, L.; Oropeza, D.; Ghila, L.; Damond, N.; Vethe,
H.; Paulo, J.A.; Joosten, A.M.; Berney, T.; Bosco, D.; Dorrell, C.; Grompe, M.; Raeder, H.;
Roep, B.O.; Thorel, F.; Herrera, P.L. Diabetes relief in mice by glucose-sensing insulinsecreting human alpha-cells. Nature 2019, 567, 43-48.

108. Hui, H.; Khoury, N.; Zhao, X.; Balkir, L.; D'Amico, E.; Bullotta, A.; Nguyen, E.D.;
Gambotto, A.; Perfetti, R. Adenovirus-mediated XIAP gene transfer reverses the negative
effects of immunosuppressive drugs on insulin secretion and cell viability of isolated
human islets. Diabetes 2005, 54, 424-433.

109. Ding, L.; Gysemans, C.A.; Stange, G.; Heremans, Y.; Yuchi, Y.; Takiishi, T.; Korf, H.;
Chintinne, M.; Carr, R.D.; Heimberg, H.; Pipeleers, D.; Mathieu, C. Combining MK626, a
novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of
new-onset diabetes in mice. PLoS One 2014, 9, e107935.

110. Belghith, M.; Bluestone, J.A.; Barriot, S.; Megret, J.; Bach, J.F.; Chatenoud, L. TGFbeta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies
to CD3 in overt autoimmune diabetes. Nat. Med. 2003, 9, 1202-1208.

111. Chatenoud, L.; Primo, J.; Bach, J.F. CD3 antibody-induced dominant self tolerance
in overtly diabetic NOD mice. J. Immunol. 1997, 158, 2947-2954.

112. Piao, S.G.; Lim, S.W.; Doh, K.C.; Jin, L.; Heo, S.B.; Zheng, Y.F.; Bae, S.K.; Chung,
B.H.; Li, C.; Yang, C.W. Combined treatment of tacrolimus and everolimus increases
oxidative stress by pharmacological interactions. Transplantation 2014, 98, 22-28.

113. Gummert, J.F.; Barten, M.J.; Sherwood, S.W.; van Gelder, T.; Morris, R.E.
Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both

131

lymphocyte proliferation and activation correlates with pharmacokinetics. J. Pharmacol.
Exp. Ther. 1999, 291, 1100-1112.

114. Allison, A.C. and Eugui, E.M. Mycophenolate mofetil and its mechanisms of action.
Immunopharmacology 2000, 47, 85-118.

115. He, X.; Smeets, R.L.; Koenen, H.J.; Vink, P.M.; Wagenaars, J.; Boots, A.M.; Joosten,
I. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere
guanine nucleotide deprivation. Am. J. Transplant. 2011, 11, 439-449.

116. Nguyen le, X.T.; Lee, Y.; Urbani, L.; Utz, P.J.; Hamburger, A.W.; Sunwoo, J.B.;
Mitchell, B.S. Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and
Ebp1. Blood 2015, 125, 2519-2529.

117. Budde, K.; Curtis, J.; Knoll, G.; Chan, L.; Neumayer, H.H.; Seifu, Y.; Hall, M.; ERL
B302 Study Group Enteric-coated mycophenolate sodium can be safely administered in
maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. 2004,
4, 237-243.

118. Jones, R.B.; Walsh, M.; Chaudhry, A.N.; Smith, K.G.; Jayne, D.R. Randomized trial
of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system
autoimmune disease. Clin. Kidney J. 2014, 7, 562-568.

119. Wu, H. and Mahato, R.I. Mesenchymal stem cell-based therapy for type 1 diabetes.
Discov. Med. 2014, 17, 139-143.

120. Huh, K.H.; Cho, Y.; Kim, B.S.; Joo, D.J.; Kim, M.S.; Kim, Y.S. PRMT3: new binding
molecule to RhoGDI-alpha during mycophenolic acid-induced beta-cell death. Transplant.
Proc. 2014, 46, 1229-1232.

132

121. Sheng, Y.; Akesson, C.; Holmgren, K.; Bryngelsson, C.; Giamapa, V.; Pero, R.W. An
active ingredient of Cat's Claw water extracts identification and efficacy of quinic acid. J.
Ethnopharmacol. 2005, 96, 577-584.

122. Zeng, K.; Thompson, K.E.; Yates, C.R.; Miller, D.D. Synthesis and biological
evaluation of quinic acid derivatives as anti-inflammatory agents. Bioorg. Med. Chem. Lett.
2009, 19, 5458-5460.

123. Bowalgaha, K. and Miners, J.O. The glucuronidation of mycophenolic acid by human
liver, kidney and jejunum microsomes. Br. J. Clin. Pharmacol. 2001, 52, 605-609.

124. Adamson, R.H.; Bridges, J.W.; Evans, M.E.; Williams, R.T. Species differences in
the aromatization of quinic acid in vivo and the role of gut bacteria. Biochem. J. 1970, 116,
437-443.

125. Kaila, N.; Somers, W.S.; Thomas, B.E.; Thakker, P.; Janz, K.; DeBernardo, S.; Tam,
S.; Moore, W.J.; Yang, R.; Wrona, W.; Bedard, P.W.; Crommie, D.; Keith, J.C.,Jr; Tsao,
D.H.; Alvarez, J.C.; Ni, H.; Marchese, E.; Patton, J.T.; Magnani, J.L.; Camphausen, R.T.
Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis,
and crystal structure in complex with E-selectin. J. Med. Chem. 2005, 48, 4346-4357.

126. Di, L.; Kerns, E.H.; Hong, Y.; Chen, H. Development and application of high
throughput plasma stability assay for drug discovery. Int. J. Pharm. 2005, 297, 110-119.

127. Konsoula, R. and Jung, M. In vitro plasma stability, permeability and solubility of
mercaptoacetamide histone deacetylase inhibitors. Int. J. Pharm. 2008, 361, 19-25.

133

128. Gill, K.L.; Houston, J.B.; Galetin, A. Characterization of in vitro glucuronidation
clearance of a range of drugs in human kidney microsomes: comparison with liver and
intestinal glucuronidation and impact of albumin. Drug Metab. Dispos. 2012, 40, 825-835.

129. Liu, X.; Sheng, L.; Zhao, M.; Mi, J.; Liu, Z.; Li, Y. In vitro glucuronidation of the primary
metabolite of

10-chloromethyl-11-demethyl-12-oxo-calanolide

A

by human

liver

microsomes and its interactions with UDP-glucuronosyltransferase substrates. Drug
Metab. Pharmacokinet. 2015, 30, 89-96.

130. Merglen, A.; Theander, S.; Rubi, B.; Chaffard, G.; Wollheim, C.B.; Maechler, P.
Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous
culture in INS-1E insulinoma cells. Endocrinology 2004, 145, 667-678.

131. Wen, D.; Chitkara, D.; Wu, H.; Danquah, M.; Patil, R.; Miller, D.D.; Mahato, R.I.
LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced
prostate cancer. Pharm. Res. 2014, 31, 2784-2795.

132. Watkins, W.J.; Chen, J.M.; Cho, A.; Chong, L.; Collins, N.; Fardis, M.; Huang, W.;
Hung, M.; Kirschberg, T.; Lee, W.A.; Liu, X.; Thomas, W.; Xu, J.; Zeynalzadegan, A.;
Zhang, J. Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of
IMPDH. Bioorg. Med. Chem. Lett. 2006, 16, 3479-3483.

133. Nelson, P.H.; Eugui, E.; Wang, C.C.; Allison, A.C. Synthesis and immunosuppressive
activity of some side-chain variants of mycophenolic acid. J. Med. Chem. 1990, 33, 833838.

134

134. Franklin, T.J.; Jacobs, V.N.; Jones, G.; Ple, P. Human colorectal carcinoma cells in
vitro as a means to assess the metabolism of analogs of mycophenolic acid. Drug Metab.
Dispos. 1997, 25, 367-370.

135. El-Araby, M.E.; Bernacki, R.J.; Makara, G.M.; Pera, P.J.; Anderson, W.K. Synthesis,
molecular modeling, and evaluation of nonphenolic indole analogs of mycophenolic acid.
Bioorg. Med. Chem. 2004, 12, 2867-2879.

136. Thomson, A.W.; Woo, J.; Yao, G.Z.; Todo, S.; Starzl, T.E.; Zeevi, A. Effects of
combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or
mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule
expression in human mixed lymphocyte cultures. Transpl. Immunol. 1993, 1, 146-150.

137. Tooley, J.E.; Vudattu, N.; Choi, J.; Cotsapas, C.; Devine, L.; Raddassi, K.; Ehlers,
M.R.; McNamara, J.G.; Harris, K.M.; Kanaparthi, S.; Phippard, D.; Herold, K.C. Changes
in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in
patients with type 1 diabetes. Eur. J. Immunol. 2016, 46, 230-241.

138. McCall, A.L. Insulin therapy and hypoglycemia. Endocrinol. Metab. Clin. North Am.
2012, 41, 57-87.

139. Little, P.J.; Cohen, N.; Morahan, G. Potential of small molecule protein tyrosine
kinase inhibitors as immuno-modulators and inhibitors of the development of type 1
diabetes. ScientificWorldJournal 2009, 9, 224-228.

140. Rewers, M. and Gottlieb, P. Immunotherapy for the prevention and treatment of type
1 diabetes: human trials and a look into the future. Diabetes Care 2009, 32, 1769-1782.

135

141. Hu, J.; Zong, Y.; Li, J.; Zhou, X.; Zhang, J.; Zhu, T.; Jiao, M.; Su, H.; Bo, B. In Vitro
and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against
Proliferation of Renal Cell Carcinoma. J. Ultrasound Med. 2016, 35, 589-597.

142. Adams, V.R. and Leggas, M. Sunitinib malate for the treatment of metastatic renal
cell carcinoma and gastrointestinal stromal tumors. Clin. Ther. 2007, 29, 1338-1353.

143. Fountas, A.; Diamantopoulos, L.N.; Tsatsoulis, A. Tyrosine Kinase Inhibitors and
Diabetes: A Novel Treatment Paradigm? Trends Endocrinol. Metab. 2015, 26, 643-656.

144. Tyrrell, H.E. and Pwint, T. Sunitinib and improved diabetes control. BMJ Case Rep.
2014, 2014, 10.1136/bcr-2014-207521.

145. Mukai, E.; Ohta, T.; Kawamura, H.; Lee, E.Y.; Morita, A.; Sasase, T.; Miyajima, K.;
Inagaki, N.; Iwanaga, T.; Miki, T. Enhanced vascular endothelial growth factor signaling in
islets contributes to beta cell injury and consequential diabetes in spontaneously diabetic
Torii rats. Diabetes Res. Clin. Pract. 2014, 106, 303-311.

146. Szalek, E.; Karbownik, A.; Sobanska, K.; Grabowski, T.; Polom, W.; Lewandowska,
M.; Wolc, A.; Matuszewski, M.; Grzeskowiak, E. The pharmacokinetics and
hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacol. Rep. 2014, 66, 892896.

147. Villalta, S.A.; Lang, J.; Kubeck, S.; Kabre, B.; Szot, G.L.; Calderon, B.; Wasserfall,
C.; Atkinson, M.A.; Brekken, R.A.; Pullen, N.; Arch, R.H.; Bluestone, J.A. Inhibition of
VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet
function. Diabetes 2013, 62, 2870-2878.

136

148. Grunwald, V.; Heinzer, H.; Fiedler, W. Managing side effects of angiogenesis
inhibitors in renal cell carcinoma. Onkologie 2007, 30, 519-524.

149. Chen, M.; Yang, Z.D.; Smith, K.M.; Carter, J.D.; Nadler, J.L. Activation of 12lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 2005,
48, 486-495.

150. Hernandez-Perez, M.; Chopra, G.; Fine, J.; Conteh, A.M.; Anderson, R.M.;
Linnemann, A.K.; Benjamin, C.; Nelson, J.B.; Benninger, K.S.; Nadler, J.L.; Maloney, D.J.;
Tersey, S.A.; Mirmira, R.G. Inhibition of 12/15-Lipoxygenase Protects Against beta-Cell
Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes.
Diabetes 2017, 66, 2875-2887.

151. Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Liposomal siRNA nanocarriers for
cancer therapy. Adv. Drug Deliv. Rev. 2014, 66, 110-116.

152. Kumar, V.; Mondal, G.; Dutta, R.; Mahato, R.I. Co-delivery of small molecule
hedgehog inhibitor and miRNA for treating liver fibrosis. Biomaterials 2016, 76, 144-156.

153. Mittal, A.; Chitkara, D.; Behrman, S.W.; Mahato, R.I. Efficacy of gemcitabine
conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic
cancer. Biomaterials 2014, 35, 7077-7087.

154. Choijilsuren, G.; Jhou, R.S.; Chou, S.F.; Chang, C.J.; Yang, H.I.; Chen, Y.Y.; Chuang,
W.L.; Yu, M.L.; Shih, C. Heparin at physiological concentration can enhance PEG-free in
vitro infection with human hepatitis B virus. Sci. Rep. 2017, 7, 14461-017-14573-9.

137

155. Christensen, J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine
kinase inhibitor with anti-angiogenic and antitumour activities. Ann. Oncol. 2007, 18 Suppl
10, x3-10.

156. Lopez-Garcia, J.; Lehocky, M.; Humpolicek, P.; Saha, P. HaCaT Keratinocytes
Response on Antimicrobial Atelocollagen Substrates: Extent of Cytotoxicity, Cell Viability
and Proliferation. J. Funct. Biomater. 2014, 5, 43-57.

157. Hatley, M.E.; Srinivasan, S.; Reilly, K.B.; Bolick, D.T.; Hedrick, C.C. Increased
production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial
interactions in diabetic db/db mice. J. Biol. Chem. 2003, 278, 25369-25375.

158. Rizvi, S.A.A. and Saleh, A.M. Applications of nanoparticle systems in drug delivery
technology. Saudi Pharm. J. 2018, 26, 64-70.

159. Huo, M.; Zhao, Y.; Satterlee, A.B.; Wang, Y.; Xu, Y.; Huang, L. Tumor-targeted
delivery of sunitinib base enhances vaccine therapy for advanced melanoma by
remodeling the tumor microenvironment. J. Control. Release 2017, 245, 81-94.

160. Adotevi, O.; Pere, H.; Ravel, P.; Haicheur, N.; Badoual, C.; Merillon, N.; Medioni, J.;
Peyrard, S.; Roncelin, S.; Verkarre, V.; Mejean, A.; Fridman, W.H.; Oudard, S.; Tartour,
E. A decrease of regulatory T cells correlates with overall survival after sunitinib-based
antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 2010, 33, 991998.

161. Simmons, K.M. and Michels, A.W. Type 1 diabetes: A predictable disease. World J.
Diabetes 2015, 6, 380-390.

138

162. International Diabetes Federation Introduction, In IDF Diabetes Atlas, 7th ed.;
Anonymous ;2015;

163. Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical
interventions in type 1 diabetes. Nature 2010, 464, 1293-1300.

164. Cantaluppi, V.; Biancone, L.; Romanazzi, G.M.; Figliolini, F.; Beltramo, S.; Ninniri,
M.S.; Galimi, F.; Romagnoli, R.; Franchello, A.; Salizzoni, M.; Perin, P.C.; Ricordi, C.;
Segoloni, G.P.; Camussi, G. Antiangiogenic and immunomodulatory effects of rapamycin
on islet endothelium: relevance for islet transplantation. Am. J. Transplant. 2006, 6, 26012611.

165. Gallo, R.; Natale, M.; Vendrame, F.; Boggi, U.; Filipponi, F.; Marchetti, P.; Laghi
Pasini, F.; Dotta, F. In vitro effects of mycophenolic acid on survival, function, and gene
expression of pancreatic beta-cells. Acta Diabetol. 2012, 49 Suppl 1, S123-31.

166. Fresno Vara, J.A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; GonzalezBaron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30, 193-204.

167. Winkler, D.G.; Faia, K.L.; DiNitto, J.P.; Ali, J.A.; White, K.F.; Brophy, E.E.; Pink, M.M.;
Proctor, J.L.; Lussier, J.; Martin, C.M.; Hoyt, J.G.; Tillotson, B.; Murphy, E.L.; Lim, A.R.;
Thomas, B.D.; Macdougall, J.R.; Ren, P.; Liu, Y.; Li, L.S.; Jessen, K.A.; Fritz, C.C.; Dunbar,
J.L.; Porter, J.R.; Rommel, C.; Palombella, V.J.; Changelian, P.S.; Kutok, J.L. PI3K-delta
and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses
activity in autoimmune and inflammatory disease models. Chem. Biol. 2013, 20, 13641374.

139

168. Balakrishnan, K.; Peluso, M.; Fu, M.; Rosin, N.Y.; Burger, J.A.; Wierda, W.G.; Keating,
M.J.; Faia, K.; O'Brien, S.; Kutok, J.L.; Gandhi, V. The phosphoinositide-3-kinase (PI3K)delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6
pathway and promotes apoptosis in CLL. Leukemia 2015, 29, 1811-1822.

169. Soond, D.R.; Bjorgo, E.; Moltu, K.; Dale, V.Q.; Patton, D.T.; Torgersen, K.M.;
Galleway, F.; Twomey, B.; Clark, J.; Gaston, J.S.; Tasken, K.; Bunyard, P.; Okkenhaug,
K. PI3K p110delta regulates T-cell cytokine production during primary and secondary
immune responses in mice and humans. Blood 2010, 115, 2203-2213.

170. Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce,
W.; Meek, S.E.; Salpekar, A.; Waterfield, M.D.; Smith, A.J.; Vanhaesebroeck, B. Impaired
B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science
2002, 297, 1031-1034.

171. Flinn, I.W.; O'Brien, S.; Kahl, B.; Patel, M.; Oki, Y.; Foss, F.F.; Porcu, P.; Jones, J.;
Burger, J.A.; Jain, N.; Kelly, V.M.; Allen, K.; Douglas, M.; Sweeney, J.; Kelly, P.; Horwitz,
S. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in
advanced hematologic malignancies. Blood 2018, 131, 877-887.

172. Flinn, I.W.; Miller, C.B.; Ardeshna, K.M.; Tetreault, S.; Assouline, S.E.; Mayer, J.;
Merli, M.; Lunin, S.D.; Pettitt, A.R.; Nagy, Z.; Tournilhac, O.; Abou-Nassar, K.E.; Crump,
M.; Jacobsen, E.D.; de Vos, S.; Kelly, V.M.; Shi, W.; Steelman, L.; Le, N.; Weaver, D.T.;
Lustgarten, S.; Wagner-Johnston, N.D.; Zinzani, P.L. DYNAMO: A Phase II Study of
Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J. Clin.
Oncol. 2019, 37, 912-922.

140

173. Vlassov, A.V.; Magdaleno, S.; Setterquist, R.; Conrad, R. Exosomes: current
knowledge of their composition, biological functions, and diagnostic and therapeutic
potentials. Biochim. Biophys. Acta 2012, 1820, 940-948.

174. Smyth, T.; Kullberg, M.; Malik, N.; Smith-Jones, P.; Graner, M.W.; Anchordoquy, T.J.
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control.
Release 2015, 199, 145-155.

175. Katakowski, M.; Buller, B.; Zheng, X.; Lu, Y.; Rogers, T.; Osobamiro, O.; Shu, W.;
Jiang, F.; Chopp, M. Exosomes from marrow stromal cells expressing miR-146b inhibit
glioma growth. Cancer Lett. 2013, 335, 201-204.

176. Kim, M.S.; Haney, M.J.; Zhao, Y.; Mahajan, V.; Deygen, I.; Klyachko, N.L.; Inskoe,
E.; Piroyan, A.; Sokolsky, M.; Okolie, O.; Hingtgen, S.D.; Kabanov, A.V.; Batrakova, E.V.
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.
Nanomedicine 2016, 12, 655-664.

177. Haney, M.J.; Klyachko, N.L.; Zhao, Y.; Gupta, R.; Plotnikova, E.G.; He, Z.; Patel, T.;
Piroyan, A.; Sokolsky, M.; Kabanov, A.V.; Batrakova, E.V. Exosomes as drug delivery
vehicles for Parkinson's disease therapy. J. Control. Release 2015, 207, 18-30.

178. Sun, D.; Zhuang, X.; Xiang, X.; Liu, Y.; Zhang, S.; Liu, C.; Barnes, S.; Grizzle, W.;
Miller, D.; Zhang, H.G. A novel nanoparticle drug delivery system: the anti-inflammatory
activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18,
1606-1614.

179. Zhuang, X.; Xiang, X.; Grizzle, W.; Sun, D.; Zhang, S.; Axtell, R.C.; Ju, S.; Mu, J.;
Zhang, L.; Steinman, L.; Miller, D.; Zhang, H.G. Treatment of brain inflammatory diseases

141

by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the
brain. Mol. Ther. 2011, 19, 1769-1779.

180. Johnsen, K.B.; Gudbergsson, J.M.; Skov, M.N.; Pilgaard, L.; Moos, T.; Duroux, M. A
comprehensive overview of exosomes as drug delivery vehicles - endogenous
nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 2014, 1846, 75-87.

181. Lai, R.C.; Yeo, R.W.; Tan, K.H.; Lim, S.K. Exosomes for drug delivery - a novel
application for the mesenchymal stem cell. Biotechnol. Adv. 2013, 31, 543-551.

182. Kordelas, L.; Rebmann, V.; Ludwig, A.K.; Radtke, S.; Ruesing, J.; Doeppner, T.R.;
Epple, M.; Horn, P.A.; Beelen, D.W.; Giebel, B. MSC-derived exosomes: a novel tool to
treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28, 970-973.

183. Wiklander, O.P.; Nordin, J.Z.; O'Loughlin, A.; Gustafsson, Y.; Corso, G.; Mager, I.;
Vader, P.; Lee, Y.; Sork, H.; Seow, Y.; Heldring, N.; Alvarez-Erviti, L.; Smith, C.I.; Le Blanc,
K.; Macchiarini, P.; Jungebluth, P.; Wood, M.J.; Andaloussi, S.E. Extracellular vesicle in
vivo biodistribution is determined by cell source, route of administration and targeting. J.
Extracell Vesicles 2015, 4, 26316.

184. Pascucci, L.; Cocce, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Vigano, L.;
Locatelli, A.; Sisto, F.; Doglia, S.M.; Parati, E.; Bernardo, M.E.; Muraca, M.; Alessandri,
G.; Bondiolotti, G.; Pessina, A. Paclitaxel is incorporated by mesenchymal stromal cells
and released in exosomes that inhibit in vitro tumor growth: a new approach for drug
delivery. J. Control. Release 2014, 192, 262-270.

142

185. Yao, Z.Q.; Eisen-Vandervelde, A.; Ray, S.; Hahn, Y.S. HCV core/gC1qR interaction
arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1.
Virology 2003, 314, 271-282.

186. Okkenhaug, K. and Vanhaesebroeck, B. PI3K in lymphocyte development,
differentiation and activation. Nat. Rev. Immunol. 2003, 3, 317-330.

187. Kuo, Y.C.; Weng, S.C.; Chou, C.J.; Chang, T.T.; Tsai, W.J. Activation and
proliferation signals in primary human T lymphocytes inhibited by ergosterol peroxide
isolated from Cordyceps cicadae. Br. J. Pharmacol. 2003, 140, 895-906.

188. Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.;
Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of Particle Size and Polydispersity
Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018,
10, 10.3390/pharmaceutics10020057.

189. Duffy, G.P.; Ahsan, T.; O'Brien, T.; Barry, F.; Nerem, R.M. Bone marrow-derived
mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent
manner in vitro. Tissue Eng. Part A. 2009, 15, 2459-2470.

190. Nassiri, S.M. and Rahbarghazi, R. Interactions of mesenchymal stem cells with
endothelial cells. Stem Cells Dev. 2014, 23, 319-332.

191. Cao, X.K.; Li, R.; Sun, W.; Ge, Y.; Liu, B.L. Co-combination of islets with bone marrow
mesenchymal stem cells promotes angiogenesis. Biomed. Pharmacother. 2016, 78, 156164.

